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Abstract
This thesis examines in depth the properties ofmixed models and considers their
application in a variety of designs used in medical research. Mixed models are a
broad class ofmodels which allow variation in the data to be modelled at several
levels and take into account correlations occurring between observations. They offer
several potential advantages over the more conventional fixed effects approaches:
more efficient estimates, effective handling ofmissing data and more appropriate
inference. The different types ofmixed model are placed into a unified format and
the properties of various fitting methods, including likelihood-based methods, least
squares methods and the Bayesian approach, are considered in detail. The practical
implications of using mixed models are examined and the submitted material would
appear to be the first to consider these in such depth. The particular features of
applying mixed models to a range of designs are considered including repeated
measures, crossover, multi-centre, meta analysis, cluster randomised, hierarchical,
bioequivalence and several more ad hoc designs. Novel approaches are introduced
for sample size estimation and for analysing crossover designs with multiple periods,
bioequivalence studies and case-control studies. Comparisons ofmixed models with
fixed effects models, which have often previously been the conventional approach,
are given particular attention. Models suitable for both normal and non-normal data
are considered and examples involving original analyses are used to illustrate the
properties described. The published material comprises two editions of a textbook




1.1 Introduction to published material and critical review 1
1.2 Introduction to mixed models 3
2 Theoretical considerations 5
2.1 The normal mixed model 5
2.2 Generalised linear mixed models 8
2.3 Mixed models for categorical data 11
3 Multi-centre trials 13
4 Cluster randomised trials 17
5 Repeated measures designs 20
5.1 Covariance pattern models 20
5.2 Random coefficients models 22
5.3 Sample size estimation 23
6 Crossed designs 24
6.1 Crossover trials 24
6.2 Case-control studies 28
7 Hierarchical designs 30
8 More complex designs 33
8.1 Designs with repeated measurements within visits 33
8.2 Multi-centre trials with repeated measurements 35
8.3 Multi-centre crossover designs 35
8.4 Multi-centre designs with centres grouped hierarchically 36
8.5 Bioequivalence studies with replicate crossover designs 36
9 Discussion 38
9.1 Mixed models in perspective 38
9.2 Fitting methods 40
9.3 Choice ofmodel 42
9.4 Summing up 43
Bibliography 45
Research publications 47
The candidate's contribution to research publications is coded below as:-
(a) primarily the work of the candidate
(b) equal contribution by the candidate and other authors, or where the
candidate is responsible only for statistical analysis and interpretation.
Additionally a statement describing the candidate's contribution to the textbook
(publications 1 and la) is provided following the publications list.
1. Brown,H.K., Prescott,R.J. Applied mixed models in medicine, second edition,
John Wiley, Chichester, 2006. (a, except where indicated in review)
la. Brown,H.K., Prescott,R.J. Applied mixed models in medicine, John Wiley,
Chichester, 1999. (a, except where indicated in review)
2. Grigor,P.N., Cockram,M.S., Steele,W.B., Le Sueur,C.J., Forsyth,R.E.,
Guthrie,J.A., Johnson,A.K., Sandilands,V., Reid,H.W., Sinclair,C. and
Brown,H.K. 2001. Effects of space allowance during transport and duration of
mid-journey lairage period on the physiological, behavioural and immunological
responses of young calves during and after transport. Animal Science, 2001,
73:341-360. (b)
3. Alexander,F.E., Anderson,T.J., Brown,H.K., Forrest,A.P.M., Hepburn,W.,
Kirkpatrick,A.E., Muir,B.B., Prescott,R.J., Smith,A., Warner,J. 'The Edinburgh
randomized trial of breast-cancer screening - results after 14 years of follow-up',
1999, Lancet (b)
4. Alexander,F.E., Brown,H.K., Prescott,R.J. 'Improved classification of socio¬
economic status explains differences in all-cause mortality in a randomised trial
of breast cancer screening, 1998, Journal ofEpidemiology and Biostatistics, 1998,
3, 219-224 (b)
5. Luis-Fuentes,V., Moran,L., Schber,K., Dukes-McEwan,J., Brown,H.,
Sutherland,G.R., McDicken,W.N. 'Measurement of cyclic variation in ultrasonic
integrated backscatter in continuously unsedated clinically normal dogs',
American Journal of Veterinary Research, 1997, 58, 1055-59 (b)
6. Brooke,H., Gibson,A., Tappin,D., Brown,H. 'Case-control study of sudden
infant death syndrome in Scotland, 1992-1995', British Medical Journal, 1997,
Vol.314, 1516-1520 (b)
7. Dixon,J.M., Ravisekar,0., Cunningham,M., Anderson,E.D.C, Anderson,T.J.,
Brown,H.K. 'Factors affecting outcome of patients with impalpable breast
cancers detected by breast screening', British Journal ofSurgery, 1996, 83, 997-
1001 (b)
8. Dallak,M., Luan,X.J., Brown,H., Pirie,L. 'Stability ofbreathing patterns in
men, rats and rabbits' Journal ofPhysiology - London, 1995, 483, 96-97 (b)
9. Humphreys,F., Symons,J.A., Brown,H.K., Duff,G.W., Hunter,J.A.A. 'The
effects of gamolenic acid on adult atopic eczema and premenstrual exacerbation
of eczema', European Journal ofDermatology, 1994, 4, 598-603, (b)
10. Brown,H.K., Kempton,R.A., 'The application ofREML in clinical trials',
Statistics in Medicine, 1994, 13, 1601-1617, (a)
11. Alexander,F.E., Anderson,T.J., Brown,H.K., Forrest,A.P.M., Hepburn,W.,
Kirkpatrick,A.E., McDonald,C., Muir,B.B., Prescott,R.J., Shepherd,S.M.,
Smith,A., Warner,J. 'The Edinburgh randomised trial of breast-cancer screening -
results after 10 years of follow-up', British Journal ofCancer, 1994, 70, 542-548
(b)
Note. Permission has been sought from publishers to include copies of the research
publications within the submission and gained from all responding publishers.
Statement describing the candidate's contribution to the textbook
This statement describes the evolution of both editions of the textbook (references 1
and la) and clarifies the contribution made by the candidate.
The first edition of the textbook evolved from a constantly changing set of course
notes that accompanied a three day course taught by the both authors entitled 'Mixed
models analysis ofmedical data: PROC MIXED and beyond'. The course was first
presented in 1993 and a comprehensive set of accompanying notes (approx 350 pages)
were prepared by the candidate with editing and suggestions from Robin Prescott. The
notes were revised with each rerun of the course to incorporate: general
improvements, comments received from delegates on the course, new software and
new examples. The revisions were made by the candidate.
In 1996 John Wiley and Sons agreed to publish a textbook to be developed from the
course notes. The first draft was produced by the candidate with the exception of
Chapter 7 and Section 6.6.1. Chapter 7 was drafted based on the material in the
crossover chapter of the course notes and Section 6.6.1 contained an example that was
first introduced in the textbook. Several edits of the draft were undertaken by the
candidate taking into account suggestions from both authors. The notes for the 1997
and 1998 courses were based on the textbook draft and comments received during the
course were also taken into account. Additionally Chapter 1 was redrafted following
comments from the series editor, Vic Barnett. The redraft was undertaken by the
candidate with the exception of Section 1.1 (The Use ofMixed Models).
In 2004 John Wiley and Sons invited the authors to write a second edition of the
textbook. This edition updated the material in the light ofnew advances and comments
on the first edition, reworked all examples using the latest SAS software and added
new sections. Both authors worked on the revision with the candidate taking the lead
on Chapters 1-4 and 9 and Robin Prescott on Chapters 5-8. Several new sections were
added or substantially expanded - first drafts of Section 8.15 (bioequivalence), the
majority of Section 8.16 (cluster randomised studies) and Section 9.1 (software for
mixed models) were written by the candidate; while first drafts of Section 8.14
(factorial design example), 8.16.1 (cluster randomised trial example) and an expansion
of Section 2.4.7 (missing data) were written by Robin Prescott. There followed several
edits of the draft taking into account suggestions from both authors.
1. Introduction
This chapter includes an introduction to the thesis in Section 1.1 followed by an
introduction to mixed models in Section 1.2.
1.1 Introduction to thesis
This thesis examines in depth the properties ofmixed models and their application to
a variety of data structures. Mixed models are a broad class ofmodels which allow
variation in the data to be modelled at several levels and take into account
correlations occurring between observations. They offer several potential advantages
over the more conventional fixed effects approaches: more efficient estimates, more
effective handling ofmissing data and more appropriate inference. Models for both
normal and non-normal data are considered.
The thesis consists ofpublished material contained in two editions of a textbook and
ten journal publications accompanied by a review which together constitute a PhD by
research publications. The remaining material in the review is broadly split into two
parts. Chapter 2 considers the properties ofmethods for fitting mixed models and the
practical implications of their application and Chapters 3-8 consider the properties of
mixed models for a variety of designs used in medical research. Particular attention
is paid to comparisons ofmixed models with fixed effects models which have often
previously been the conventional approach. Many original analyses are included to
illustrate the properties described. The designs considered primarily relate to the
medical field but are equally applicable in other fields of application.
The textbook forms the major part of the published material and two editions are
submitted. All direct references to chapters or sections in the review correspond to
the second edition of the textbook unless otherwise stated. However, the first edition
is additionally included to demonstrate the originality of some of the material at the
time of first publication. Due to the length of the textbook, only sections referenced
in the review form part of the submission and, in particular, sections specifying SAS
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code and output are not included. One journal publication is statistical (publication
10) and the remaining nine are publications in medical and veterinary journals where
the applicant has contributed the statistical analysis and conclusions. These
publications are used to provide examples and are in some cases contrasted to re-
analyses within the textbook.
The published material referenced in each chapter of the review is listed below.
Review Chapter
1.1 Introduction to mixed models
2. Theoretical considerations
3. Multi-centre trials
4. Cluster randomised trials
5. Repeated measures designs
6. Crossed designs
7. Hierarchical designs




1 (Chapters 2, 3 and 4) and 10
1 (Chapter 5) and 10
1 (Section 8.16), 3, 4 and 11
1 (Chapter 6, and 8.13), 9 and
10
1 (Chapter 7) and 10
1 (Sections 8.7, 8.8, 8.9, 8.10,
8.11,8.12), 5, 7 and 8
1 (Sections 8.1, 8.2, 8.3, 8.4,
8.15) and 2
Various sections of 1
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1.2 Introduction to mixed models
Benefits can often be gained by using a mixed model compared to the more
conventional fixed effects approaches. The advantages may include more efficient
estimates, effective handling ofmissing data and sometimes a wider generalisation.
The benefits occur because mixed models take into account correlations between
groups of observations. These correlations can be modelled either by fitting random
effects or coefficients to allow random variation at several levels, or by specifying
correlation structures for groups of observations. Fitting random effects or
coefficients causes correlations to be induced between observations within the same
random effect category. For example, if patients are fitted as random in a cross-over
trial, correlation is induced between observations on the same patient. Alternatively
in a repeated measures trial a correlation pattern across timepoints may be specified
for observations on the same patient. Examples are given in Section 1.1 to illustrate
these properties.
Section 1.2 introduces a mixed model from first principles by developing it from a
very simple fixed effects model and describes the main differences between fixed
and random effects approaches.
In Section 1.3 a trial of treatments for hypertension is introduced. The trial was a
randomised double blind comparison of three treatments for hypertension and is
reported in Hall et al. (1991). One treatment was a new drug (A) and the other two (B
and C) were standard drugs for controlling hypertension (A = Carvedilol, B =
Nifedipine, C = Atenolol). Twenty-nine centres participated in the trial and two pre-
treatment and four post-treatment visits were made. Two hundred and eighty eight
patients were randomised to receive one of the three treatments and thirty patients
dropped out during the study. Measurements ofblood pressure, laboratory values and
adverse events were recorded at each visit. Diastolic and systolic blood pressure were
the primary outcome variables. The trial had been previously analysed in Hall et al.
(1991) using a fixed effects approach. In Sections 1.3 and 1.4 analyses of the trial
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are used to illustrate the features of the three main types ofmixed model - random
effects models, random coefficients models and covariance pattern models.
Section 1.5 and publication 10 (Section 1) consider the key distinguishing features of
mixed models in more detail, the benefits that can be gained from them, their
particular application in medicine and a history of their use.
Definitions of containment, balance and error strata are given in Section 1.6. While
there are fairly standard definitions for containment and error strata, balance in
mixed models is not straightforward to define. Two definitions ofbalance are
proposed, complete balance and balance across random effects, and the different
model properties resulting from each definition are considered. Most other texts
have provided a simple definition ofbalance as arising when there are an equal
number of observations per 'cell' (where a cell relates to each combination of effects
fitted) or omit to provide a specific definition. The published material would appear
to be novel in providing definitions of balance for the mixed model and in examining
the effect of each form of balance on results.
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2. Theoretical Considerations
This chapter considers the methods and properties ofmixed models. Section 2.1
considers models for normally distributed data, Section 2.2 considers generalised
linear mixed models (GLMMs) which are suitable for analysing many types of non-
normally distributed data and Section 2.3 considers mixed models for categorical
data. The textbook (publication 1) provides a comprehensive comparison of the
different fitting methods available and a rigorous evaluation of the pros and cons of
using mixed models in practice. It forms the first assessment made ofmixed models
in such detail.
2.1 Normal mixed models
In this section mixed models with normally distributed errors are considered. While
these are referred to as 'normal mixed models', it is not necessarily implied that
values of the response variables follow a normal distribution. The published material
relates to Chapter 2 and to publication 10. It includes a specification of the normal
mixed model using a general matrix notation which can be used for all types of
mixed model. This notation allows an easier understanding of the overall theory
underlying mixed models and the methods used to fit them. Fitting methods for
mixed models based on both classical statistical techniques and Bayesian approaches
are defined and contrasted. Practical issues relating to the use and interpretation of
mixed models are considered, and these are illustrated in a worked example.
The normal mixed model is specified using a general matrix notation in Section 2.1
and the covariance matrix structure is defined for the three most common types of
mixed model - the random effects model, the random coefficients models and the
covariance pattern model. Covariance pattern models are defined as models which
have correlated residuals. These models are often used to analyse repeated measures
data.
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Section 2.2 and publication 10 (Section 1) describe a variety ofmethods for fitting
the normal mixed model based on likelihood and iterative generalised least squares
approaches. A mixed model is defined using fixed effects, random effects and
covariance patterns. Fixed effects are not assumed to vary randomly, for example
treatment effects in a clinical trial would normally be assumed to be fixed, whereas
random effects are assumed to be a sample from a population. For example, the
patients recruited to a clinical trial could be considered a sample from the population
of interest and hence fitted as random. Covariance patterns directly define the
covariance structures within groups of observations, for example repeated
measurements on the same patient. Likelihood functions are defined in terms of the
fixed effects and variance component parameters. The residual maximum likelihood
(REML) function is derived from the ordinary maximum likelihood function and the
property of unbiased variance components is shown. The alternative method of
iterative generalised least squares is described and shown to lead to the same results
as likelihood-based approaches, provided the same assumptions are made. In
particular, iterative generalised least squares leads to the same results as ordinary
maximum likelihood where the estimated fixed effects are assumed to be constants
rather than unknown parameters when estimating the variance components, and
restricted iterative generalised least squares leads to the same results as REML where
fixed effects are assumed to be unknown parameters.
Derivations of closed form expressions for the fixed effects estimates and their
variances are obtained by differentiating the log likelihood. It is shown that the
expressions for these effects are identical regardless of the fitting method used.
Random effects are assumed to be realisations of a distribution and hence have zero
estimates. However, predictions of random effects can be formed by redefining the
likelihood function so that it is conditioned on the random effects and from this a
closed form expression for the random effects solutions and their variances is
obtained.
In Section 2.3 the Bayesian approach to fitting mixed models is considered. The
section includes an introduction to the approach and to the simulation methods that
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are often used to fit the models. Comparisons are made to classical approaches and it
is shown that the posterior distribution is analogous to the REML likelihood when
flat priors are used, and furthermore that this is almost the case when other
uninformative priors are used. The potential advantages of fitting a Bayesian model
arise because the distributions of the model parameters are fully evaluated providing
exact estimates, standard errors and confidence regions. This contrasts with classical
approaches where standard errors and confidence intervals are calculated based on
point estimates and are often subject to biases (see below).
In Section 2.4 the general properties and potential deficiencies ofmixed models are
explored. Negative variance component estimates are considered in Section 2.4.1.
The probability of obtaining a negative estimate by chance is defined and calculated
over a range of scenarios. Approaches to handling a negative estimate are described
and it is suggested that negative estimates are usually fixed at zero or removed from
the model. However, an alternative interpretation ofnegative correlation between
observations within random effect categories is also considered. This can be allowed
for by redefining the model as a covariance pattern model where negative correlation
is allowed within the categories.
Section 2.4.2 considers the importance of estimating variance parameters with a
reasonable accuracy and suggests that an effect should have a minimum of five
categories to be fitted as random and should otherwise be fitted as fixed.
Section 2.4.3 describes the bias that occurs in fixed and random effect standard error
estimates and defines situations where it is likely to be most noticeable. The amount
ofbias is related to the precision of the variance component estimates, the size of the
variance components and the degree of imbalance in the data. It is recommended that
standard errors are adjusted using the approach suggested by Kenward and Roger
(1997).
Section 2.4.4 defines formulae forWald F and t tests for testing contrasts of fixed
effect estimates and random effect predictions using matrix notation. The degrees of
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freedom for these tests need to reflect the combination of error strata on which the
test contrast is based and methods for their calculation are described. The use of
Bayesian models to provide probability values equivalent to a two-sided classical test
is demonstrated. Approaches for testing the significance of variance parameters are
also suggested. Confidence intervals are defined in Section 2.4.5 following the
standard method of calculation but using the mixed models degrees of freedom.
The assumptions made when fitting a normal mixed model are specified in Section
2.4.6. Approaches to model checking using normal and residual plots corresponding
to each error strata are described. For models with correlated residuals it is
recommended that the residuals are standardised using Cholesky's decomposition
matrix before being checked.
Section 2.4.7 considers the implications ofusing mixed models when there are
missing data. In many situations mixed models are able to overcome the problems
caused by missing data. However, this is based on the assumption that the data are
missing at random. Three recognised types ofmissing data are described: missing
completely at random, missing at random and missing not at random. Suggestions
are made of how to categorise missing data and how situations where data are not
missing at random can be handled.
A worked example of data from the hypertension trial described in Section 1.3 is
provided in Section 2.5. Analyses fitting a variety of alternative models are described
including models using a Bayesian approach. These demonstrate some of the features
defined for mixed models and also consider each of the aspects covered in Section
2.4.
2.2 Generalised linear mixed models
Generalised linear mixed models (GLMMs) are suitable for analysing non-normal
data provided it can be assumed to follow a distribution from the exponential family.
Random effects, random coefficients or covariance patterns can be included in a
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GLMM in much the same way as in normal mixed models, and again either balanced
or unbalanced data can be analysed. Chapter 3 defines the GLMM using a general
matrix notation, building the model from its fixed effects counterpart the generalised
linear model (GLM). Alternative methods for fitting the GLMM are defined and
contrasted. Aspects relating to practical application are considered and a worked
example is provided.
In Section 3.1 the fixed effects GLM is introduced. Definitions of common
distributions are provided along with a specification of the general form for
distributions from the exponential family. The GLM is specified using matrix
notation and a fitting method based on maximum likelihood is illustrated. The
conditional logistic regression approach is also defined as an alternative fixed effect
approach.
Section 3.2 specifies the extension of the GLM to a GLMM using matrix notation.
The likelihood function is defined for random effects models and a quasi-likelihood
for situations where a true distribution cannot be defined. Fitting methods
corresponding to pseudo-likelihood, generalised estimating equations and Bayesian
methods are introduced and their relative benefits are discussed.
The practical application and the implications of using GLMMs are considered in
Section 3.3. The material would appear to be the first to consider these aspects in
such depth.
Section 3.3.1 considers the alternative ways in which binary data can be analysed.
The section concludes that analyses based on Bernoulli rather than binomial data are
preferable for fitting GLMMs. Analysis of the data in this form allows for a more
appropriate modelling of the variance structure and also allows covariates recorded at
the observation level to be fitted.
Section 3.3.2 considers the effects of 'uniform' categories. A category is defined as
uniform when all observations within it have the same value, for example a patient
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effect category in a cross-over trial is uniform if all results for the patient are the
same. While a uniform category causes infinite effect estimates to occur in a
conventional GLM, often satisfactory estimates can be obtained when the effect is
modelled as random in a GLMM. However, if too many categories are uniform
fitting problems can also arise in the GLMM.
Section 3.3.3 considers negative variance component estimates. The same
considerations apply as in the normal mixed model, however potential biases caused
by the fitting methods can make a negative variance component estimate even more
likely.
Section 3.3.4 describes how fixed and random effect estimates can be meaningfully
expressed by applying the inverse of the link function to the estimates obtained on
the linear scale from the GLMM.
The accuracy of variance parameters is considered in Section 3.3.5. As for normal
data it is suggested that a reasonable accuracy is required because the variance
components are used to estimate both effect means and their standard errors. At least
five categories for an effect are again recommended to fit it as random. The potential
bias of variance parameters in GLMMs caused by random effects shrinkage, and in
particular in the presence ofuniform categories, is described.
Section 3.3.6 considers biases in fixed and random effects standard errors. These are
biased both for the same reason as in normal mixed models (see Section 2.1 of
review), and also due to biases in the variance component estimates. Biases for the
first reason can again be overcome by using the adjustment suggested by Kenward
and Roger (1997).
The effects of including a dispersion parameter in the model are considered in
Section 3.3.7. Inclusion of the parameter helps to overcome biases in the variance
component estimates and in some situations allows over-dispersion in the data to be
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modelled. It is concluded that the parameter should always be included in GLMM
analyses.
Significance tests for GLMMs are considered in Section 3.3.8 and Wald F and t tests
based on the linear effects estimated from the GLMM are recommended. Confidence
intervals are defined in Section 3.3.9 and follow the conventional approach.
An illustrative example of a binary variable from the hypertension trial (see Section
1.2 of review) is provided in Section 3.4. Analyses fitting a variety of alternative
models are carried out including models using the Bayesian approach. These
demonstrate some of the features defined for GLMMs and also consider each of the
methodological aspects described above and covered in Section 3.3.
2.3 Mixed models for categorical data
Categorical data often occur in clinical trials, for example adverse events may be
classified on an ordinal scale as mild, moderate or severe. The published material
describes the fixed effects ordinal logistic regression model and extends this to
mixed models for analysing ordinal and unordered categorical data. Fitting methods
and the practical implications of fitting the models are considered, followed by a
worked example.
The ordinal logistic regression model is defined in Section 4.1. An alternative
specification is also provided in matrix notation using an extended binary format for
the multinomial observations. This allows the correlations occurring between the
multinomial categories to be defined in a covariance matrix.
Section 4.2 specifies the ordinal mixed model using the extended binary format
following the specification given by Lipsitz et al. (1994). Structures for covariance
matrices are provided taking account of random effects, covariance patterns and the
multinomial correlations. Likelihood and quasi-likelihood functions are defined. The
methods available for fitting categorical mixed models are summarised.
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A mixed model for unordered categorical data is specified in Section 4.3. This has a
similar form to the mixed model for ordinal data except that parameters
corresponding to each category are now needed to model each fixed and random
effect. For variance components a separate parameter is needed for each pair of
categories.
The practical implications of fitting mixed models to categorical data are considered
in Section 4.4. The proportional odds assumption made in analyses of ordinal data is
described in Section 4.4.1. This assumption is made because the same fixed effect
parameter is used to model all partitions of the categories. It is concluded that the
assumption is usually appropriate as different fixed effects for each partition would
be difficult to interpret and usually an overall estimate across partitions is ofmost
interest. However, the partitions can be modelled separately in situations where each
partition of categories may give rise to a different interpretation.
In Section 4.4.2 the requirement for a larger number of covariance parameters
required compared to an equivalent GLMM is discussed. It is recommended that
more complex terms in the covariance matrix are introduced cautiously. Section
4.4.3 recommends that a covariance pattern is chosen by carrying out likelihood ratio
tests to test whether more complex patterns can be justified. The difficulty in
interpretingmultiple covariance parameters is discussed in Section 4.4.4.
A worked example is provided in Section 4.5. This is based on an analysis of an
adverse event 'cold feet' recorded in the hypertension study (see Section 1.1 of
review). Cold feet were recorded on an ordinal scale of 1- 5: 1 = none, 2 =
occasionally, 3 = on most days, 4 = most of the time, 5 = all of the time. The
analyses demonstrate the use of alternative covariance structures to model the
repeated measurements.
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3. Multi-Centre Trials and Meta-Analyses
The analysis of data that are collected from several centres or trials is considered in
this chapter. A multi-centre trial is carried out using several centres either because
insufficient patients are available for any one centre, or with the deliberate intention
of assessing the effectiveness of treatments in several settings. The published
material relates to Chapter 5 and publication 10. The statistical and interpretational
implications of fitting mixed models to multi-centre data compared to fixed effects
approaches are considered in depth and the alternative inferences that can be made
from a range ofmodels are described. Two worked examples are included. Sample
size formulae are derived corresponding to the mixed model fitting centre and
centre.treatment effects as random. This would appear to be the first time such
formulae have been specified. Meta-analysis data have the same basic structure as
data from multi-centre trials and it is demonstrated that similar mixed models can be
applied.
Sections 5.1 and publication 10 (Section 4) provide an introduction to multi-centre
trials and their analysis using mixed models. Sometimes there will be extra
variability in a multi-centre trial due to differences between the centres (e.g. different
investigators, types ofpatients, climates). This extra variation can be taken into
account in the analysis by including centre and centre.treatment effects in the model.
In most situations a more efficient analysis will be obtained by fitting centre effects
as random. However, deciding whether centre.treatment effects should be fixed or
random can be the subject of debate. In practice, the choice will depend on whether
treatment estimates are to relate only to the set of centres used in the study or, more
widely, to the circumstances and locations ofwhich the trial centres can be regarded
as a sample. In the former case, 'local' treatment estimates for the sampled set of
individual centres are obtained by fitting centre.treatment effects as fixed. To obtain
'global' treatment estimates with a wider inference, centre.treatment effects should
be fitted as random. When this is done the standard error of treatment differences is
increased to reflect the heterogeneity of the treatment effects across centres.
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The potential reasons for extra variability in treatment effects across centres are
considered. Variation in a treatment effect across centres is likely to be most
noticeable in trials that do not compare drugs. For example, in a trial to compare
surgical procedures there may be varying levels of experience available at each
centre with the different procedures.
The statistical implications of fitting the following models are defined in Section
5.2:-
• Centre and centre.treatment effects fixed
• Centre effects fixed, centre.treatment effects omitted
• Centre and centre.treatment effects random
• Centre effects random, centre.treatment effects omitted
For each model: formulae for the variability of the treatment estimate are specified,
the implications for treatment effect estimates at each centre are described, and the
inferences that can be drawn are described. The section clarifies the two main
purposes of using a mixed model in multi-centre trials. Firstly fitting centre effects as
random provides more efficient treatment effects whenever there is imbalance in the
data as occurs in most multi-centre trials. Secondly fitting centre.treatment effects as
random allows a wider interpretation based on the assumption that treatment effects
vary between the centres. The effect of fitting alternative models is illustrated in a
worked example in Section 5.3 and in publication 10 (Section 4.1).
Section 5.4 considers in more depth the interpretation of results from alternative
models and the practical aspects relating to fitting mixed models to multi-centre data.
The generalisability of results is discussed depending on whether or not random
centre.treatment effects are included in the model. It is concluded that generalisation
often cannot be clearly defined and needs to be by degree. Several aspects need to be
considered when generalising results: whether the study is single or multi-centre; the
assumptions made by the model fitted; the particular application. Multi-centre studies
may be considered more generalisable than studies carried out at a single centre, and
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results from analyses ofmulti-centre studies fitting centre.treatment effects as
random may be considered still more generalisable than analyses that do not. An
interaction between treatment and centres is more plausible in situations where
variation in treatment effects across centres, for example in a trial of a surgical
technique where there may be differences in surgeon experience. However, in a
situation where it is less plausible for a treatment effect to vary across centres, for
example in drug trials, results from analyses omitting random centre.treatment
effects may still have a high level of generalisability.
Section 5.4 also considers how results are affected by the number of centres and the
sizes of centres. It is suggested that as variance component estimates are used to
estimate both the fixed effects and their standard errors, they should be estimated
with a reasonable accuracy based on a minimum of about five centres. Mixed models
are recommended even when some centre sizes are very small, perhaps containing
only one patient. This avoids the approach sometimes used in fixed effects analyses
where data from small centres are combined, often using an arbitrary rule to define
when a centre is 'small'.
In Section 5.5 formulae for estimating sample size are derived to provide adequate
power to carry out an analysis where centre.treatments are fitted as random.
Formulae are also derived for non-normal data. The three situations listed below are
considered:-
• Number ofpatients required per centre when the number of centres is
specified
• Number of centres required per centre when the average centre size is known
• Number of centres and patients per centre when the relative costs of
managing a centre compared to that of recruiting a patient can be estimated.
Section 5.6 demonstrates that mixed models can be applied in meta analyses with the
same implications as in multi-centre trials, by replacing centre effects with trial
effects. In a meta analysis a trial.treatment interaction is often more plausible than a
centre.treatment interaction due to the likely differences in study protocols. The
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wider inference provided by a mixed model then becomes more attractive. A worked
example in Section 5.7 illustrates the effects of taking alternative modelling
approaches.
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4. Cluster Randomised Trials
This chapter considers the use ofmixed models to analyse cluster randomised trials.
Cluster randomised trials are carried out when it may not be practical or ethical for
subjects to receive different treatments within the same cluster (eg centre, hospital,
clinic, GP practice). In this situation clusters rather than subjects are randomised to
treatment groups to form a so-called 'cluster randomised' design. The published
work considers the implications ofmixed model approaches compared to alternative
more conventional approaches. Additionally methods to classify socio-economic
status to adjust for biases between groups in cluster randomised trials are considered.
Data from the Edinburgh Breast Screening Trial (publications 3, 4 and 11) are used
to demonstrate differences in approaches and the methods for socio-economic
adjustment.
Section 8.16 describes the use of a mixed model with treatment effects fitted as fixed
and cluster effects as random. The variance of the difference between treatments is
given by,
vaiit,-tj) = cr2 (\/ni +\/nj) + a2J(\/ct +1 /Cj)
where a2 is the residual variance, nt and «,■ are the numbers of subjects receiving
treatments i and j, a2 is the centre variance component, and c, and Cj are the number
of centres allocated to groups i and j. This compares to an analysis taking no account
of cluster effects where the variance would be varfr,. -tj) = a 2(1jni +\/rij). It is
concluded that a mixed model with cluster effects fitted as random should be the
norm for analysing this type of data since treatments are estimated at the cluster level
of variation. Unlike the multi-centre trial a choice ofmodels offering alternative
inferences is not available since randomisation has taken place at the cluster level.
For non-normal data a GLMM fitting cluster effects as random is compared to the
alternative approach of fitting a generalised linear models (GLM) with an over-
dispersion parameter. The GLMM is considered preferable because it provides a
more appropriate modelling of variance and also allows covariates recorded on
individual observations to be fitted to help adjust for differences between groups.
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In Section 8.16.2 and publications 3, 4 and 11 analyses of the Edinburgh randomised
trial are considered. This was a large cluster randomised trial involving 54654
women aged between 45-64 from 87 general practices in Edinburgh. It was started in
1978 at a time when there was no breast screening programme in Scotland. Practices
were randomly assigned to either an intervention or control group. Women in the
intervention group were invited to participate in a screening programme involving an
annual screen for breast cancer, while those in the control group received normal
medical care. All subjects in the intervention practices were considered part of the
intervention group, whether or not they attended for screening. The primary
endpoints were death from breast cancer and death from all causes. It became
apparent early in the study that there was an imbalance between the treatment groups
in terms of socio-economic status and analyses have sought to adjust for this
(publication 4).
Analyses of the study were carried out after 7 years (Roberts et ah, 1990), 10 years
(publication 3) and 14 years (publication 11) of follow up. For consistency a standard
statistical approach was used across all the analyses. This involved fitting GLMs
withWilliams' modification (Williams, 1981) to model the extra variability (or
'over-dispersion') occurring between practices and differences between the practices
were adjusted for fitting categories to represent the overall socio-economic status of
each practice.
Data from the same trial were re-analysed in Section 8.16.2 using software that was
unavailable at the time of the original analysis. The analyses demonstrated the
benefits of fitting cluster effects as random in a GLMM rather than the alternative
approach of fitting an over-dispersion parameter in a GLM. Analysing individual
data in Bernoulli form was shown to be preferable to analysing summary data for
each cluster in binomial form. This benefit was particularly noticeable in analyses
adjusting for age and socio-economic status. This indicates that the use of summary
covariate statistics for clusters can be inadequate and that fitting individual covariate
values with the data analysed in Bernoulli form is likely to be preferable.
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While the analyses carried out in Section 8.16.2 demonstrated that adjusting for
differences in clusters using summary characteristics may be inadequate, they did not
address a potential bias between the groups in the classification of socio-economic
status. The bias was specific to this study. It occurred because the status was defined
from each woman's postcode and postcodes ofwomen who moved house during the
study were only updated for women in the study group and not those in the control
group. This bias is considered in publication 4 and a method to determine a
potentially unbiased classification is specified. This new classification was calculated
at the GP practice level and was used as an adjustment in the 14 year analysis
(publication 11). While the approach potentially overcame the problem of bias
between the groups caused by individual women's classifications, the adjustment
may still have been inadequate since it was based on summary statistics and not
individual classifications of socio-economic status for individual women.
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5. Repeated Measures Designs
Mixed model approaches to analysing repeated measures data are considered in this
chapter. Any dataset in which subjects are measured repeatedly over time can be
described as repeated measures data. Repeated measurements are either made at pre¬
determined intervals (e.g. at fortnightly visits), or in a less controlled fashion so there
are variable intervals between the repeated measurements. The type of analysis
model chosen will depend on whether or not the intervals are fixed.
The published material relates to Chapter 6 and publications 9 and 10. The
properties of two mixed model approaches for analysing repeated measures data are
defined. These are based on either specifying a covariance structure for the repeated
measurements or using random coefficients to model the repeated measurements as a
function of time. Several worked examples are used to illustrate the models
suggested for both normal and non-normal data. Sample size formulae are derived
for the situation where it is planned to analyse the data using a covariance pattern
model and the average treatment effect across visits will be of interest.
5.1 Covariance pattern models
In Section 6.1 the repeated measures design is introduced and a variety of fixed
effects analysis approaches suitable for the situation where repeated measurements
are made at fixed time points are described. These include the analysis of the mean
response over time, separate analyses at each time point, analyses of response
features and analyses of the raw data. The statistical and interpretational implications
ofusing each of these models and the potential benefits ofmixed models are
described.
Covariance pattern models are defined in Section 6.2 and publication 10 (Section 3).
A variety of approaches to defining the covariance structure for the repeated
measurements are introduced and methods for choosing between alternative models
are considered. The effects of including different fixed effects in the model are also
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described. In particular the inclusion of a treatment.time interaction causes an overall
treatment effect estimate to be an unweighted average across time points, whereas
omitting this term will result in a treatment estimate based on using different weights
at each time point.
Four worked examples illustrate the properties of covariance pattern models applied
to normal data, binary data, count data and ordinal data.
The first is described in Section 6.3 and is based on analysing diastolic blood
pressure from the hypertension dataset measured at four post treatment visits (see
Section 1.2 of review). This example considers models with a variety of covariance
patterns. It illustrates the use of likelihood ratio tests to choose between models, and
the effect of including and excluding the treatment.time fixed effect. A check of
model assumptions is demonstrated involving use of the Cholesky decomposition
matrix to take account of the correlated residuals. A complex covariance structure is
selected involving separate sets of covariance parameters for each treatment group.
However, estimates of treatment differences are shown to be very similar to those
obtained from a simple structure with a constant correlation across treatments. It is
concluded that the similarity is likely to have occurred because the amount of
missing data is small and hence there is little imbalance in the data. In other less
balanced datasets a greater difference in the results might have been expected.
The second example is described in Section 6.4. Data from a placebo controlled trial
of an anti-convulsant treatment for epilepsy reported in Thall and Vail (1990) are
analysed. The study involved fifty nine patients and the number of epileptic seizures
was counted over an eight-week period prior to treatment and then over four two-
week periods following treatment. No patients dropped out of the study. A histogram
of the number of epileptic episodes suggested that a Poisson distribution could be
used to model the data and an initial analysis was carried out using a GLMM.
However, subsequent checks indicated that model assumptions were not met and the
data were re-analysed using a mixed model for ordinal data after classifying the
numbers of seizures into four categories.
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The third example considers data from a placebo-controlled trial to assess the
efficacy of gamolenic acid for treating eczema and is described in publications 9 and
10. Fifty two patients were recruited and several dropped out before the study end.
Measurements were made at baseline and at six post-treatment visits. The severity of
eczema is measured by a redness score covering twenty parts of the body. Fixed
effects models are used to analyse data recorded at each time point in publication 9.
In publication 10 analyses using covariance pattern models were carried out using
the same data and these are contrasted to the fixed effects approaches previously
used.
The fourth example is described in Section 8.13 and considers the situation where an
effect of interest varies over time. Data were again taken from the eczema trial
described above. Dailymeasurements of eczema were recorded in patients' diaries
and women also recorded details of their menstrual cycle. These data were analysed
using a covariance pattern model to assess the effect of the menstrual cycle on
eczema severity and whether this interacted with treatment. The study showed
subjects were more likely to experience severe itchiness during menstrual bleeding
and that this was not influenced by treatment.
5.2 Random coefficients models
Random coefficients models are considered in Section 6.5. These models assume
random variation in the time slopes (or curves) for each patient and provide an
appropriate estimate and standard error of the differences in slopes between
treatment groups. The invariance of the results to the specification of time origin is
demonstrated. Approaches to handling negative variance components corresponding
to random coefficients are considered and it is suggested that random coefficients are
removed in order of decreasing order of complexity until all variance components are
positive. Alternative approaches to using baseline measurements are considered.
These can either be fitted as a covariate or included as an initial time point depending
on the interpretation required.
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An example comparing two treatments for HIV positive patients is described in
Section 6.6.1 (b, not primarily work of candidate). The treatments are compared in
terms of changes in patients' CD4 counts using a linear random coefficients model.
A second example involving a polynomial random coefficients model is described in
Section 6.6.2. Here measurements of herpes virus levels made on children suffering
from either leukaemia or solid lump tumours were analysed. Their hospital visits did
not occur at fixed intervals making the use of a random coefficients model
appropriate. The models compared the differences in the pattern of change in virus
levels between the two cancer groups and the data were used to demonstrate the
invariance of the results to the time origin.
5.3 Sample size estimation
Sample size formulae corresponding to a covariance pattern fitting a compound
symmetry structure are derived for normal and non-normal data in Section 6.7. These
formulae produce smaller sample sizes than the standard parallel group calculation.
While the exact covariance structure for the repeated measurements is not known in
advance it is likely that the assumption of a compound symmetry structure will
provide an adequate sample size estimate.
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6. Crossed designs
A crossed design can be defined when the effect of interest (eg treatment) is crossed
with another 'nuisance' effect (eg patients). For example, in a cross-over design each
patient receives several treatments and treatment effects are then crossed with
patients. Another example of this design is the matched case-control study where
'matched sets' of patients contain at least one case and control. Crossed designs have
also been frequently used in crop trials in agriculture where treatments are allocated
within rows of a field. The ANOVA technique and early applications ofmixed
models were initially developed for analysing of such experiments (for example see
Talbot, 1984).
The published material concentrates primarily on cross-over trials and considers a
variety of designs. The benefits of fitting patient effects as random rather than fixed
are assessed for each design. For some designs this has involved the derivation of
algebraic formula. A novel approach involving the use of covariance patterns to
structure the correlations occurring between repeated measures by either period or
treatment is also described. The matched case-control study is considered and the
benefits of fitting matched set effects as random rather than fixed are shown.
Practical aspects specific to crossed designs are considered and worked examples
involving normal and non-normal data are provided.
6.1 Cross-over trials
The cross-over trial is introduced in Section 7.1 and publication 10. In cross-over
trials, subjects are randomised to receive different sequences of treatments, with the
outcome being assessed for each treatment period. Most cross-over trials have the
same basic design where every subject receives each of the treatments being
evaluated, for a standard period of time, with the outcome variables being assessed in
the same way in each period of treatment. Examples ofmore complex designs
include 'incomplete block' designs, where patients are randomised only to receive
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some of the treatments being studied, and 'optimal' designs where patients may
receive the same treatment more than once.
The potential advantages of using a mixed model to analyse cross-over data are
described in Section 7.2. These include more efficient estimates of treatment effects
whenever there are missing data and the potential to model the covariance structure
of the data when there are more than two periods in the trial.
The AB/BA cross-over trial is introduced in Section 7.3. Formulae for within- and
between- patient estimates of treatment variation are specified in publication 10 and
re-presented in Section 7.3. From these the relative efficiency of the mixed model
estimate compared to the fixed effects model estimate is given under different
circumstances. Gains in efficiency are shown to be greatest when the patient variance
component is small compared to the residual, and when a larger proportion of data is
missing. In order to assess the amount of gain likely in practice, the ratio of the
patient variance component relative to the residual is calculated for a range of
examples. A worked example is provided in Section 7.3.1 illustrating the gain in
efficiency.
In Section 7.4 higher order complete block designs are considered. In these designs
there are as many treatment periods as there are treatments to be compared, and each
patient receives every treatment. If there are no missing data, then a conventional
least squares analysis fitting treatment, period and patient effects is fully efficient.
However, when there are missing data, some of the within-patient treatment
comparisons are unavailable for every patient and additional between-patient
information can then be utilised. The analysis of a four-period, four-treatment trial
taken from Jones and Kenward (1989) is considered in Section 7.4.2. The effects of
the treatments on cardiac output are compared in terms of left ventricular ejection
time. Fourteen patients participated in the trial and the original data were complete.
In order to demonstrate the benefits ofusing a mixed model thirteen observations
chosen arbitrarily were set to missing. The results showed small gains in efficiency
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in all the mixed models. These were slightly more noticeable when carryover effects
were included.
Incomplete block designs are introduced in Section 7.5. In this design the number of
periods is less than the number of treatments to be evaluated so complete balance is
not achieved even when data are complete. In this situation a mixed model will
always provide a more efficient analysis because it utilises between-patient
information in estimating treatment effects. Formulae for the variances of treatment
effect estimates are derived for the three-treatment two-period design in publication
10 (and reproduced in Section 7.5.1) for models fitting patient effects as fixed or
random, and for models including and excluding carryover effects. The gains in
efficiency are shown to be particularly great when carryover effects are fitted. The
large gains in efficiency are illustrated in a worked example using data from Mead
(1988) in publication 10 and in Section 7.5.1.
Section 7.6 considers optimal designs such as Balaam's design involving the
randomisation of patients to treatment sequences AA, AB, BA or BB. These designs
are suitable in situations where carryover effects are expected. When carryover
effects are to be included in the analysis model, this design will provide uniformly
most powerful unbiased estimates of treatment and carry-over effects. Analysis of
this design using a mixed model further increases the efficiency of the estimates. A
trial using Balaam's design taken from Hunter et al. (1970) is analysed in Section
7.6.1 and demonstrates the benefits of using a mixed model.
The use of covariance pattern models in cross-over trials containing more than two
periods is considered in Section 7.7. Models structuring the covariance by period
effects and alternatively by treatment effects are specified in Sections 7.7.2 and 7.7.3.
Structuring the covariance matrix by treatment allows observations on different
treatments to have different variances and covariances. The models are illustrated in
a worked example in Section 7.7.3 again using data from the four-period four-
treatment trial considered above. Comparisons showed that a model structuring the
covariance by treatment led to a better model fit. This would appear to be the first
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published specification and application of this approach. Since the publication of the
first edition of the textbook, this approach has been more widely applied and the
calculation ofpopulation bioequivalence is based on structuring the covariance by
treatment (as considered in Section 8.5 of the review).
The analysis ofbinary data is considered in Section 7.8 and a worked example of a
two-way cross-over design is provided. The benefits of the mixed model are shown
compared to fixed effects approaches suggested by Prescott (1981) and Senn (1993).
To avoid the potential problems caused by a large number of uniform patient effects,
it is recommended that a GLMM with a compound symmetry structure is preferable
to a GLMM with patient effects fitted as random. In Section 7.9 an example using a
mixed model for analysing ordinal data from a two-way cross-over trial taken from
Jones and Kenward (1989) is considered.
Knowledge of variance component sizes can be used in trial design to help decide
whether a cross-over or between patient trial is most appropriate. This is illustrated in
Section 7.10. The variance components obtained in the analysis of the oral
mouthwash trial in Section 7.3.1 are used to determine the design of a future trial of
mouthwashes.
General points relating to the practical application ofmixed models in cross-over
trials are made in Section 7.11. It is suggested that in situations where the amount of
missing data is minimal, the small gain in efficiency obtained from using a mixed
model may be outweighed by the benefits of using a simpler fixed effects model
where there are no issues such as biased standard errors. Caution is particularly
suggested when modeling non-normal data. The pros and cons of fitting carryover
effects are considered and following Senn (2002) it is recommended that cross-over
designs are only used when carryover effects are not expected, since these effects
cannot be adequately accounted for in a statistical model.
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6.2 Matched case-control studies
Matched case-control studies are considered in Section 8.5 and publication 6. In this
design a group of subjects who have a particular disease or outcome (cases) are
compared with a group of subjects who do not have the disease or outcome
(controls). Each case is matched to one or more controls using one or more factors
that are known to be connected with the disease. For example, age and sex are often
used. The primary objective in a case-control analysis is to determine which factors
(not used in the matching) differ between the case and control groups. However, in
doing so it is important to allow for the matched nature of the data. The published
material describes the analogy between the case-control design and cross-over
designs, demonstrates the advantages of using a mixed model compared to the more
conventional fixed effects approaches, and provides examples of analyses of normal
and non-normal data.
The design of the matched case-control study is similar to that of the cross-over trial.
In the cross-over trial the treatment effects are 'crossed' with patient effects (i.e. each
patient may receive several treatments). In the matched case-control study, group
effects (i.e. whether case or control) are crossed with matched set effects (sets of
matched subjects are referred to as 'matched sets'). The effect of fitting matched sets
as random in a case-control study is similar to that of fitting patients as random in a
cross-over study. Results will be identical to an analysis fitting matched sets as fixed
whenever there are the same number of controls for every case and the matched set
variance component is positive (when it is negative and set to zero, the mean group
differences will be identical but their standard errors will differ). In a fixed effects
analysis fitting matched sets as fixed, information is completely lost on group effects
in any matched sets which either contain only a case or only controls. Additionally,
in a fixed effects analysis of binary data (which can be performed using conditional
logistic regression), matched sets whose members all have identical outcomes (i.e.
are uniform) do not contribute information to the analysis. This loss of information
does not occur when matched sets are fitted as random because information is then
'recovered' from the matched sets error stratum. When data are non-normal the
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problems caused by uniform categories (see Section 2.2 of review) may occur when
matched set effects are fitted as random in a GLMM. It is suggested that a GLMM
with a compound symmetry covariance structure is used to avoid these difficulties.
Analyses of a study carried out by the Scottish Cot Death Trust are used to illustrate
the use ofmixed models and their advantages. The study aimed to interview the
parents of every sudden infant death syndrome (SIDS) baby in Scotland during 1992-
1995. The parents of two matched control babies born immediately before and after
each case at the same hospital were also interviewed. However, not all parents agreed
to participate and this caused some of the matched sets to be incomplete.
An analysis of all variables recorded in the study using conditional logistic
regression analyses is reported in publication 6. Conditional logistic regression is a
fixed effects approach where results are conditioned on matched set effects and is
equivalent to fitting matched set as fixed. While it is a less efficient technique than
using a GLMM when there are missing data, at the time ofpublication it was the
standard approach for analysing this type of data and requested by the journal
reviewers! In Section 8.5 mixed model analyses of selected quantitative and binary




Designs where data can be grouped into hierarchies and where the primary objective
is not to estimate a fixed effect can be described as 'hierachical'. Often interest
centres on one or more of the following:-
estimating variance components to determine sources of variation in the data
estimating shrunken random effects
providing appropriate estimates of an overall mean value and standard error.
Six examples are considered. Each demonstrates the benefits of using mixed models
for use with a particular data structure and compares these models to corresponding
fixed effects.
Section 8.7 and publication 8 describe an experiment to calculate variance
components for breathing measurements in rabbits. The inspiration times for one
hundred breaths were measured on four rabbits on each of four days. This gave rise
to four potential sources ofvariation - rabbits, days, rabbit.day interaction and
residual (between breaths). A random effects model was fitted to inspiration time
with each of the above effects taken as random. A positive variance component was
obtained corresponding to each random effect allowing the relative sizes of variation
from the different sources to be interpreted. In Section 8.7.1 the variance components
are used to design a future clinical trial to compare two treatments. Sample sizes for
trials with between- and within- rabbit designs are considered. Formulae are
specified for the variation of the mean treatment difference in inspiration time. From
this, formulae are derived for the treatment difference that can be detected for a given
sample size and power, calculated over a range of sample sizes.
Data from an informal study carried out by Edinburgh radiographers to measure
inter- and intra- observer variation in foetal age predicted from ultrasound scan
measurements is analysed in Section 8.8. Six radiographers participated in the
experiment. Fifty-two women in the latter stages ofpregnancy with a mean gestation
of 29.9 (SD 3.2) weeks were each scanned by two of the radiographers selected at
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random. Both scans were carried out in the same session. A random effects model
was fitted to the data with radiographer effects taken as random and subject (women)
effects as fixed. Subjects were fitted as fixed because they each have a different
gestation and therefore cannot be treated as a randomly distributed sample. The
radiographer variance component was zero demonstrating that there was no
systematic bias in the assessments of individual radiographers. A measure of intra-
observer variation was provided by the residual estimate and was used to calculate
the accuracy of foetal gestation predictions.
An experiment to measure components of variation and to provide a mean estimate
in a cardiology experiment on dogs is described in Section 8.9 and publication 5.
The heart wall thickness of eleven healthy dogs was measured using ultrasound
scans. Each scan consisted of twenty thickness measurements taken over a single
heartbeat cycle. Each dog had between two and six scans and each scan was assessed
by between one and three observers. Thus the data are not balanced. A random
effects model with dog, observer, dog.observer and scan effects fitted as random is
used to estimate variance components and to calculate an appropriate estimate for the
mean and standard error of heart wall thickness. The variance components estimates
allowed the sizes of variation from different sources to be assessed. The overall mean
estimate weighted the observations appropriately according to the covariance
structure of the data. It was shown to be quite different from a crude mean and
standard error based on treating the observations as independent.
Cluster sample surveys are considered in Section 8.10. In such surveys data occur
within clusters and clusters are usually sampled at random. The purpose of a cluster
sample survey is to provide an appropriate estimate and standard error of a
measurement. This contrasts with cluster randomised trials which seek to compare
treatment effects and randomise treatments to clusters. A mixed model fitting cluster
effects as random provides results that can be related with some confidence to the
population of clusters. The model also produces shrunken cluster estimates. These
avoid the potential problem ofunrealistic estimates occurring due to chance variation
when cluster sizes are small. Such an analysis using cluster sample survey data taken
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from Thrusfield (1995) is described in Section 8.10.1. A GLMM is applied to
estimate the prevalence of a disease in animals.
A GLMM is used in Section 8.11 to provide shrunken estimates ofmortality
estimates for each postcode area in Edinburgh. The shrunken estimates avoid the
extreme estimates that may arise in small areas.
In publication 7 data recording the outcome from mastectomy operations at an
Edinburgh hospital were analysed using fixed effects GLM models. The analyses
tested the effect of surgeon experience and other factors likely to affect outcome.
However, the fixed effects approach was unable to provide satisfactory estimates of
individual surgeon performance, particularly for a surgeon who only carried out three
operations. In Section 8.12 the same data were analysed using a GLMM to provide
shrunken estimates of complication rates of surgeons carrying out mastectomy
operations. These shrunken estimates helped to avoid the extreme estimates that may
arise for surgeons only carrying out a few operations.
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8. More complex designs
The designs considered in this chapter use combinations of the features that have
already been considered in the critical review - hierarchical structures, crossed
designs and repeated measurements designs. Hierarchical repeated measures
structures, multi-centre repeated measures data, multi-centre cross-over data, multi¬
centre trials with centres that are grouped hierarchically and bioequivalence studies
with replicate cross-over designs, are included. The flexibility ofmixed models to
incorporate several design aspects into a single model is demonstrated and the
practicalities connected with fitting such more complex models are considered.
Comparisons are made with other more conventional methods of analysis.
8.1 Designs with repeated measurements within visits
Designs with repeated measurements occurring within visits are considered in
Section 8.1. These designs can arise in both cross-over and repeated measures trials.
For example, bioequivalence trials often record several blood or urine measurements
at each visit in a cross-over design. Studies in cardiology sometimes involve exercise
tests where repeated measurements are made throughout the test at each visit. The
published material defines a variety of alternative mixed models based on covariance
pattern models and random coefficients models. The properties of the alternative
models are compared. Methods for model building and model selection are
considered. Three worked examples illustrate the properties of the models suggested.
The use ofmixed models with covariance patterns structured across visits and across
repeated measurements within visit is considered in Section 8.1.1. These models are
contrasted to an alternative simpler approach based on analysing summary statistics
for each visit (e.g. area under the curve, maximum value or time to maximum value)
with methods appropriate for ordinary repeated measures or cross-over data. While
this latter approach has the advantage of simplicity and gives a straightforward
interpretation, it cannot test the interaction between treatments and repeated
measurements within visits or satisfactorily overcome problems caused by missing
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data. The mixed model takes account ofmissing data and allows the interaction
between treatment and the 'within visit' repeated measurements to be tested. Several
alternative approaches to structuring the covariance matrix are described. The two
hierarchies of repeated measurements leads to a wide choice of covariance structures
and care is required to ensure that parameters are not confounded. It is recommended
that a model is built up from a simple structure and that more complex features are
added one by one and using likelihood ratio tests to test whether they make a
significant contribution.
A worked example is provided in Section 8.1.2 illustrating the use ofmodels with
covariance patterns structured both by visits and repeated measurements within
visits. Data were taken from a three-period, cross-over trial taken from Jones and
Kenward (1989) to compare the effects of three treatments on systolic blood
pressure. There were twelve patients and ten measurements were made at each visit.
The trial was previously analysed in Jones and Kenward (1989) using approaches
based on ANOVA. While this is satisfactory because the data are complete, more
care is required in determining the appropriate sums of squares and degrees of
freedom for significance tests and for calculating the standard errors for each effect,
than when a mixed model is used. This is demonstrated in the analysis carried out in
Section 8.1.2. If there had been missing data in the study then an ANOVA approach
would not have been appropriate.
A second example involved an experiment where repeated measurements were made
within visits and is described in publication 2. This study was carried out in calves to
examine the effects of space allowance during transportation. Ninety six calves were
randomised to one of four groups - smaller space allowance with food and water,
larger space allowance with food and water, smaller space allowance without food
and water, and larger space allowance without food and water. The study involved
four periods - journey 1, lairage, journey 2 and post treatment. Measurements were
made at two timepoints within each period, at one and twelve hours. Mixed models
were fitted with space allowance, food and water, timepoint and their interactions
taken as fixed effects. In this example constant covariances across periods and across
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timepoints were used to provide a straightforward interpretation as many variables
were analysed.
In Section 8.1.3 the use of random coefficients models to analyse data with repeated
measurements made within visits is considered. Models fitting slopes across either
visits, repeated measurements within visits or across both are specified. This type of
model is appropriate if greatest interest is centred on explaining the relationship of a
measurement with time or if either set of repeated measurements occur at irregular
intervals. In Section 8.1.4 the application of random coefficients models is
demonstrated, again using data from the repeated measures cross-over study taken
from Jones and Kenward (1989).
8.2 Multi-centre trials with repeated measurements
Multi-centre trials with repeated measurements are considered in Section 8.2. A
mixed model fitting centre and centre.treatment effects as random, and also using a
covariance pattern to model correlations between the repeated measurements is
specified. Mixed models with this structure are illustrated in Section 8.2.1 using data
from the hypertension trial introduced in Section 1.3. In this example the results
obtained were similar to the analysis ignoring the effects of centres carried out in
Section 6.3. However, treatment effects estimates were slightly more accurate due to
the inclusion of random centre effects.
8.3 Multi-centre cross-over designs
The multi-centre cross-over design is considered in Section 8.3. Three alternative
mixed models are considered with different specifications for centre and
centre.treatment effects. It is recommended that centre and patient effects are always
fitted as random to allow any additional information on treatments from the patient
and centre error strata to be recovered. If, additionally, it is assumed that treatment
effects vary randomly across centres a wider inference can be obtained by fitting
centre.treatment effects as random as described for the multi-centre design.
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8.4 Multi-centre designs with centres grouped hierarchically
Multi-centre designs where centres are grouped hierarchically, for example by
country, are considered in Section 8.4. A mixed model fitting centre, country,
centre.treatment and country.treatment effects as random is suggested. This model
assumes that treatment effects vary across centres and countries and leads to wider
inferences. It also allows shrunken estimates of treatment effects at each centre and
country to be calculated.
8.5 Bioequivalence studies with replicate cross-over designs
Bioequivalence studies with replicate cross-over designs are considered in Section
8.15. In these designs treatments are received more than once by each patient. They
can be used to assess the within subject variability on each treatment, the variability
of the within subject treatment difference, and the between subject variability of each
treatment. The parameters obtained can then be used to establish 'individual
bioequivalence' and 'population bioequivalence'. A common design has four periods
and patients are randomised to receive treatments in one of the sequences: ABAB,
ABBA, BABA, BAAB. Approaches based on analysing summary statistics
calculated at each visit (eg AUC, time to maximum concentration) are considered for
this design.
The published material considers several mixed model approaches with a variety of
covariance structures. The implications of each model are considered in depth
including those suggested by the FDA (the Food and Drug Administration). It is
suggested that the model used to assess average bioequivalence should be chosen by
using likelihood ratio tests to statistically justify the inclusion of variance and
covariance terms in the model. The FDA guidance specifies that a sequence and
sequence by period interaction are fitted as fixed effects. Flowever, the inclusion of
these effects has no bearing on the overall bioavailability results. Special
consideration is given to approaches for establishing population and individual
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bioequivalence and a novel approach to calculating confidence intervals for the
criteria using a Bayesian model is suggested.
A worked example illustrates several alternative models for analysing a four period
trial to compare two formulations of an anti-anxiety agent where patients were
randomised to receive treatments in the sequences ABAB, ABBA, BABA, BAAB. It
was taken from the FDA website of datasets and utilises data provided by
GlaxoSmithKline Pharmaceuticals (http://www.fda.gov/cder/bioequivdata). In this
example the choice of covariance structure did not affect the conclusion in relation to
average bioequivalence. However, the probability intervals resulting from the
Bayesian model were wider than the confidence intervals obtained from the REML
models indicating that the Kenward-Roger standard error adjustment may not have
overcome the bias known to occur in fixed effects standard errors. The posterior
sample obtained from a Bayesian analysis is used to calculate population and
individual bioequivalence criteria and to provide exact probability intervals. In
contrast to other complex approaches that have been suggested for calculating
confidence intervals for the criteria, this method is relatively straightforward and the
resulting probability intervals are unbiased.
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9. Discussion
The material submitted in this thesis has provided an wide-ranging examination of
mixed models for both normal and non-normal data for a variety of designs and data
structures used in the medical field and beyond. This chapter reflects on the factors
underlying the establishment ofmixed models as a mainstream technique, considers
some of the difficulties posed by the fitting methods, discusses the choice ofmodels
available, and highlights areas where more work is required.
9.1 Mixed models in perspective
The benefits ofmixed models have been known about for some time, see for
example Yates (1940), but it is only in recent years that their use has become
widespread. It is interesting to consider the reasons behind this. One factor is
undoubtedly the increased availability of computer power. When mixed models were
first proposed carrying out a maximum likelihood analysis would have been time-
consuming, however such an analysis is now virtually instant and computer power is
not usually a consideration. Adequate computer power has encouraged software
producers to include mixed models software into their packages. In 1989 mixed
models software was introduced into two well known packages, Genstat and SAS,
making the approach widely accessible to practising statisticians. The introduction of
the comprehensive MIXED procedure into SAS had particular significance as this
package was widely used within the pharmaceutical industry. However, software
producers need to bear in mind the influence that their method of application and
presentation of results will have on a user's understanding of a new methodology and
interpretation of results. Unless the user's knowledge is comprehensive there may be
a tendency to accept results produced by software regardless ofwhether or not they
are completely appropriate for a situation. For example, early versions ofPROC
MIXED were misleading because the correct DF was not used for F and t tests and
inappropriate z-tests were given for variance components. Thus, while the statistician
always has ultimate responsibility for the integrity of an analysis, software
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developers need to assume some responsibility for ensuring an appropriate and clear
presentation of results and for providing thorough documentation.
The ready availability of software and computer power are not by themselves
sufficient to cause a methodology to become mainstream. There need to be clear
improvements over other available methods, the new technology should not be so
complex that it cannot be understood by the majority ofpractising statisticians and
there needs to be an area of application where it may be frequently applied. Mixed
models are one of several techniques suitable for the common situation involving an
experiment where the effect of one or more factors is examined in relation to an
outcome variable and where typically an objective is to test the null hypotheses that a
particular factor (eg treatment) has no effect on the outcome variable. Previously
methods such as t-tests, ANOVA and regression along with other analogous methods
for non-normal data have been the mainstay for analysing this type of experiment.
Mixed models are important because they too are suitable for analysing such
experiments and additionally offer the advantage of taking into account correlations
in the data. Although more complex, the broad principles can be understood by the
majority of statisticians. By contrast, many other new and complex techniques which
have become available with increased computer power have not found a place in the
average statistician's repertoire because they are less easily understood, despite
offering advantages for particular situations.
Mixed models have also been developed in parallel in the social sciences where they
are referred to as 'multilevel' models. However, there has been little interaction
between the alternative disciplines during these developments and different
terminologies and techniques have evolved. Despite this, the main features ofboth
approaches to modelling are identical and the same results are usually obtained by
the different fitting techniques. Recently there has been more recognition of the
overlap between the two areas of application and there have been examples of the
MIXED procedure in SAS being used to fit 'multilevel' models by social scientists.
There would appear to be potential for a more unified development in the future,
particularly as issues associated with the approach are common to both areas.
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9.2 Fitting methods
A variety ofmethods are available for fitting mixed models. Techniques based on
optimisation such as maximum likelihood or generalised iterative least squares have
been most frequently applied. However, the use of these techniques has several
consequences. Negative variance components can be obtained even though they are
not permitted by the definition of random effects which are assumed to have a
distribution with a positive variance. Standard error estimates for fixed and random
effects are biased downwards and although approximations are available to correct
for this bias (see Section 2.4.3), it is never clear whether the corrections are
completely adequate. For example, in the bioequivalence study described in Section
8.15 the Bayesian standard error for the treatment difference was notably different
from the standard error obtained using REML even after correction with the
Kenward-Roger approximation. Degrees of freedom for significance tests also need
to be computed using approximations to allow for the different error strata used for
estimating effects from mixed models (see Section 2.4.4). Although the use of
approximations will provide satisfactory results in most situations, it may cause us to
consider whether optimisation methods form the most natural approach for fitting
mixed models. More work is required to examine the adequacy of approximations for
standard errors, degrees of freedom and the resulting significance tests produced,
across a variety of experimental situations.
The Bayesian approach, however, is not based on using optimisation and the
problems described above are therefore not encountered. Rather than optimising a
criterion, the joint distribution of the model parameters is obtained and this allows
exact standard errors, probability intervals and 'Bayesian p-values' to be derived. Its
use, with uninformative priors, is therefore perhaps the more suited for fitting mixed
models as the use of approximations is avoided. It also allows more complex
statistics from an analysis such as measures ofpopulation and individual
bioequivalence and their confidence intervals (see Section 8.15) to be derived.
However, its use is far less widespread and accepted than optimisation approaches.
There are likely to be several reasons for this. There is a lack of understanding of the
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approach by statisticians whose training is usually based on frequentist techniques
and who may sometimes assume that Bayesian methods necessarily incorporate prior
information. A lack of user-friendly software has also made these methods less
accessible to statisticians. Although a Bayesian analysis can be carried out in PROC
MIXED, it requires several manual steps which would not be immediately apparent
to statisticians who do not already have a firm understanding of the approach (see
Section 2.3). While packages such as BUGS are freely available for carrying out
Bayesian analyses, they are not as user friendly as well established packages such as
SAS and appear to be little used by statisticians outside academia. A potential
drawback of the Bayesian approach is that simulation methods are frequently used
and the user is left to determine when the posterior distribution has been adequately
sampled. More systematic approaches for assessing this are needed to allow such
analyses to be applied reliably in clinical trials. This is an area where further work is
required. Lastly there can be a reluctance by regulatory bodies and medical journals
to accept results from a Bayesian analysis. This is only likely to change if the
approach becomes more widely understood and systematic methods to determine
when the posterior is adequately sampled become available.
Mixed model methods for analysing non-normal data based on optimisation (eg
pseudo-likelihood, generalised estimating equations) are more complex than those
for normal data. Usually a two-stage optimisation approach is required and
approximations are used within the optimisation process as well as for calculating
standard errors and degrees of freedom. A second complexitywith both GLMMs and
mixed models for categorical data is the discrepancy between the expected means
and variances which occurs because, in the common situation where a 'one
parameter' binomial or Poisson distribution is assumed, the expected variances are
computed from the expected means based on shrunken random effects estimates (see
Section 3.3.5). This discrepancy occurs regardless of whether the models are fitted
using a technique based on optimisation or a Bayesian approach. Although the use of
a dispersion parameter helps to overcome the biases caused, it is not completely
adequate and it can be unclear when a satisfactory analysis has resulted. GLMMs are
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an area where more research is urgently required, particularly with the introduction
ofuser-friendly software into statistical packages such as PROC GLIMMIX in SAS.
9.3 Choice of model
The published material describes several potential advantages offered bymixed
models compared to more conventional fixed effects methods. These may relate to a
gain in efficiency, an alternative interpretation, a more appropriate model, or a
combination of these. However, careful consideration is required in deciding whether
a mixed model should be used and, if so, which type ofmixed model is the most
appropriate.
In some situations the use of a mixed model may lead to more accurate estimates of
treatment effects, for example when patient effects are fitted as random in a cross¬
over trial. However, this is not the case if the data are balanced and sometimes the
gains in efficiency may disappear once approximations have been applied to correct
bias in the standard error estimates.
In other situations, the use of a mixed model may give rise to potential new
inferences. For example, in multi-centre trials treatment effects can be assumed to
vary randomly across the centres by fitting centre.treatment effects as random. This
gives a wider treatment effect standard error than in a fixed effects model and a
wider generalisation of effectiveness over the population of centres can be made.
Thus a mixed model here presents the analyst with a choice ofmodel relating to the
inference they would like to make. However, it is important that the limitations of
alternative inferences are understood. For example, the representiveness of the
centres included in a multi-centre trial must be taken into account since centres are
rarely sampled at random.
For repeated measures data with missing values, an ANOVA or regression approach
is inappropriate for modelling treatment effects because the correlations between the
repeated measurements are not adequately accounted for. Here a mixed model
provides a clearly preferable approach with its ability to model correlations between
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observations. Additionally it also provides an attractive alternative to the 'last value
carried forward' approach when the primary objective is to analyse the last repeated
measurement. There is a wide choice of covariance patterns available and it is
possible to search for the pattern that is most appropriate to the covariance structure
of the data. However, it should be borne in mind that the choice ofpattern may affect
results, particularly when data are unbalanced. In an experimental situation, an open-
ended facility to search for a pattern is potentially open to misuse, particularly when
results are to be submitted to a regulatory body. Thus it is desirable when writing
statistical analysis plans to specify both a strategy for selecting a pattern, and also the
range of patterns that will be considered. However, at present it is unclear which
search strategy or range of covariance patterns are appropriate for a specific
situation. This is another area where further work is required.
9.4 Summing up
Mixed models are unarguably more complex and involve more assumptions than
most fixed effects models and thus more expertise is required to use them effectively
and more explanation is needed when presenting results to non-statisticians. Looking
more broadly at the use ofmodelling, situations where a single model or technique
forms the only appropriate approach for an analysis are unusual and often several
alternative models will adequately represent the 'truth'. However, from the opposite
perspective there is rarely a technique that is perfect for a situation, for example there
is unlikely to ever be complete certainty that the normality assumption for residuals
is satisfied. Thus the selection of a model always involves a degree of compromise. It
is also necessary to take into account other factors such as its complexity and the
ease of interpretation of results when deciding which approach to use. Sometimes a
simpler technique that is readily understood may be preferable to a more complex
one, even when the latter offers advantages. For example, in Section 6.2 of the
review a situation is described where GLMM analyses were criticised by British
Medical Journal reviewers due to not being mainstream, and the less efficient, but
better known, conditional logistic regression approach was suggested.
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Considering the complexity as a factor influencing model choice brings to the fore
the question ofwhen it is appropriate for non-statisticians to perform statistical
analyses. Ideally statistical analysis would always be performed by an analyst who
has a full understanding of the methodology. However, there are many practical
reasons why it is often desirable for researchers who are not professional statisticians
to carry out their own analyses and the availability ofuser-friendly software has
made this feasible. This may sometimes be satisfactory when the broad principles of
a modelling approach can be understood by a non-professional statistician but less so
when an approach is more complex. For example, checking normality and producing
summaries and test results for a simple comparison of groups (eg t-tests and
regression analysis) is relatively straightforward and can, with appropriate support,
often be satisfactorily carried out by a non-professional statistician. However, this is
less advisable when a methodology is more complex and mixed models would
appear to fall into this category. The use of statistical analysis by non-professional
statisticians is perhaps an area where the statistical profession need to establish a
clearer view?
In summary, although mixed models are more complex than fixed effects
approaches, this drawback is frequently outweighed by their advantages and their use
is becoming more widespread as these are recognised. However, it is important that
the growth takes place at a pace that allows issues requiring further examination to
emerge and for these to be examined by researchers. This will provide practising
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Abstract
The effects of space allowance during transportation and duration of a mid journey lairage period on measurements
of stress, injury, dehydration, food restriction and rest in young calves were assessed during and after transport.
Groups of calves were transported for two 9-h journeys (at a space allowance of either 0-375 or 0-475 m2 per calf)
separated by a mid-journey lairage period ofeither 1 or 12 h. Non-transported calves were offered milk replacer and
drinking water either at the usual times or only at the same times as the transported calves.
During transport, transported calves spent significantly less time lying down and had a greater plasma Cortisol
concentration than control calves. Under the driving conditions used, increased space allowance was not associated
with greater injury or loss ofstability. The duration of the mid journey lairagc was not an importantfactor; the shorter
lairage time, giving the calves sufficient time to receive milk replacer but little opportunity to rest, had no major
detrimental effects on the variables used to assess welfare. Although there was little evidence that transport affected
immunological variables, therewas some evidence that it adversely affected the health of the calves post transport.
Keywords: animal welfare, behaviour, calves, physiology, transport.
Introduction
When young calves are transported, they are
potentially exposed to a number of factors that,
either on their own or in combination, could affect
their welfare (Cockram and Mitchell, 1999). Many
aspects of the transportation of young calves are
regulated by legislation. In the UK, the Welfare of
Animals (Transport) Order 1997 (Great Britain
Parliament, 1997) implements European Directive
91/628/EEC (European Council, 1991) as amended
by Directive 95/29/EC (European Council, 1995) and
depending on the type of vehicle used, this
legislation stipulates: the journey length and
structure, the intervals at which the calves should be
offered food, water and rest, and provides
recommended space allowances to be used during
transport. However, there have been few detailed
studies to evaluate the scientific basis of the
legislation and to identify the important factors
likely to affect the welfare of young calves during
transport. The effects of transport on the welfare of
cattle and calves have been reviewed by Tarrant
(1990), Trunkfield and Broom (1990), and Knowles
(1999).
Young calves can be stressed (Johnston and
Buckland, 1976; Kent and Ewbank, 1986),
dehydrated, fatigued (Mormede et at., 1982;
Atkinson, 1992) and experience either muscular
exertion or damage (Knowles ef al., 1997 and 1999) as
a result of transport. Transportation of young calves
has also been associated with an increased risk of
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mortality from diseases, such as pneumonia that
occur several weeks post transport (Staples and
Haugse, 1974; Rnowles, 1995). Prolonged transport,
and inadequate and irregular feeding and watering
are considered to be risk factors for 'shipping
fever' in that they reduce the resistance of cattle
sufficiently for viruses, such as bovine herpesvirus
type 1 (BHV-1) to infect the respiratory tract, further
reduce the animal's resistance and allow bacteria,
such as Pasteurella haemolytica, to spread and cause
fibrinous pneumonia (Yates, 1982; Roth and
Kaeberle, 1982). Immunosuppression has been
reported in weaned calves following either
transportation (Blecha et ai, 1984; Murata, 1989;
Murata and Hirose, 1990 and 1991) or administration
of ACTH (Roth et al, 1982). In the present study, the
measurement of specific immunological responses to
BHV-1 inoculation was used as a potential means of
assessing whether various transport conditions were
sufficient stressors to induce clinically relevant
immunosuppression.
This paper examines the effects on the welfare of
calves of a journey structure that represents the
maximum times that young calves could be
transported (i.e. two 9-h journeys separated by a
mid-journey resting or lairage period), compares the
effects of the minimum mid-journey lairage duration
(1 h) with an extended lairage duration of 12 h, and
examines the effects of transporting calves at the
extremes of the space allowances recommended in
current legislation. In particular, the experiment
investigated whether increasing the duration of the
mid-journey lairage provided greater opportunity for
rest and to replenish nutrient energy used and water
lost during the previous journey. The extremes of
space allowances currently recommended for the
transport of young calves were compared to
investigate whether the higher space allowance
provided a greater opportunity for the calves to lie
down and adjust their, posture during a long journey
without reducing their stability and increasing their
risk of stress and injury.
Material and methods
Animals and management
Over a period of 6 months, four batches of 24
unweaned, 10-dav-old male Holstein-Friesian calves
were transported for about 1 h from a livestock
market to the experimental accommodation. The
calves were housed in single pens (1-95 m X 1-24 m)
with straw bedding (replenished at intervals to
ensure a comfortable and dry lying area) and ad
libitum water from a bucket. On the day of arrival,
each calf was offered 21 of an oral rehydration
solution (Energaid, Elanco, Co. Down) and given an
intramuscular injection of oxytetracycline
(Engemycin LA, Intervet, Cambridge, UK). The
calves were offered 2 1 of milk replacer (Denkavit
Herdbuild 297, milk-based protein 210, oil 170, fibre
2-5 and ash 100 g/kg) at 38°C by bucket twice daily
(08:00 and 15:00 h). After 17 days, the calves were
also offered 200 g/day of concentrates (Dalgety
Agriculture Ltd, 2222 Northern County Coarse
Mixture, protein 180, oil 37-5, fibre 70 and ash 80 g/
kg). After a total of 18 to 21 days (depending on
initial consumption of concentrates), 300 g/day of
concentrates were offered, increasing to 700 g/day
after a total of 21 to 25 days.
Treatments
The effects of two 9-h periods of either transport (at a
spade allowance of either 0-375 m2 per calf or
0-475 m2 per calf) or food and water deprivation,
separated by either a 1-h or a 12-h mid-journey
lairage period were investigated. Within each of the
batches, the calves were randomly allocated to one of
four treatment groups (six calves per group),
balanced by initial live weight, and initial serum
concentrations of total gamma-globulin and BHV-1
antibody, as follows: non-transported fed controls
(offered food and water during the transport
periods); non-transported unfed controls (not offered
food and water during the transport periods);
transported at a space allowance of 0-375 m2 per calf;
and transported at a space allowance of 0-475 m2 per
calf. To minimize disturbance to the non-transported
calves, these calves were allocated to a section of the
accommodation separated from the section
containing the transported calves by a central
feeding area. The effects of transport, food and water
deprivation and space allowance during transport
were investigated within each batch but the effects of
different lairage durations were investigated in
different batches in the following order : 1-h, 12-h, 1-
h and 12-h lairage durations. The effects of lairage
duration were compared by starting the second
journey at the equivalent time of day for all batches.
The mean initial live weights (measured on arrival at
the unit) in the four batches of calves were 48 kg (s.e.
1-3), 49 kg (s.e. 0-9), 48 kg (s.e. 1-0) and 48 kg (s.e. 0-7),
respectively, with the mean per treatment group
ranging from 47 kg (s.e. 1-9) to 51kg (s.e. 2-3). The
mean initial serum concentrations (g/1) of total
gamma-globulin in the four batches of calves were
7-6 (s.e. 1-00), 7-3 (s.e. 0-84), 8-2 (s.e. 0-80) and 8-23 (s.e.
0-92), respectively, with the mean value per treatment
group ranging from 5-6 (s.e. 1-53) g/1 to 8-7 (s.e.
2-4) g/1. The mean initial titres of BHV-1 antibody in
the four batches of calves were 165 (s.e. 45-6), 232 (s.e,
109-0), 192 (s.e. 63-1) and 178 (s.e. 55-4) arbitrary units,
respectively, with the mean value per treatment
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group ranging from 33 (s.e. 23-4) to 477 (s.e. 359 0)
arbitrary units.
After each batch of calves had been housed for 8
days, the groups to be transported were loaded at
either 12:00 h (batches with 12-h lairage duration) or
23:00 h (batches with 1-h lairage duration) on to a
single deck, non-articulated vehicle and transported
for 9 h (journey 1). The vehicle (described by
Cockram et al, 1996) consisted of an observation area
and a livestock area divided into two pens by a weld
mesh partition, a metal tread-plate floor and metal
walls. The floor was covered with straw bedding that
was replenished after each journey. In the first and
fourth batches, the calves in the front pen (101 m
long X 2-22 m wide) were transported at a space
allowance of 0-375 m2 per calf and those in the back
pen (1-30 m long X 2-22 m wide) were transported at
a space allowance of 0-475 m2 per calf. In the second
and third batches, the sizes of the pens were adjusted
so that the calves transported at the 0-475 m2 per calf
space allowance were in the front pen and those
transported at the 0-375 m2 per calf space allowance
were in the back pen. Each 9-h journey consisted of
five similar circuits of about 80 min on public roads
at an average speed of 50km/h. The vehicle was
stationary for a period of 25 min after each circuit
with the engine switched off to allow blood sampling
of the calves. Each journey consisted of
proportionately 0-80 A roads (single and dual
carriageway), 0-15 town roads and 0-05 unclassified
roads. The median frequencies of occurrence of
roundabouts, sharp corners, and starts/stops during
a circuit were 14,10 and 6-5, respectively.
When the transported calves had been loaded, the
drinking water was removed from the non-
transported, unfed group and no food was offered to
these calves during the time that the transported
calves were on the vehicle. The non-transported fed
controls had access to drinking water during the time
that the transported calves were on the vehicle and
were offered food at the normal feeding time.
After journey 1, the transported calves were
unloaded and returned to their pens for a lairage
period of either 1 h or 12 h. Drinking water was
offered to all groups at the start of the lairage period.
During the 12-h lairage period, transported groups
and non-transported unfed controls were offered
milk replacer at the start of the lairage period, and all
groups in all batches were offered milk replacer 1 h
before the start of journey 2.
After the lairage period, the transported groups were
reloaded into the same pens on the vehicle and
transported for a further 9 h (journey 2), as described
for journey 1. During journey 2, the non-transported
calves were treated as described above for journey 1.
After journey 2, the transported calves were
unloaded and returned to their pens. Drinking water
and milk replacer were offered to the non-
transported, unfed group and the transported
groups.
The transport treatment therefore involved several
changes to the calves, including removal from their
single pen, loading, group penning at one of two
space allowances, withdrawal of milk replacer and
drinking water, transportation, unloading and return
to their original single pen.
Temperature and relative humidity
Air * temperature and relative humidity were
recorded at 5-min intervals using Tinytalk Data
Recorders (Orion Components, Chichester). In the
four batches, the mean air temperatures in the calf
peris during observation periods were 17°C, 20°C,
15°C and 11 °C, respectively, and in the vehicle during
journeys were 18°C, 21°C, 16°C and 15°C,
respectively. In the four batches, the mean relative
humidities in the calf pens were 0-53, 0-61, 0-73 and
0-73, respectively, and in the vehicle were 0-53, 0-65,
0-73 and 0-61, respectively.
Blood biochemistry
Two days before the start of the transport treatments,
a jugular cannula was inserted into each calf under
local anaesthetic. An extension tube containing
heparinized saline was connected to the cannula and
taped to the dorsal area of the neck to allow manual
blood sampling to be performed ma a three-way tap
with either minimal or no restraint of the calves.
Seven ml of blood was manually collected from all
treatment groups into 'Sarstedt' monovette tubes
containing lithium heparin and 1 ml was decanted
into a tube containing fluoride at the following times:
at 3-h intervals for 24 h before the start of treatment,
immediately before and after the transported calves
were loaded (both journeys), at 1-75-h intervals
during each journey, immediately after unloading
and before feeding (both journeys), at 3-h intervals
during the 12-h lairage (second and fourth batches),
and at 3-h intervals for 24 h after journey 2 (post
treatment). The jugular cannulae were removed 24 h
after the end of journey 2.
The blood samples were refrigerated, and packed cell
volume was measured using a Wifug haemicrofuge
centrifuge. The blood samples were then centrifuged,
and the plasma removed and stored at -20"C for
subsequent analysis. The plasma osmolality was
measured by freezing point depression using a
micro-osmometer (Advanced Micro-Osmometer
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Model 3 MO, Vitech Scientific Ltd, West Sussex).
Plasma Cortisol concentration was measured using a
chemiluminescent enzyme immunoassay (Immulite
Cortisol Kit LK C05) on an Immulite Automated
Analyser (Euro/DPC Ltd, Glyn Rhonwy, Llanberis,
Gwynedd). Bovine standard serum (Multi Sera
Elevated Randox Laboratories Ltd, Antrim) was
assayed and was found to provide Cortisol values
similar to the quoted range for a radioimmunoassay
(RIA) method (Immulite method, 513 nmol/1, RIA
method, 303 to 511 nmol/1). Parallelism was
demonstrated by serial dilution of the bovine
standard serum (513, 251, 127, 63, 37 nmol/1
respectively). The detection limit was 5 nmol/1. The
inter- and intra-assay coefficients of variation were
0-04 and 0-16, respectively. The plasma creatine
kinase activity (Bayer Diagnostics Kit T01-1882-01)
and the plasma concentrations of free fatty acids
(Randox Laboratories Kit FA/115S), glucose (Randox
Laboratories Kit GL 586) and albumin (Bayer
Diagnostics Kit 01137702) were measured on a Bayer
Diagnostics RA-2000 random access chemistry
analyser (Bayer Diagnostics, Basingstoke) at 37°C.
The plasma concentrations of sodium, potassium and
chloride were measured on a Corning 644 electrolyte
analyser using ion-selective reagents.
Behaviour
The behaviour of all calves was recorded using Psion
hand-held computers using the Observer Software
(Noldus Information Technology, 1993 and 1994) for
24 h before the first journey, during both journeys,
during the lairage period, and for 24 h after
transport. Behaviour in the pens was monitored
remotely via a video-monitoring system connected to
a Sprite DX Multiplexer (Dedicated Micros,
Manchester). The behaviour of calves on the
transporter was recorded by direct observation from
the semi-concealed area on the vehicle.
The calves were scan-sampled every 10 min and the
occurrence of the following behaviour was recorded:
standing-still: either alert (head raised, ears pricked)
or non-alert (not involved in any of the following
activities and not performing any other obvious
activity); moving; lying; eating straw; drinking milk
substitute; drinking water; oral investigation (licking
or sniffing the pen walls); ruminating; self-grooming
and interacting with another calf. The proportion of
observations in which each behaviour was observed
(vas calculated for each 3-h observation period
during the 24-h pre- and post-transport periods and
during the 12-h lairage period, for the 1-h lairage
oeriod, and for each of the circuits in journeys 1 and
I. During transportation, orientation (the direction in
vhich an individual was aligned in relation to the
direction of travel) was recorded during each scan.
Except during blood-sampling, the behaviour of
transported calves was also continuously observed
during both journeys, and the following events were
recorded: standing up, lying down, losing balance
(momentary loss of body stability in which calf
moves its foot position to remain standing), falling,
colliding with vehicle wall, colliding with another
calf, being trampled on by another calf; and
expressed as the number of events per calf per hour.
After unloading, the latencies of transported calves
to drink water and to lie down were recorded. The
latency of transported calves and non-transported
non-fed calves to drink milk replacer following both
journeys, and the number of calves requiring
assistance to drink milk replacer, were also recorded.
Heaft rate
Two days before the start of the transport treatments,
each calf was fitted with heart rate recording
equipment (Polar Accurex Plus, Polar Electro Oy,
Kempele, Finland). The area behind the left foreleg
was shaved, gauze and electrode gel were applied to
each transmitter to aid conductivity and the
transmitters and receivers were held in place by an
elastic strap. Heart rate was recorded at 60-s
intervals, beginning 24 h before the start of journey 1
until approximately 12 h after journey 2.
Live weight, food and water intakes
The calves were weighed on the day of arrival at the
experimental accommodation, immediately before
transport, immediately after journey 2, and at 1, 2
and 3 weeks post transport. Daily intakes of milk
replacer, drinking water and concentrates were
recorded for the duration of the experiment.
Immunological measurements
Serum total gamma-globulin concentration. On arrival at
the unit, a blood sample was taken by jugular
venipuncture and the total serum gamma-globulin
concentration in each calf was determined using a
tubometric method (Wolfison et al., 1948).
BHV-1 infectivity in nasal swabs. On the day before
transport, all calves were intranasally inoculated
with the Oxford type strain of BHV-1 at a dose of
approximately 1 X 106 plaque forming units (p.f.u.)
per calf. Nasal swabs were taken immediately before
inoculation and then daily for at least 7 days after
inoculation. The weight of material adhering to each
swab was recorded and the swabs stored ip 5 ml of
transport medium (1 X Hanks [Gibco BRL], 10mg/
ml BSA, 0-4mg/ml sodium bicarbonate (NaHC03),
800 units/ml penicillin, 1 mg/ml streptomycin and
60 units/ml polymixin) at -70°C. Embryonic bovine
tracheal cells (EBTr) were plated onto a 12 well tissue
culture plate (Corning) (1 X 105 cell per ml, 1 ml per
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well) and grown overnight at 37°C in proportionately
0-05 carbon dioxide containing medium 1X199
(Gibco BRL) supplemented with proportionately 0-1
foetal calf serum, proportionately 0-1 tryptose
phosphate broth, 100 units per ml penicillin, 0-1 mg/
ml streptomycin, proportionately 0-01 amphotericin,
proportionately 0008 NaHC03 and 0-1 mol/1
glutamine. The medium was removed from the cells
and dilutions of the nasal swab sample added. The
plates were incubated at 37°C in proportionately 0-05
carbon dioxide for 1 h and overlaid with media
containing carboxymethyl cellulose. This medium
was similar to the growth medium except that the
concentration of foetal calf serum was
proportionately 0-02 and carboxymethyl cellulose
was added to a final concentration of proportionately
0-01. The plates were then incubated at 37°C in
proportionately 0-05 carbon dioxide for a further 3
days and stained with a solution of proportionately
0-001 crystal violet and 0-1 methanol. Plaques due to
virus infection were then counted and the results
presented in p.f.u. per g of material adhering to the
swab.
Lymphocyte stimulation assay. Ten ml heparinized
blood samples were obtained by jugular
venipuncture immediately before intranasal
inoculation with BHV-1, and 7 and 14 days after
inoculation. Lymphocyte stimulation assays were
performed as described by Burrells and Wells (1977)
and Burrells et al. (1995) using the following
antigens: Concanavalin A (Con A) (ICN Biomedical,
High Wycombe, UK) at a final concentration of
7-5mg/ml as a positive control and inactivated BHV-
1 (Psoralin, HRI associates) as the test antigen. The
concentration of virus used for the test was 4 X 107
p.f.u. per ml (pre-inactivation).
Serum BHV-1 antibody assay. Seven ml blood samples
were obtained by jugular venipuncture on the day
that the calves arrived at the unit, immediately
before intranasal inoculation with BHV-1 and at 5-
day intervals over a 20-day period. The clotted
samples were centrifuged and the serum stored at -
20°C. The concentration of serum BHV-1 antibody
was determined by an enzyme linked
immunosorbant assay (ELISA) method as previously
described by Lyaku et al. (1990). The plates were read
using a Dynatech plate reader and results presented
as arbitrary units related to the optical density of
490 mm of the sample read against concentration of a
known positive serum on a standard curve.
Serum ovalbumin antibody concentration. All calves
were given a 1 ml intra-muscular injection of 5 mg
ovalbumin in Freund's incomplete adjuvant on the
day before transport. Serum ovalbumin antibody
measured 5,10,15, and 20 days after was titrated by
using plates (Dynatech 129A) coated with ovalbumin
at a concentration of 10 mg/ml in coating buffer
(0-2 mmol/1 NaHCOj, 0-2 mmol/1 Na2C03).
Health
Rectal temperatures and clinical signs of disease
were recorded daily for the duration of the
experiment. Dehydration was scored on the basis of
skin elasticity and presence of sunken eyes
(Constable et al., 1998). Diarrhoea was assessed by
scoring faecal consistency. Respiratory signs were
assessed by scoring respiration rate, ocular and nasal
discharges, inflammation and lesions of the nasal
mucous membranes and conjunctiva and presence of
cough and salivation. Veterinary treatment was given
wherfappropriate and treatments were recorded. The
calves were euthanased 20 days post treatment and
any gross pathological changes in the lungs were
recorded.
Statistical analyses
The data were grouped into the following
experimental periods: pre-treatment, journey 1,
lairage, journey 2, and post treatment. For the scan-
sampled behavioural data, heart rate data and blood
variables, a repeated measures analysis of covariance
(Laird and Ware, 1982) using the mixed procedure
within SAS version 6 (SAS Institute Inc., Cary, USA)
was used to examine the effects of 'period' (journey
1, lairage, journey 2, post treatment), 'Treatment'
during transport periods (non-transported fed
controls, non-transported unfed controls, transported
at 0-375 m2 per calf space allowance and transported
at 0-475 m2 per calf space allowance), and 'lairage'
duration (1-h or 12-h). In addition to the main effects,
the following interactions were examined: treatment
X period, lairage X treatment, and lairage X
treatment X period. As the responses of the calves
may have been correlated within batches, batch
effects were fitted in each model as random. Thus, all
treatment and lairage effects were compared against
a background of between-batch variation. To allow
for between-treatment differences prior to the start of
the transport period, pre-treatment values were used
as a covariate, with analyses carried out on
differences between pre-treatment values and means
of values in subsequent periods. Where appropriate,
data were log-transformed to maximize normality.
These analyses allowed the following specific
comparisons to be made: (a) treatment differences
during each period, (b) lairage differences and (c)
differences between the first and second journeys.
These follow-up analyses produced many pair-wise
comparisons. To avoid the problems of multiple
testing, a Bonferroni adjustment (in which the P
values are multiplied by the number of comparisons
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of the effect) was applied to the resultant P values.
Where the main effects were non-significant (e.g.
treatment X period), but the corresponding estimate
comparisons produced significant effects, treatment
effects are reported as being statistically significant,
as these latter comparisons were of primary interest.
Where it was considered to be appropriate to
investigate treatment effects at the following specific
time-points: (a) each circuit of both journeys and
each 3-h post-treatment observation period for scan-
sampled behavioural data and (b) each blood sample
on both journeys and during the 24-h post-treatment
period, the same repeated measures model was used,
except that the observation period (or sample
number) was substituted for the period effects. The
same overall method was used to analyse live-
weight change, water intake, immunological
measurements and rectal temperature, except that
the post-treatment period was divided into
appropriate periods. The effect of space allowance
during transport on the median frequency of
continuously recorded events was examined during
journey 1 using Mann-Whitney tests. The effects of
lairage duration on the median frequency of events
during journey 2 was analysed using Mann-Whitney
tests. The effects of transport, food and water
deprivation, space allowance during transport and
lairage duration on the incidence of respiratory
disease and the incidence of dehydration/diarrhoea
during the post-treatment period were investigated
as a stratified cohort study using Win Episcope 1.
Spearman's rank correlations were performed to
investigate relationships between some
physiological, immunological and health
measurements.
During the week before the start of the treatment
period of the fourth batch, some calves had clinical
signs of dehydration and diarrhoea. Four calves were
replaced and two calves allocated to the fed control
group were removed from the experiment.
Results
4
Statistical significance of main effects and
interactions are shown in Table 1. Table 2 shows
effects of transport, lairage duration during
transport, space allowance during transport and food
and water withdraw on mean values of blood
chemistry, lying behaviour and water intake of
young calves. Table 3 shows effects of transport,
space allowance during transport and food and
water withdrawal on further mean values of blood
chemistry and live weight of young calves.
Table 1 Statistical significance of main effects and interactions of lairage duration (1 h and 12 h) (L), treatment (space allowance
during transport, non-transport with normal food and water, and no food and no water) during transport period (T), and experimental
period (pre-treatment, journey 1, lairage, journey 2 and post-treatment) (P) on young calves
Significance
LX
L T p TXP LXT TXP
Plasma Cortisol concentration »»» ***
Plasma creatine kinase activity ** ** » «♦ **
Packed cell volume »»» ***
Plasma albumin concentration ,
Plasma osmolality * »
Plasma sodium concentration if
Plasma potassium concentration *
Plasma chloride concentration ***
Plasma glucose concentration
Plasma free fatty acid concentration ***
Lying down (mean proportion of scans) «■** *** *«•* »»»
Heart rate *
Live-weight change (day 0 to day 20 post treatment) ***
Water intake (day 1 post treatment) *** **
**
BHV-1 infectivity in nasal swabs *
Lymphocyte stimulation assay
Serum BHV-1 antibody titre **» * **
Serum ovalbumin antibody titre
Rectal temperature *+*
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Table 2 Effects of transport, lairage duration during transport, space allowance during transport, and food and water withdrawal on









No transport Transport No transport Transport
Space Space
No food allowance allowance
Normal and no 0-375 m2 0-475 m2 Normal
feeding water per calf per calf feeding
Space Space
No food allowance allowance
and no 0-375 m2 0-475 m2















Pre-treatment 180-6 167-6 167-6 152-3 170-8 149-1 161-1 146-6
Journey 1 168-3'' 163-4 212-7 148-5 165-6" 155-4 177-7 185-9
Lairage 148-6" 150-0 224-8b 146-6b 148-8* 149-1 160-9" 155-0"
Journey 2 146-3" 159-5 240-0" 158-0b 144-4" 145-4 144-0b 138-1"
Post-treatment 148-6" 164-3b 207-3b
i
169-7* 138-7" 156-lb 134-9" 136-3"
Pre-treatment 277-6 276-9 280-2 281-9 288-0 282-6 282-8 283-9
Journey 1 276-4 273-8 281-7 281-0 286-5 282-0 283-7 281-9
Lairage 277-8 274-0 282-2 281-0 282-6 283-0 283-3 281-4
Journey 2 278-5 273-4 283-4 282-9 283-1 281-7 283-2 280-1
Post-treatment 278-8 276-5 282-8 281-9 285-0 282-0 282-7 279-7
Pre-treatment 4-81 4-73 4-68 4-47 4-49 4-65 4-66 4-61
Journey 1 4-84 4-87 4-77" 4-69" 4-54 4-61 4-42* 4-47*
Lairage 4-77 4-78 4-76 4-81 4-46 4-68 4-67 4-70
Journey 2 5-08 5-09 5-01" 4-99y 4-51 4-60 4-49" 4-58"
Post-treatment 4-88 4-79 4-97 4-80 4-57 4-57 4-51 4-61
Pre-treatment 4-69 4-73 4-73 4-50 5-44 5-14 5-07 5-11
Journey 1 4-52b 4-40" 4-19" 3-96" 5-20b 4-70* 4-60" 4-46"
Lairage 4-08 4-48 3-93 3-80 4-75 4-92 5-15 4-90
Journey 2 4-96 4-77" 4-94T 4-67" 4-96 4-86" 4-90" 4-79"
Post-treatment 4-80 4-95 4-89 4-65 4-86 4-94 5-01 4-74
Pre-treatment 0-31 0-28 0-23 0-27 0-25 0-26 0-21 0-21
Journey 1 0-33" 0-32"x 0-42"" 0-39"" 0-13* 0-25"" 0-33b" 0-33""
Lairage 0-44b 0-38") 0-441 0-381 0-37*> 0-24*1 0-27P 0-23P
Journey 2 0-25* 0-22"" 0-25bx 0-27t"1 0-18" 0-20" 0-26"x 0-28"x
Post-treatment 0-25 0-21 0-24 0-24 0-29 0-22 0-23 0-25
Pre-treatment 0-76 0-77 0-72 0-73 0-74 0-74 0-75 0-77
Journey 1 0-83b 0-88b 0-34"" 0-41" 0-71b 0-62b 0-22" 0-37"
Lairage 0-17"P 0-32P 0-44bP 0-32bP 0-76*1 0-821 0-87"i 0-83"i
Journey 2 0-78" 0-75b 0-52"'' 0-54*" 0-66b 0-76" 0-50b" 0-64""
Post-treatment 0-80 0-80 0-87 0-84 0-77 0-80 0-81 0-80
Pre-treatment 0-46 0-62 0-22 0-35 0-43 0-54 0-50 0-35
Lairage 0-10 0-01 0-03 0-00 0-21 0-39 0-22 0-21
Day 1
0-60b 0-53"post treatment 0-14" o b-l.00 0-25" 0-25* 0-39* 0-29*
12 12 12 12 10 12 12 12
*■" Different superscripts within a row indicate a significant difference between treatments within an experimental period
(P < 0-05).
p-i Different superscripts within a row indicate a significant difference between lairage durations within a treatment
(P < 0-05).
Different superscripts within a column indicate a significant difference between journey 1 and journey 2 within a
treatment (P < 0-05).
Plasma Cortisol concentration concentration was significantly greater in
Treatment comparisons during experimental periods transported calves than in control calves (P < 0-001;
showed that during journey 1, plasma Cortisol Figure 1).
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able 3 Effects of transport, space allowance during transport, and food and water luithdrazoal on mean values of blood chemistry and
ye xveight ofyoung calves
reatment No transport Transport
reatment during No Space Space
Tansport period food allowance allowance
Normal and no 0-375 m2 0-475 m2
ariable Experimental period feeding water per calf per calf
lasma Cortisol concentration (nmol/1) Pre-treatment 15-9 23-6 12-7 17-9
Journey 1 12-5" 16-3a 25-0by 25-2b)
Lairage 13-5 15-6 10-8 17-9
Journey 2 10-3 14-0 16-4* 18-0*
Post treatment 11-0 12-4 13-1 13-6
acked cell volume Pre-treatment 0-364 0-364 0-369 0-375
Journey 1 0-354)' 0-349y 0-358 0-364
Lairage 0-354 0-348" 0-364b 0-374b
Journey 2 0-343* 0-339"* 0-354b 0-363b
Post treatment 0-343 0-332" 0-349b 0-362b
lasma albumin concentration (g/1) Pre-treatment 31-7 32-6 32-2 31-5
Journey 1 31-6 32-7 32-7 32-0
Lairage 31-5 32-5 32-8 32-2
Journey 2 32-3 32-3 33-3 32-0
Post treatment 32-0 32-1 32-2 31-9
lasma sodium concentration (mmol/1) Pre-treatment 136-0 134-1 136-2 135-5
Journey 1 135-3 133-5 136-7 135-9
Lairage 135-1 133-7 136-5 135-8
Journey 2 135-4 133-5 136-2 135-3
Post treatment 136-3 134-3 135-9 135-2
lasma chloride concentration (mmol/1) Pre-treatment 102-1 100-7 101-8 101-4
Journey 1 101-6 100-5 102-2 101-9
Lairage 102-4 101-3 102-4 102-0
Journey 2 101-6 100-1 101-7 101-4
Post treatment 102-3 101-1 102-4 101-4
ive weight (kg) Pre-treatment 48-1 50-1 49-8 49-2
Day 20
post treatment 55-0 56-2 55-2 55-0
o. of calves 22 24 24 24
' Different superscripts within a row indicate significant differences between treatments within an experimental period
' < 0 05).
' Different superscripts within a column indicate significant differences between journey 1 and journey 2 within a
eatment (P < 0 05).
asma creatine kinase activity
•eatment comparisons during experimental periods
towed that the increase in the mean plasma creatine
nase activity from pre-treatment values was
gnifkantly greater in transported calves than in fed
mtrols during the lairage period, during journey 2
id during the 24-h post-treatment period (Figure 2;
<0-05).
ehydration indicators
icked cell volume. There were significant effects of
eatment and period (P < 0-001) but no significant
eatment X period interactions.
asma albumin concentration. There were no
gnificant lairage duration or treatment effects
during the experimental periods. However, after
8-75 h of journey 1, the change in plasma albumin
concentration from pre-treatment values was
significantly greater among transported calves (to
32-6 g/1) than among non-transported calves (to
31-2 g/1) (P < 0-05).
Plasma osmolality. Although there was a significant
lairage X treatment X period interaction (P < 0-05),
there were no significant treatment effects during the
experimental periods.
Plasma sodium concentration. Although there was a
significant treatment X period interaction (P < 0-05),
there were no significant treatment differences
during the experimental periods. However, during
o. Km tho Rritich I ihrnru _ "Tho ui/nrlrl'c knnwlorino" \nr\*r\M hi Ilk
Space allowance and lairage during transport of calves 349
50-1
Pre-transport Journey 1 Lairage Journey 2 Post transport
(24 h) (9h) (lh) (9 h) (24 h)
Treatment period (not to scale)
Figure 1 Effect of transport with a 1-h mid-journey lairage period on the mean plasma Cortisol concentration: transported
calves (—•—) and non-transported controls (—□—). Vertical bars show s.e.
journey 1, the plasma sodium concentration was calves (137 mmol/1) than in fed controls (135 mmol/
significantly greater after 5-25 h of transport in 1) (P < 0-01).
transported calves (136 mmol/1) than in unfed
controls (133 mmol/1) (P < 0-05), and after 8:75 h of Plasma potassium concentration. Although there was a
transport it was significantly greater in transported significant lairage X treatment X period interaction
300 -i
0 i '
Pre-transport Journey 1 Lairage Journey 2 Post transport
(24 h) (9h) (lh) (9 h) (24 h)
Treatment period (not to scale)
Figure 2 Effect of transport with a 1-h mid-journey lairage period on the mean plasma creatine kinase activity: transported
calves (—•—) and non-transported fed controls (—O—).
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Pre-transport Journey 1 Lairage Journey 2 Post transport
(24 h) (9h) (lh) (9 h) (24 h)
Treatment period (not to scale)
Figure 3 Effect of transport and food restriction with a 1-h mid-journey lairage period on the mean plasma glucose
concentration: transported calves (—•—) and non-transported unfed controls (—O—) and non-transported fed controls
(—o-).
(P < 0-001), there were no significant treatment
differences during the experimental periods.
Plasma chloride concentration. There were no
significant treatment effects during the experimental
periods.
Nutritional indicators
Plasma glucose concentration. During journey 1, there
was a greater decrease in the mean plasma glucose
concentration from pre-treatment values in
transported than in fed control calves (P < 0-05;
Figure 3).
Plasma free fatty acid concentration. During both
journey 1 and journey 2, the difference between the
pre-treatment free fatty acid concentration and the
mean concentration during transport was greater in
transported calves than in either fed or unfed
controls (P < 0-01; Figure 4). After 8-75 h of food
restriction, the plasma free fatty acid concentration in
unfed controls was significantly greater than in fed
controls (P < 0-05).
Lying behaviour
During transport, the calves spent proportionately
0-56 of observations standing stationary,
proportionately 0-44 of observations lying down
and less than 0-01 of observations moving. As the
time spent standing and time spent lying down
were inversely proportional, only the data for time
spent lying down were statistically analysed.
Treatment comparisons during experimental periods
showed that, during both journey 1 and journey 2,
transported calves spent significantly less time lying
down than control calves (P < 0-01; Figures 5 and 6).
There were no significant effects of space allowance
during transport on the time spent lying down
during the transport period. However, during the
fourth circuit of journey 1, calves transported at the
0-475 m2 per calf space allowance spent significantly
more time lying down than those transported at the
0-375 m2 per calf space allowance (P < 0-01; Figure
7). During the lairage period, transported calves
spent significantly more time lying down than fed
controls (P < 0-01). In all treatments, calves spent a
significantly greater proportion of observations
lying down during the 12-h lairage period than
during the 1-h lairage period (P < 0-01; Figures 5
and 6). However, there was no effect of lairage
duration on lying behaviour either during journey 2
or post treatment (Figures 5 and 6). Transported
calves spent a greater proportion of time lying
during journey 2 than in journey 1 (P < 0-001).
There were no overall treatment effects on the mean
lying behaviour during the 24-h post-transport
period. However, 6 to 9 h after journey 2, fed
controls spent significantly less time lying down
than either transported calves or unfed controls
(P < 0-05).
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0-0 1 , , '
Pre-transport Journey 1 Lairage Journey 2 Post transport
(24 h) (9 h) (12 h) (9 b) (24 h)
Treatment period (not to scale)
Figure 4 Effect of transport and food restriction with a 12-h mid-journey lairage period on the mean plasma free fatty acid
concentration: transported calves (—•—) and non-transported unfed controls (—O—) and non-transported fed controls
(-0-).
Behaviour during transport and lairage these behaviours were not statistically analysed. The
The calves engaged in few behavioural activities calves spent proportionately 0-13 of observations in
during transport and therefore treatment effects on an alert state i.e. with their head raised and ears
Pre-transport Journey 1 Lairage Journey 2 Post transport
(24 h) (9 h) (lh) (9 h) (24 h)
Treatment period (not to scale)
Figure 5 Effect of transport with a 1-h mid-journey lairage period on the mean proportion of scans per observation period
(see text for details) during which the calves were observed lying down: transported calves (—•—) and non-transported
controls (—□—). Vertical bars show s.e.
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Pre-transport Journey 1 Lairage Journey 2 Post transport
(24 h) (9h) (12 h) (9 h) (24 h)
Treatment period (not to scale)
:igure 6 Effect of transport with a 12-h mid-journey lairage period on the mean proportion of scans per observation period
see text for details) during which the calves were observed lying down: transported calves (—•—) and non-transported
ontrols (—□—). Vertical bars show s.e.
tricked, and 0-03 of observations performing oral observations either ruminating, self-grooming or
nvestigation. They spent less than 0-01 of interacting with another calf. There was some
(24 h) (9h) (12 h) (9 h) (24 h)
Treatment period (not to scale)
igure 7 Effect of space allowance during transport with a 12-h mid-joumey lairage period on the mean proportion of scans
er observation period (see text for details) during which the calves were observed lying down: transported calves space
llowance of 0-375 m2 per calf (—♦—) and at 0-475 m2 per calf (—A—).
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evidence of an increase in alert behaviour (compared
with pre-treatment values) among transported calves
during journey 1 (mean proportion of observations
was 017 compared with an overall mean of 0-09) but
not during journey 2.
The most common orientation observed during
transport was perpendicular to the direction of
travel. At the 0-475 m2 per calf space allowance,
calves tended to orientate themselves either parallel
to or perpendicular to the direction of travel (mean-
proportion of observations = 0-36 and 0-37,
respectively). Calves transported at the 0-375 m2 per
calf space allowance tended to align themselves
perpendicular to the direction of travel (mean
proportion of observations = 0-54), whereas parallel
orientations were less common (mean proportion of
observations = 0-15).
During journey 1, there were no significant effects of
space allowance on the median frequencies of losses
of balance (4 events per calf per h), traumatic events
i.e. falls + collisions with vehicle + collisions with
another calf (1 event per calf per h), trampling (1
event per calf per h), and changes in posture (1 event
per calf per h). During journey 2, when space
allowance treatments were pooled and the effects of
lairage duration were analysed at the batch level,
there were significant effects of lairage duration.
During journey 2, after a 1-h lairage, the median
frequencies of losses of balance (4 events per calf per
h) and trampling (2 events per calf per h) were
greater than after the 12-h lairage (median
frequencies of losses of balance were 2 events per calf
per h and trampling were 0-5 events per calf per h)
(P < 0-05).
Latency to drink water, drink milk replacer and lie down
post transport
The mean time taken by transported calves to first
drink (put their head in the water bucket) when they
were returned to their pens after either journey was 6
min (range 0 to 54 min). Proportionately 0-57 of the
transported calves drank water before lying down
and there was no apparent effect of lairage duration
on the proportion of calves that drank water before
lying down. When offered milk replacer after a
journey, the time taken by most transported calves to
start to drink after the bucket was placed in front of
the pen was between 0 and 35 s. However, after
journey 1, seven transported calves were assisted to
drink milk replacer (because they did not get up
from a lying posture when the milk replacer was
offered), compared with one unfed control. After
journey 2, six transported calves were assisted to
drink milk replacer, compared with two unfed
controls. There was no significant difference between
journeys 1 and 2 in the mean (23 min, range 0 to 93
min) time taken to lie down when the calves were
returned to their pens. There was no effect of lairage
duration on the time taken to lie down after journey
2. However the time taken for the calves to first lie
down in their pens after journey 2 was shorter in
calves that had been transported at the 0-375 m2 per
calf space allowance (mean latency was 966 s) than in
those that had been transported at the 0-475 m2 per
calf space allowance (mean latency was 2022 s)
(P < 0-01).
Heart rate
Although there were significant differences between
some treatments in the change in heart rate from pre-
treatment values during journey 1, these differences
were not consistent and there was no difference
between transported calves (mean 82 beats per min)
and fed control calves (mean 86 beats per min). The
heart rate values and pattern were similar during the
transport periods to those pre- and post-transport, as
shown by the example in Figure 8.
Live weight, food and water intakes
Transported calves lost proportionately 0-03 of their
live weight during the transport and lairage
treatment period, whereas fed controls gained
proportionately 0-02 of their live weight during this
period (P < 0-01). There were no other significant
treatment effects on live-weight change during either
the transport and lairage period or the post-transport
period. With very few exceptions, the calves
consumed all the milk replacer that they were offered
and there were no significant treatment effects on
concentrate intake during the post-treatment period
(mean intake was 255 g per calf per day). There was
no significant difference between transported calves
and fed controls in the change in water intake from
pre-treatment to that either during lairage or during
the first 24-h post treatment. There was a decrease in
water intake (by 0-081 per calf per meal) from the
pre-treatment values during the first 24-h post
treatment in transported calves but not in unfed
controls (P < 0-05).
Immunological measurements
BHV-1 infectivity in nasal swabs. BHV-1 was not
detected in the nasal swabs from all of the calves.
Only two calves from the fourth batch had detectable
BHV-1 in the nasal swabs, so this batch was excluded
from the statistical analysis. The proportion of calves
with detectable BHV-1 in the nasal swabs was
significantly greater in transported calves (0-81) than
in control calves (0-58)' (chi-square = 3-93, d.f. = 1,
P < 0-05). Among calves with detectable BHV-1 in the
nasal swabs, the concentration increased between 1
and 5 days after the start of the transport period and
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Journey 1 Journey 2
(9 h) (9 h)
Lairage
(1 h)
Treatment period (not to scale)
Post transport
(24 h)
igure 8 Example of heart rate recording from a calf transported at 0-475 m2 per calf space allowance with a 1-h mid-journey
iirage period.
tere was a significant treatment X period interaction
P < 0-05). However, there were no significant
ifferences between transported calves and controls.
ymphocyte stimulation assay. There was no
rtnphocyte stimulation response to the BHV-1
ntigen and no treatment effects on the mean
^mphocyte response to Con A at either 6 or 13 days
■ost transport.
treatment values in transported calves but not in
control calves (P < 0-05; Figure 9). There were no
significant treatment effects on rectal temperature
during the subsequent post-treatment period.
erum BHV-1 antibody titre. Although there was a
airage X treatment X period interaction (P < 0-01),
here were no significant treatment effects on the
hange in the mean serum BHV-1 antibody titre from
're-treatment to that at either 4, 9,14 or 19 days post
ransport.
'erum ovalbumin antibody titre. Although there was a
lear antibody response to the injection of
'Valbumin, there were no significant treatment
ffects on the change in the mean serum antibody
itre from pre-treatment to that at either 4, 9,14 or 19
iays post transport.
iealth
lectal temperature. Although rectal temperatures
aken during lairage were similar to those pre-
reatment, during the 1st week post transport there
vas an increase in rectal temperature from the pre-
Respiratory disease. There was no effect of either
lairage duration or space allowance during transport
on die incidence of respiratory disease (either
number of calves with clinical signs of respiratory
disease or number of calves treated for respiratory
disease) in transported calves during the post-
transport period. There was no significant effect of
transport on the proportion of calves that received
veterinary treatment for respiratory disease during
the post-transport period (percentage of transported
calves that received veterinary treatment for
respiratory disease was 48% and the percentage of
control calves that received veterinary treatment was
30%). However, as shown by Figure 10, there was
some evidence that transport increased the risk of
respiratory disease. When respiratory disease was
classified as the occurrence of at least one of the
following clinical signs: increased respiration rate,
obvious serous or mucous nasal discharge, obvious
serous or mucous ocular discharge or cough, the
relative risk that transport was associated with
respiratory disease during the 2- to 8-day post-
transport period was 1-335 (P0.95 confidence intervals
were 1-020 to 1-746) and during the 9- to 20-day post-
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Post transport
No. of days
-i 1 I i
14 16 18 20
Figure 9 Effect of transport on the mean rectal temperature of calves: transported calves (—•—) and non-transported
controls (—□—). Vertical bars show s.e. Vertical arrow indicates the timing of the BHV-1 intranasal inoculation.
transport period was 1-221 (P0 95 confidence intervals for more transported calves (69%) to show gross





































FigurelO Effect of transport on the mean proportion of calves with clinical signs of respiratory disease: transported calves
> * ) ancl non-transported controls (—□—). Vertical bars show s.e. Vertical arrow indicates the timing of the BHV-1
intranasal inoculation.
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rntrol calves (55%) this difference was not
.atistically significant. The rectal temperature of
ansported calves during the 1st week post-
ansport was significantly correlated with the 1st
'eek post-transport clinical respiratory disease score
•s 0-649, P < 0-01). However there were no other
gnificant correlations between: post-transport
leasures of immunity and clinical signs of disease;
ost-transport measures of immunity and stress
;sponses to transport; and post-transport clinical
gns of respirator}' disease and stress responses to
■ansport.
Rehydration and diarrhoea. There was no effect of
ither lairage duration or space allowance during
■ansport on the incidence of either dehydration
rlinical signs of dehydration i.e. sunken eyes and
>ss of skin elasticity) or diarrhoea (faecal
onsistency) in transported calves during the post-
•ansport period. There was also no effect of
•ansport on the incidence of either dehydration or
iarrhoea post-transport (percentages of transported
nd control calves with respectively either signs of
ehydration or liquid faeces were 42% and 46%
.uring the 1st week post transport and 12% and 11%
:om 9 to 20 days post transport). Only three calves
squired veterinary treatment for dehydration
uring the post-treatment period.
discussion
he plasma Cortisol response to the first 9-h road
jurney indicated that one or more components of
ne transport treatment were a stressor for young
alves. The absence of a transport effect on the mean
ieart rate was consistent with previous studies
Stephens and Toner, 1975; Knowles et ai, 1997).
here was no evidence that food and water
withdrawal for a 9-h period affected either the
'lasma Cortisol concentration or the heart rate,
iinsbergen et al. (1994) also found no effect of fasting
alves for up to 24 h on either plasma Cortisol
oncentration or heart rate. As in studies of
imulated transport (Agnes et al., 1990), the peak in
he plasma Cortisol concentration occurred during
he first part of the journey, rather than at the end of
he journey. Although a delayed response to either
oading, change from single to group penning or
onfinement may have contributed to the peak
ortisol response measured after the first circuit,
here was no evidence of a treatment effect in the
>lood sample taken after loading but before the start
>f the journey. The decrease in plasma Cortisol
oncentration between the two journeys suggests
ither that the second 9-h journey was a less stressful
•xperience than the first journey or that the calves
vere less able to produce an adrenal response during
he second journey.
There was some evidence from raised plasma
creatine kinase activity during transport to indicate
that the calves experienced either increased muscular
exertion or trauma associated with transport. The
lack of a significant difference in the plasma creatine
kinase activity between transported calves and
controls during journey 1, but a significant difference
between these treatments during journey 2 and the
post-transport period, may have been due to the
relatively slow release and slow clearance rate of the
enzyme (Anderson et al., 1976).
The behaviour of the calves immediately after
transport was variable and suggested that some of
the calves were either thirsty and seeking drinking
water, f or hungry and seeking milk replacer;
however, for some calves the priority was to lie
down and rest. In the environmental conditions of
this experiment, the calves did not show any
biochemical or clinical signs of dehydration either
during the two 9-h journeys or during the two 9-h
periods without food and water. The significant
differences between transported and control calves in
the plasma concentrations of albumin and sodium in
the last blood sample taken during journey 1
occurred because of slight falls in the plasma
concentrations of the control calves rather than
because of an increase in the transported calves. The
plasma concentrations of albumin and sodium, and
the plasma osmolality were within their normal
ranges and not indicative of dehydration (Kaneko et
al., 1997). In transported calves, the lower post-
transport water intake compared with that pre-
transport, suggests that the calves did not drink
additional water to replace a water deficit
accumulated during transport.
The major factor that appeared to affect the plasma
free fatty acid concentration was the time since the
last meal. Peak plasma free fatty acid concentrations
coincided with the longest time since feeding. This
finding is consistent with Kinsbergen et al. (1994)
who also showed an increase in the plasma free fatty
acid concentration during fasting and a subsequent
fail after feeding. In fasted calves, a rise in plasma
free fatty acids is associated with a mobilization of
fat reserves in response to an energy deficiency
(Kinsbergen et al., 1994; Feiber and Golay, 1995;
Penicaud et al., 2000). A second, but less important
factor affecting the plasma free fatty acid
concentration was the transport treatment.' In
transported calves, the plasma free fatty acid
concentration rose earlier and reached a higher peak
during both journey 1 and journey 2 than in unfed
controls. This may have been due to a stress response
to the transport treatment resulting in increased
plasma catecholamine concentrations that mobilized
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fat reserves (Frohli and Blum, 1988). However, the
greatest difference in the plasma free fatty acid
concentration between transported and unfed
controls was at the end of the journey, whereas the
stress response was greatest at the start of the
journey, suggesting that this effect was more likely to
have been due to a greater energy demand in the
transported calves compared with that in the non-
transported unfed controls. During journey 1 there
was a fall in the plasma glucose concentration,
howe%rer the rectal temperatures taken during lairage
were similar to those pre-treatment indicating that
the calves had not become hypothermic as a result of
an energy deficiency during transport. Differences in
feeding times and the rise in the plasma glucose
concentration that follows after feeding (Kinsbergen
et ah, 1994), are the likely explanations for the
differences in the plasma glucose concentration both
between treatment groups and between journey 1
and journey 2.
Although at both space allowances there was
sufficient floor space for the calves to lie down (in
both space allowances, for short periods of time all
calves in a pen lay down), there was less lying
behaviour in transported calves than in control
calves. This suggests that some aspect of
transportation was inhibiting lying behaviour. As the
duration of transport increased, either within a
journey or during the second journey, there was
more lying behaviour which suggests that either the
calves became habituated to some extent or became
fatigued and the motivation to lie down overcame
the inhibitory influences of transportation. During
the lairage period, transported calves spent
significantly more time lying down than fed controls
and the amount of lying behaviour was greater
during journey 2 than during journey 1. This
suggests that the calves may have become fatigued;
however during journey 2, the mean proportion of
observations during which the calves were lying
down was less than 0-6 and although 3 to 12 h post
transport it was greater than 0-9, there tvas no
significant difference between the post-transport
lying behaviour of transported and control calves.
The mean time of 23 min (range 0 to 93 min) taken by
transported calves to first lie down when they were
returned to their pens after either journey 1 or
journey 2 suggests that most calves were not
completely exhausted after their journey.
Transported calves tended to take longer to lie down
after journey 2 than after journey 1, possibly due to
the increased time spent lying down during journey
2 compared with journey 1. Fit and healthy calves
would normally drink their milk replacer almost
immediately. The delay of some of the transported
calves in getting up from a lying posture to drink
and the failure of some of these calves to voluntarily
get up from a lying posture to drink is an indicator
that at least some of the transported calves were
fatigued after the journey.
The most common orientation observed during
transport (perpendicular to the direction of travel)
may have afforded the most stability during
transport. In both journeys, calves transported at the
lower space allowance tended to align themselves
less often either directly towards or away from the
direction of travel than calves at the higher space
allowance. This may have been a consequence of
reduced floor area to adjust their posture, but it may
also have been a consequence of the lower pen
length at the lower space allowance than at the
higher space allowance. At the greater space
allowance, which allowed calves more opportunity
to adopt their preferred orientations, calves tended to
orientate themselves either perpendicular or parallel
to the direction of travel.
There were few significant effects of space allowance
on the behavioural and physiological responses of
the calves to transport. There was no evidence that
the calves were at greater risk of injury at the higher
space allowance due to loss of stability in response to
vehicle movements.
There were few significant effects of lairage duration
on the physiological and behavioural responses of
the calves. To compare the effects of lairage duration
at equivalent times of day during journey 2 and post
transport, journey 1 had to be started at 12:00 h for
the 12-h lairage treatment and at 23:00 h for the 1 h
lairage treatment. These differences in starting time
for journey 1 could have confounded any effects of
lairage duration, however, there was no evidence
that this was the case. Although the median number
of starts/stops during journey 1 was five with a
starting time of 12:00 h and two with a starting time
of 23:00 h, there were no significant differences
between the starting times in the median frequency
of losses of balance or traumatic events experienced
by the calves during journey 1. It was also possible
that the responses to journey 1 could have been
influenced by circadian rhythms; however, the
patterns of both lying behaviour and plasma Cortisol
concentration were similar for each starting time. A
12-h mid-journey lairage period provided additional
time for calves to lie down and rest as compared
with a short mid-journey lairage period of 1 h.
However, a 1-hmid-journey lairage period compared
with a 12-h mid-joumey lairage did not appear to be
detrimental to the welfare of the calves during the
subsequent 9-h journey or post transport. The only
evidence that the calves were more fatigued after the
hw tho Rritich I ihrarv - "Thp world's knowledoe" WWW.bl.Llk.
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rtorter lairage period was a slight increase in the
•equency of losses of balance and trampling during
ie second journey. Although the calves did spend
ignificantly more time lying down during the 12-h
iirage period than during the 1-h lairage period,
aere was no effect of lairage duration on lying
ehaviour either during the subsequent 9-h journey
or post treatment.
Vs there were no significant effects of a 9-h period
without food and water on the biochemical
neasurements of dehydration, there was no major
ienefit in providing a prolonged time to drink
luring the lairage period. There was no significant
lifference in the free fatty acid response of the calves
o a subsequent 9-h transport period after they were
ed once during a 1-h mid-journey lairage period
.•ompared with being fed both at the start and the
aid of a 12-h mid-journey lairage period. Offering
:alves milk replacer, either immediately before or
ifter transport did not result in diarrhoea and
iehydration. However, in the circumstances of this
ixperiment, the milk replacer offered during lairage
md immediately post transport was the same
nutritional composition, was prepared in the same
way and was offered at the same feeding level, as
aefore transport.
Another difference between the lairage treatment
here and that likely to be experienced by calves
transported commercially was that for experimental
reasons, the transported calves were returned to their
original single pens and were individually offered
food and water by bucket, whereas commercial
practice would normally involve group penning in a
novel environment and food and water would be
offered by either bucket, trough or teat. If group
penned, die behaviour of the calves is likely to be
influenced by social facilitation and social
interactions. However, if legislation for staging
points (European Council, 1997) is followed, there
should be facilities and staff to ensure that each
liquid fed calf is offered water and sufficient
appropriate food to satisfy its bodily needs during its
stay and for the expected duration of its journey to
the next feeding point.
Although there was an obvious Cortisol response to
the transport treatment, there was little evidence of
immunosuppression post transport. The absence of
both a lymphocyte stimulation response to the BHV-
1 antigen and a detectable antibody response to the
BHV-1 virus inoculation, but virus recovery from
nasal swabs and a clinical response after BHV-1
inoculation was most likely due to the presence of
maternal antibodies in some of the calves (Bradshaw
and Edwards, 1996). It was expected that the use of
the Oxford strain of BHV-1 would provide an
immunological response in calves with maternal
antibodies and permit virus recovery, particularly if
the calves had become immunosuppressevi as a
result of the transport treatments. Although, tn the
circumstances of this study, the immunological
responses of the calves to inoculation with. 8HV-1
did not provide a suitable model on which to
evaluate the effects of different transport treatments,
the other immunological responses that were not
affected by the presence of maternal antibodies did
allow the treatment effects to be assessed. However,
there were no treatment effects on the general
responsiveness of either the humoral or the cellular
components of the immune system.
4
There was some evidence that the transport
treatment adversely affected the health of the calves
post transport. The effects of the transport treatment
were raised rectal temperatures and greater clinical
signs of respiratory disease post transport. Tiie rise
in rectal temperatures in the transported calves
compared with pre-treatment levels and With non-
transported controls indicates a greater clinical
response to either the BHV-1 inoculation or other
infections. There was no evidence that the
inoculation resulted in either pyrexia or other clinical
signs during transportation and it was unlikely that
the BHV-1 inoculation affected the plasma Cortisol
concentration of the calves (Arthington et 1997).
However, the post-transport clinical response of the
calves to the BHV-1 inoculation may have
exaggerated some effects of the transport treatment
(e.g. calves with an active infection after BHV-1
inoculation can experience a negative nitrogen
balance (Orr et al., 1988)) and the risk of post-
transport respiratory disease in the transported
calves may have been greater than in healthy calves
that had not been exposed to a viral challenge before
transportation. Respiratory disease can reduce live-
weight gain (Donovan et al., 1998) and the
respiratory disease that occurred during ||,e post-
transport period may have affected the subsequent
live-weight gain (0-3 kg/day). Although the calves
lost live-weight during the transport and lairage
treatments and there was some evidence that the
transport treatment affected health, there was no
effect on subsequent live-weight gain.
The main conclusions from this study are that an
aspect of the transport treatment was a stressor to the
calves, and the effect of this stressor appeared to
decrease with journey duration and during a
subsequent journey. With the type of feeding used,
the time since the last meal was an imporlnnt factor
in the response of the calves to the journey, ns during
a 9-h journey the calves mobilized free faliy acids,
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probably in response to an energy deficiency. Under
the environmental conditions of this experiment,
there was no evidence that lack of drinking water
was an important factor during a 9-h journey. Under
the driving conditions used, and the range of space
allowances studied (0-375 to 0-475 m2 per calf),
increasing the space allowance was not associated
with a greater loss of stability and greater risk of
injury. The duration of the mid-journey lairage was
not an important factor, as although a longer lairage
period did provide greater opportunity for rest, a
short lairage duration of 1 h, sufficient for the calves
to receive milk replacer, but with little opportunity
for the calves to rest, had no major detrimental
effects on the variables used to assess the welfare of
the calves. Although there was no evidence that
transport affected the immunological variables
measured during the post-transport period, there
was some evidence that transport adversely affected
the health of the calves post transport.
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14 years of follow-up from the Edinburgh randomised trial of
breast-cancer screening
F E Alexander, T J Anderson, H K Brown, A P M Forrest, W Hepburn, A E Kirkpatrick, B B Muir, R J Prescott, A Smith
Articles
Summary
Background The Edinburgh randomised trial of breast-
cancer screening recruited women aged 45-64 years from
1978 to 1981 (cohort 1), and those aged 45-49 years
during 1982-85 (cohorts 2 and 3). Results based on 14
years of follow-up and 270 000 woman-years of observation
are reported.
Methods Breast-cancer mortality rates in the intervention
group (28628 women offered screening) were compared
with those in the control group (26 026) with adjustment for
socioeconomic status (SES) of general medical practices.
Rate ratios were derived by means of logistic regression for
the total trial population and for women first offered
screening while younger than 50 years. Analyses were by
intention to treat.
Findings Initial unadjusted results showed a difference of
just 13% in breast-cancer mortality rates between the
intervention and control groups (156 deaths [5-18 per
10 000] vs 167 [6-04 per 10000]; rate ratio 0-87 [95% CI
0-70-1-06]), but the results were influenced by differences
in SES by trial group. After adjustment for SES, the rate ratio
was 0-79 (95% CI 0-60-1-02). When deaths after diagnosis
more than 3 years after the end of the study were censored
the rate ratio became 0-71 (0-53-0-95). There was no
evidence of heterogeneity by age at entry and no evidence
that younger entrants had smaller or delayed benefit (rate
ratio 0-70 [0-41-1-20]). No breast-cancer mortality benefit
was observed for women whose breast cancers were
diagnosed when they were younger than 50 years. Other-
cause mortality rates did not differ by trial group when
adjusted for SES.
Interpretation Our findings confirm results from randomised
trials in Sweden and the USA that screening for breast
cancer lowers breast-cancer mortality. Similar results are
reported by the UK geographical comparison, UK Trial of
Early Detection of Breast Cancer. The results for younger
women suggest benefit from introduction of screening before
50 years of age.
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Introduction
The Edinburgh randomised trial of breast-cancer
screening was started in 1978.1 Between 1978 and 1981,
the trial recruited 44 288 women aged 45-64 years of
age from 87 general practices in Edinburgh to form the
initial cohort. Subsequently, further eligible women who
became patients of these practices and existing patients
who reached 45 years of age were recruited in two
further cohorts, 4867 in 1982-83 (cohort 2) and 5499 in
1984-85 (cohort 3).2 Participating practices were
randomly assigned to intervention and control groups,
women taking their status from their general medical
practice at their time of entry. Women in the
intervention group were invited to participate in a
screening programme, which included clinical
examination every year and two-view mammography
every 2 years. Control-group women received only
normal medical care. The prospectively defined
hypothesis was that breast-cancer mortality would be
lower in the intervention group than in the control group
after 7 years and longer periods of follow-up. At that
time, there was no reason to believe that the effect might
differ by age of entry to the trial and no subgroup
analyses were planned. Subsequent evidence from other
randomised controlled trials of mammographic
screening have placed importance on two age-groups
(<50 years, 5=50 years at entry).
There have been two reports2,5 of mortality from
breast-cancer relating to experience of women in the
initial cohort followed up for 7 and 10 years,
respectively. The second report also included the
later cohorts over a shorter follow-up period. For both
these follow-up periods, we report that breast-cancer
mortality was 17-18% in the screening group; these
differences were not significant. The 10-year analysis
reported that breast-cancer mortality was 22% lower in
the screening group for younger women aged 45-59
years at entry.
As a result of the cluster randomisation, there was bias
between the two groups, women in the control group
having higher all-cause mortality rates and lower
socioeconomic status (SES) than those randomly
assigned to intervention.1 Attempts to adjust for these
differences by quantifying SES in samples from each
practice were unsuccessful.2,5 An improved method of
quantifying SES has now been developed, which we
believe adjusts for this bias.5 We include in this report
the effect of this adjustment on breast-cancer mortality
rates after 14 years and separately consider the effect of
screening for younger women.
With longer periods of follow-up, the inclusion of.
women whose diagnosis could not have been influenced
by screening becomes difficult. The consequences of
Copyright © 1999. All rights reserved.
different policies on censoring of deaths by their date of
diagnosis were considered in the Swedish overview
analysis6 and the 14-year report of the Health Insurance
Plan (HIP) trial7 and are now considered for the first
time for the Edinburgh randomised trial. The HIP
investigators7 were the first to note that for entrants
younger than 50 years to the intervention group benefit
was restricted to women whose breast cancers were
diagnosed when they were in their fifties. Indeed, breast-
cancer mortality for women whose breast cancers were
diagnosed when they were younger than 50 years was
higher in the intervention than in the control group. A
corresponding analysis is now done for the Edinburgh
trial. Women in the intervention group of the Edinburgh
trial formed the Edinburgh component of the UK Trial
of Early Detection of Breast Cancer (TEDBC).8 The
latest results of TEDBC are also reported in this issue.9
Methods
Study participants and design
The geographical base for this trial was 87 general medical
practices within the city of Edinburgh.1 The only practices not
included were those that had participated in a pilot study or
refused to take part. Every woman aged 45-64 years registered
at one of these practices and without a previous diagnosis of
breast cancer was eligible for entry to the trial. Practices were
individually randomised after stratification by number of
partners (to balance the numbers in the two groups) and
entered sequentially between 1978 and 1981. All women aged
45-64 years from each practice were entered as the practice was
recruited (with cluster randomisation of women) to form an
initial cohort (cohort 1). During two 2-year periods (1982-83.
and 1984-85), newly eligible women registered with
participating practices were also recruited to form cohorts 2 and
3. We included only women aged 45-49 years at entry in these
two cohorts. Older entrants to these cohorts were mainly
women who had moved to Edinburgh and were not
representative of the population. The only exclusion criterion
applied at trial onset was a previous diagnosis of breast cancer,
but this was normally ascertained after randomisation (figure 1).
Informed consent was obtained for the screening process, but
not for trial entry. The trial was approved by the Lothian
Research Ethics Committee. The primary outcome measure
was the rate ratio of breast-cancer mortality rates .in the two
groups; the trial was designed to have 80% statistical power to
detect a 30% lower mortality rate in the intervention group
after 7 years of follow-up (rate ratio ^0-70), by a one-sided
test.1 Power calculations ignored the cluster randomisation.
The study continued until 1988, with women in the
intervention group offered a maximum of four mammographic
screenings every 2 years for cohort 1, three screenings for
cohort 2, and two screenings for cohort 3. During the study
period these women were also offered clinical breast
examinations once a year. With the start of service screening in
Edinburgh in June, 1988, all trial women younger than 65 years
were eligible to be screened. Those who had participated in
regular screening during the trial were invited for their first
service screening 3 years after their last trial screening. Controls
were invited for their first service screening at the
corresponding time: year 10 from entry for the initial cohort,
and years 8 and 6 for cohorts 2 and 3, respectively.
The records of all women in the trial were flagged by the
General Registry Office in Edinburgh in 1985. This standard
UK procedure allows follow-up information on cancer
incidence, breast-cancer mortality, and other-cause mortality to
be sent to the trial administrators wherever individual
participants are living. This report is restricted to the 98% of
women whose records were successfully flagged. Failure of
flagging is therefore a second exclusion criterion; most of the
women whose records were not flagged had died or left
Figure 1: Trial profile
Edinburgh before the trial began, although their records
remained on their general practice list.1
Data analysis
Mortality statistics were based on death certification accessed
through the flagging process. Breast-cancer deaths are those in
which breast cancer was mentioned on the death certificate as
the underlying cause, according to WHO rules.10 All such
deaths were checked against the trial database and, if necessary,
additional sources. They were included only after confirmation
that the date at which breast cancer was diagnosed was later
than that of randomisation. All deaths in which breast cancer
was not the underlying cause were recorded as other-cause
mortality. The follow-up period is 14 years for cohort 1, 12
years for cohort 2, and 10 years for cohort 3, from date of
randomisation. To counteract the effect of the inclusion of
deaths from breast cancer that could not have been influenced
by screening, results are presented not only for all deaths during
follow-up, but also with death censored if diagnosis occurred
after a specified date (1987, 1989, 1991) and if the diagnosis
occurred after a specified number of years in the study.
Additional analyses censored deaths after diagnoses before or
after age 50 years to allow comparisons with results from the
HIP trial.7
Breast-cancer and other-cause mortality rates were calculated
as rates per 10 000 woman-years at risk for the two groups in
the trial, and the risk ratio calculated with a modified logistic
regression procedure, as in previous studies,2,1 incorporating
adjustment for extrabinomial variation by the method of
Williams" to respect the cluster randomisation. These analyses
were done in SAS Proc Logistic version 6.12 and stratified by
age at randomisation (45-49 years, 50-54 years, 55-59 years,
60-64 years). When the later cohorts were included further
stratification by cohort was added. Age-specific results were
derived from fitting of interaction terms for age with trial group,
but all women were included in the modelling process.
Cumulative mortality curves were expressed as rates per 10 000
women entered, but were adjusted to take account of woman-
years at risk. Our method of analysis differs somewhat from that
used for TEDBC; that trial used Poisson rather than logistic
regression, but we used the TEDBC method" to confirm that the
differences in statistical methods do not explain the divergence
between their results and ours. Analyses are by intention to treat.
The trial database, during the study phase, held and still
holds the best (most accurate) address for each woman. These
addresses did not include postal codes. When we noted in 1983
that there was an imbalance in all-cause mortality between the
Copyright © 1999. All rights reserved.
Age at entry Intervention group Control group
(years)
Number of Woman- Number of Woman-
women years of women years of
follow-up follow-up
Cohort 1
45-49 5777 78 761 5594 75726
50-54 5878 78 838 5168 68316
55-59 6109 79500 5749 73 507
60-64 5162 64055 4831 58814
45-64 22 926 301155 21342 276363
Cohort 2
45-49 2495 29414 2381 28029
Cohort 3
45-49 3207 31693 2292 22658
Table 1: Trial population and woman-years of follownip
two trial groups, addresses of 20% of women from each general
practice were given postal codes manually and 1981 census
data derived from these postal codes were used to allocate an
SES score to each practice.' From this score, practices were
classified into three groups (high, medium, and low SES). This
classification system (SES-1) has the strength that it was
derived before any inspection of breast-cancer mortality but it
did not succeed in eliminating the difference in other-cause
mortality." Postal codes have now been allocated by computer
to the addresses of almost all women in the trial, allowing
retrieval of the Carstairs index of deprivation3 for the area of
residence of each woman. The mean value of Carstairs index
for general practices was used to derive a continuous variable
(Carstairs score) for general practices.' The Carstairs score was
used to assign practices into three groups (system SES-2) as
before.
All analyses were repeated with adjustment for each of SES-1
(as used previously), and SES-2 and Carstairs score in the
logistic regression model. In these adjusted analysis, we fitted
terms for SES using the total trial population, even to report
age-specific results. This approach assumes that the effect of
SES is independent of age entry to the trial. That assumption
has been verified; the interaction between SES and age at entry
did not approach conventional levels of significance.
Results
Table 1 shows the number of women and woman-years
at risk in cohort 1 by age at entry and for those aged
45-49 years at entry in cohorts 2 and 3. Women in
cohorts 2 and 3 were generally younger at age of entry
than those in the 45-49-year age-group in cohort 1
(mean age cohort 1, 47-4 years; cohort 2, 46-1 years;
cohort 3, 45-8 years). When the cohorts are combined,
they allow a direct comparison of 22 746 women who
were younger than 50 years at entry (11 479
intervention and 10 267 control).
Women in the intervention group were offered
an initial screening and up to six further screenings
(three mammographic) for the initial cohort, four (with
two mammographic) for cohort 2, and two (one
SES-2 Number of women from Intervention group Number of first-time






8212 (79%) 5747 (55%)
39§1 (73%) 2632 (49%)




Table 2: Proportions of women attending for screening
according to SES-2
mammographic) for cohort 3. 61-3% of women in the
intervention group accepted the first invitation to
screening, but attendance rates fell with time and were
just over 50% during the final year of the study.
Attendance at screening for women in the intervention
group was strongly associated with SES (table 2).
Younger women (45-49 years at entry) began trial
screening under age 50 years but many continued to
receive trial screening after 50 years. Of all trial
screenings for these younger women 46-0% for the
initial cohort, 79-0% for cohort 2, and 97-5% for cohort
3 were done when they were under 50 years. Little
screening was available in Edinburgh during the study
period (1978-88) and we believe that very few women in
the control group arranged screening for themselves,
although we have no way of confirming this assumption.
In cohort 1 followed up for 14 years there were 323
deaths in which breast cancer was the underlying cause.
Analysis without adjustment for SES or with the
previous method of adjustment (SES-1) showed
differences of 13-16% between the intervention groups,
which were not significant (table 3). Analysis of the
unadjusted data by the TEDBC method gave almost
identical point estimates.
However, adjustment by SES-2, in three categories or
as a continuous variable (Carstairs score), gave point
estimates for differences in breast-cancer mortality rates
of 21-22%, which are of borderline significance
(p=0-055 and 0 05, respectively). There was no
significant interaction between age-group at entry and
trial group (p=0-6), but we show results by age of entry
within cohort 1 in table 3. All 95% CI are wide, but
point estimates for all groups, except those of 50-54
years, are similar to the overall results; the difference in
breast-cancer mortality between intervention and control
groups for the youngest women (45-49 years) in the
initial cohort was 30%.
When the late entrants (cohorts 2 and 3) were
included in the 45-49-year age-group, the point estimate
of the difference in breast-cancer mortality rates was
25%. Although the 95% CI was narrower, this
difference in mortality is not significant. Cumulative
breast-cancer mortality rates for the initial cohort at all
ages and for women in all three cohorts entered at ages























































0-78 (0-50-1-21) 0-75 (0-48-1-18)
♦Intervention group versus control group.
Table 3: Breast-cancer mortality during 14 years of followup
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Figure 2: Cumulative mortality from breast cancer (underlying
cause of death) for all women in cohort 1 and for women
aged 45-49 years at trial entry in all cohorts
•Deaths following diagnoses up to study year 10.
When general practices were grouped by SES-2 there
was a strong trend in the control group ofmortality rates
in cohort 1 and a weaker trend in the intervention group
towards higher breast-cancer rates in those of higher
SES (table 4). The benefit of screening seems to be
concentrated in women of higher SES, but neither the
interactions with SES-2 nor those with Carstairs score
were significant.
Other-cause mortality rates were significantly lower in
the intervention group than in the control group (rate
ratio 0-84 [95% CI 0-79-0-90]) but after adjustment for
Carstairs score (the continuous variable) this difference
was no longer apparent (0-98 [0-92-1-04]).
In general, the results were not affected by censoring
by study year of diagnosis. When censoring was applied
to cases diagnosed after study year 10, the observed
benefit in the intervention group was 29% (rate ratio
0-71 [0-53-0-95] if deaths after diagnoses after study






♦Breast cancer was the underlying cause of death. Rates are those per 10 000
woman-years at risk.
tAdjusted for age at survey entry, and, where appropriate, for cohort.
Table 4: Breast-cancer mortality by SES-2 in cohort 1
(45-64 years)
mortality with this censoring applied. Results were
similar for the other censoring imposed for diagnosis
around 3-4 years after the end of the study (study years
9-12, calendar years 1990-92).
If deaths in the 45-49-year age-group were censored
according to age at diagnosis, no benefit in the
intervention group was observed when analyses were
restricted to deaths of women whose breast cancers were
diagnosed before they reached age 50 years (rate ratio
2-36 [0-79-7-08]); substantial benefit was seen when
these deaths were excluded (0-47 [0-25—0-89]). The
question of benefit from screening offered to women
before they reach age 50 years (in addition to that from
routine screening in their fifties) can be addressed, but
with limited power, by comparison of breast-cancer
mortality by trial group for younger women (entrants
45-46 years) in cohorts 2 and 3; for these women the
rate ratios were 0-83 and 0-50, respectively (with wide
95% CI, 0-32-2-18 and 0-11-2-23).
Discussion
This report of the Edinburgh randomised trial of breast-
cancer screening, with "before randomisation" consent
and no offer of screening to the control group, includes
nearly 70 000 woman-years of follow-up. Trials in
Canada included a volunteer population all of whom,
including the control group, received some form of
intervention at entry to the trial" or throughout the
study." Because of recruitment of two later cohorts of
women aged 45-49 years, the Edinburgh trial provides a
substantial contribution to the total information
available on the screening of younger women (more than
270 000 woman-years of follow-up). A limitation of this
trial has been the imbalance between the intervention
and control groups for other-cause mortality rates. New
computer software has enabled us to access postal codes
for all women, so we have been able to derive an
improved estimate of general practice SES (SES-2).'
The variation in SES explains the difference in other-
cause mortality rates and thus allows best estimates of
effects on breast-cancer mortality.
Application of SES-2 gave an overall point estimate
for the difference between intervention and control
groups in breast-cancer mortality rates in the Edinburgh
trial at 14 years of follow-up as 21%; this estimate is of
borderline significance (rate ratio 0-79 [95% CI
0-60-1-02]). If SES-2 is applied to our previously
reported results at 10 years of follow-up, the difference
in breast-cancer mortality rates is 24%, compared with
the 18% first reported. This difference approaches
significance (rate ratio 0-76 [0-55-1-06]).' These
benefits do show some variation by age, with the largest
benefits in women first screened in their late fifties and
none in those first screened in their early fifties.
Although this latter observation is consistent with results
from some other trials," we emphasise that the formal
test of heterogeneity by age-group did not approach
significance.
Breast cancers diagnosed after a suitable period from
the end of the study clearly cannot have been influenced
by trial screening, and the inclusion of deaths after these
later diagnoses dilutes the comparison by trial group. In
the HIP study, screening seemed to have no impact on
diagnoses 3-0-3-5 years after the end of the study.7 The.
first comparisons of the Swedish overview, based on
Control Rate ratiof
n Rate/104 (95% CI)
31 811 0-68 (0-44-103)
60 608 0-86 (0-58-1-27)
76 5-45 0-78 (0-49-1-44)
Copyright© 1999. All rights reserved.
short follow-up periods (mean 10 years) found only
slight differences between follow-up (without censoring)
and evaluation (with censoring) models, but later
comparisons have shown increased estimates of benefit
when censoring is imposed." We found that estimated
benefit was slightly larger when deaths from diagnoses
more than 3-4 years after the end of the study
were censored, with no evidence for attenuation of
benefit at 14 years of follow-up. The HIP study7 did
show attenuation with, for example, deaths from
diagnoses up to study year 7 showing benefits of 34-7%,
29-3%, and 22-2% at 7 years, 10 years, and 14 years of
follow-up.
In view of the controversy over age at which screening
should start, the results for women aged 45-49 years at
entry are particularly important. Since there is no
statistical evidence of heterogeneity between breast-
cancer mortality benefit and age at entry, there is no
reason to suppose that benefit is less for women first
screened under 50 years than for older women.
Furthermore, when age-specific results were derived, the
estimated difference in breast-cancer mortality rates for
those aged 45-49 years, although not significant by
itself, is no less than in older entrants. In addition, there
is no evidence that the benefit emerged later in these
younger women. The 25% difference in mortality rate at
14 years of follow-up in women aged 45-49 years at
entry agrees closely with most meta-analyses of
randomised trials."
There are the two critical components to the decision
whether population screening for breast cancer should
be available to women younger than 50 years. First, do
women first screened when younger than 50 have lower
breast-cancer mortality than those not so screened; and
can the same benefit be achieved by screening from the
age of 50 years? Even after a US National Institutes of
Health consensus conference these issues remain
controversial." 20 Although our numbers for such women
are small, the Edinburgh trial findings make an
important contribution to the first question.
The second question is more complex. Deaths
classified by age at diagnosis require careful
interpretation; for purposes of comparison with the HIP
trial7 we have presented results for younger entrants to
the trial with diagnoses at 50 years or older and
diagnoses at less than 50 years censored. Our results
agree with those of the HIP trial that the benefit in
women entering the trial before the age of 50 years is
evident only in deaths occurring in their fifties and from
cancers diagnosed after age 50 years. These observations
could be artefacts with lead time advancing age at
diagnosis to under 50 years in some women in the
intervention group who, if unscreened, would have been
diagnosed in their fifties. A proportion of the benefit
(possibly 70%)21 will be attributable to screening of
women in their fifties. The design of the Edinburgh trial
means that its analyses, based on randomisation, can
address the second question for younger entrants to
cohorts 2 and 3 (since almost all trial screening was
done before age 50 years and women in both trial groups
were eligible for Forrest screening), but the numbers
available for analysis are small and the results equivocal.
An observational study22 on these cohorts and entrants at
ages 45-49 years and 50-52 years to the initial cohort of
the intervention group reported lower mortality rates for
women in their fifties screened under 50 years.
The improved method of analysis and longer follow-
up period have now shown a reduction of 21% in breast-
cancer mortality for women aged 45-64 years at entry to
the intervention group of the Edinburgh trial; this
difference is of borderline significance. Consideration of
the results at follow-up periods of 7 years and 10 years,
and 14 years follow-up censored by study year of
diagnosis indicates a benefit of 25-29% in a population
offered regular screening (the steady state). The
reduction is close to but smaller than the 30% expected
when available data were restricted to HIP trial, the
Swedish two-county trial, and case-control analyses of
screening.21 Compared with the Swedish two-county
trial21 pathological characteristics of cancers in screened
women in Edinburgh showed that screening in
Edinburgh (which used current mammographic
technology) has not advanced the diagnosis sufficiently
to influence histological grade despite reducing size and
frequency of node involvement.25 Although there is no
reason to believe this finding is not typical of the UK,
it may explain why mortality benefit has not been larger.
Mammographic standards have certainly improved
since the Edinburgh study but our data come from a
research setting with a 2-year interval between
screening. These data may not be applicable without
reduction in benefit to screening done as part of routine
health service with a 3-year interval. Only cautious
optimism is appropriate. Subgroup analyses presented
here and by the Swedish investigators," and one
Swedish trial of younger women,2' are very promising
for women younger than 50 years when first screened,
but we believe that decisions on service screening in
this age-group should await the results of specifically
designed randomised trials (UK Age Trial and
EUROTRIAL).
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Improved classification of socio-economic status
explains differences in all-cause mortality in a
randomised trial of breast cancer screening
FE ALEXANDER, HK BROWN and RJ PRESCOTT
Department ofPublic Health Sciences, University ofEdinburgh Medical School, Teviot Place, Edinburgh, UK
Background The Edinburgh trial is one of only seven ran¬
domised controlled trials conducted to compare breast
cancer mortality in women offered mammographic
screening, with those having routine health care. Its
importance has been diminished because cluster ran¬
domisation led to bias between the two arms: control
women had higher all-cause mortality and lower socio¬
economic status (SES). Previous methods of quantifying
SES could not explain the mortality bias.
Methods The Carstairs deprivation index has been used to
derive an improved estimate of cluster SES. This has
been validated by comparisons of non-breast cancer
mortality using logistic regression and adjustment for
SES. Similar analyses have been applied to breast can¬
cer mortality.
Results Using the new estimate of cluster SES, the adjust¬
ed risk ratio for other-cause mortality for the interven¬
tion arm = 98 [95% confidence interval (CI) 0.92-1.14].
Adjusted risk ratios for breast cancer mortality at 7 and
10 years of follow-up are 0.79 and 0.77 respectively,
with 95% CI = 0.54-1.18 and 0.56-1.06.
Conclusions The improved method of estimating cluster
SES has overcome the problems which had previously
been encountered. Analyses of breast cancer mortality
using this adjustment should be free of bias. The esti¬
mated benefits in breast cancer mortality in women
offered screening are larger than those previously
reported at 7 and 10 years of follow-up.
Keywords breast cancer screening, mammography, socio¬
economic status, randomised controlled trial.
Introduction
The Edinburgh Randomised Trial of Breast Cancer
Screening1 (ERT) recruited women aged 45-64 years
between 1978 and 1981. These women (it = 44 288)
form the initial cohort. Younger women (45^)9 years)
also entered the trial in two further cohorts, 1982-3 (/; =
4876), 1984-5 (n = 5499). A cluster randomisation
process was based on an initial randomisation of 87 CP
practices; women entering the trial were allocated by the
status of their current GP into intervention and control
arms.
Two reports of breast cancer mortality have been
published: relating to 7 years2 and 10 years2 of follow-
up. For both these follow-up periods we reported reduc¬
tions of breast cancer mortality of 17-18%, which were
not statistically significant.
Cluster randomisation is less effective than individual
randomisation and, in this trial, it allowed bias between
the two arms. Women in the control arm had higher all-
cause mortality and lower socio-economic status4
(SES). When the bias was first noted, addresses of a
20% sample of women were post-coded and several UK
census variables related to SES were retrieved for the
areas of residence in this sample. The first principle
component of the census variables averaged over GP
practices provided an estimate of practice SES4.
Although this was significantly associated with all cause
mortality, it failed to explain the differences between the
two arms of the trial2-3.
These biases have made interpretation of the results
of the ERT difficult and diminished its perceived impor¬
tance, although it is one of just seven randomised con¬
trolled trials of mammographic screening to have been
conducted world-wide and one of only three outside
Sweden. Adjustment for previous estimates of GP prac¬
tice SES was applied in. the 7-year analysis2 and the esti¬
mated benefit in breast cancer mortality was somewhat
increased as a result. This was not possible for the 10
year analysis because of a statistically significant inter¬
action between the trial arm and SES3.
Small area classification in the UK is now routinely
based on well-validated indices of deprivation and/or
socio-economic status derived from census data5-6; the
index most widely used in Scotland is the Carstairs
index7. Since computerised post-coding of addresses has
become available, it is now possible to retrieve these
indices for all women in the trial. The present report
describes and justifies an improved method of quantify-
Correspondence lo: FE Alexander. Department of Public Health Sciences, Uni¬
versity of Edinburgh Medical School. Teviot Place. Edinburgh, EH8 9AG. UK.
O 1998 Isis Medical Media Limited
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ing SES using the Carstairs index and validates it in
terms of other-cause mortality at 14 years of follow-up.
Results at 7 and 10 years for breast cancer mortality,
adjusted by this new measure, are also presented.
Detailed examination of breast cancer mortality at 14
years follow-up will be reported separately elsewhere.
Methods
The trial population
Detailed methods have been described previously1. The
geographical base was 87 general practices within the city
of Edinburgh. All women aged 45-64 years registered
with one of these and without a previous diagnosis of
breast cancer were entered into the trial. The initial cohort
was formed as the practices were entered sequentially
between 1978 and 1981. During each of the 2 year periods
1982-3 (Cohort 2) and 1984—5 (Cohort 3) eligible women
moving into one of these practices or attaining the age of
45 years and not already in the trial population were
recruited. The majority of these were aged 45-49 years
and only these have been included in the present report.
The GP practice for each woman in the trial is the one
with whom she was registered at randomisation.
Socio-economic status: initial classification
The trial database held, during the field work phase, and
still holds, the 'best' address for each individual woman.
These were not post-coded at the outset. When the poten¬
tial bias was noted (1983), addresses of 20% of women
from each GP practice were post-coded manually and
1981 census data were derived for the small census areas
corresponding to these post-codes. The data included pro¬
portions of households with heads in social class I—II and
IV-V, with no car and over-crowded and proportions of
people seeking employment. The first principal compo¬
nent was taken as a socio-economic score (Princ_Comp)
for each practice4. Low values of the score correspond to
high SES. Princ_Comp showed a significant association
with all-cause mortality and with mortality from several
specific causes known to be associated with SES. From
this score, practices were classified into three groups
(high, medium, low), this is SES-1, corresponding to
approximate tertiles of the distribution.
SES: logic of the new classification
• The Carstairs index of deprivation (DEPCAT7) for
the small census area containing the post-code of
the last recorded address is available for each
woman and has been taken as the best measure of
the SES of her area of residence.
• This is, however, biased since there was a system¬
atic difference in time of recording of addresses
between the two arms of the trial. Addresses of
women screened, but not of other women, were
routinely updated during the fieldwork period. In
particular, a drift to lower SES may be anticipated
for women who experience adverse health8.
• We have an imperfect (since based on a 20% sam¬
ple and using an ad hoc index), but unbiased, esti¬
mate of practice baseline SES, namely
Princ_Comp.
• By averaging DEPCAT over GP practices we have
another measure of practice SES, but subject to the
bias noted above. However, after standardising the
scales of this and Princ_Comp, the drift can be
estimated and used to apply a bias correction to
the measure based on DEPCAT.
• Since the drift is expected to be focused in women
who have died (in the 14 years of follow-up now
available) the procedure described above should
exclude these women. We have also restricted our
calculation to the initial cohort, as being more rep¬
resentative of the age range 45-64 years. The
result (CarstairsjScore) is the best measure of
practice SES now available to us.
SES: details of the new classification
Using current technology for computer address recogni¬
tion, we have allocated post-codes to addresses of
almost all (97%) women in the trial and using these, the
Carstairs index of deprivation7 for the area of residence
of each woman has been retrieved. This index (DEP¬
CAT) uses 1981 census data for the small areas in which
the post-code is situated (low social class of head of
household, households with no car, seeking employ¬
ment, over-crowding). It has been extensively validated
and is coded 1 (highest SES) to 7 (lowest SES).
The new measure (Carstairs_Score) has been derived
in steps:
Step 1: the mean value (GP-DEPCAT) of the Carstairs
index has been computer for each GP practice.
Step 2: the distributions of Princ_Comp and GP-DEP¬
CAT across the women were compared and the former
scaled so that the means and ranges of both were the
same. This also stabilised the variance.
Step 3: the difference between (the scaled) Princ_Comp
and GP-DEPCAT in the two arms of the trial were com¬
pared and the means for women in each trial arm calcu¬
lated using only women in the initial cohort still alive at
14 years of follow-up. These mean differences were
subtracted from GP-DEPCAT to yield Carstairs_Score.
From this score, the practices were assigned to one of
three groups (SES-2) with as nearly as possible the
same number of women in each.
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In order to investigate the SES drift for women who
have died during follow-up, multiple regression analysis
has been applied to the difference between individual
DEPCAT and practice SES (Princ_Comp or Carstairs_
Score). The effect of trial arm has been examined after
adjusting for age.
Mortality ascertainment and analysis
Women in the trials were flagged with the General Reg¬
istry Office in Edinburgh in 1985 to obtain information
on all-cause mortality. This ensures consistent follow-up
for all women, even those who have left the city. The
present report is restricted to women who were success¬
fully flagged (98%). If breast cancer is mentioned on a
death certificate then it is classified as underlying, or
other cause, using WHO rules9 as previously described3.
All deaths of trial women for which breast cancer is not
the underlying cause have been taken as 'other-cause'
mortality.
For the statistical analysis of mortality, rates of
death/104 women-years at risk have been computed and
the ratio between the two arms of the trial calculated. As
in previous analyses2,3 a modified logistic regression
procedure at the practice x age group level incorporated
adjustment for extra-binomial variation10 to respect the
cluster randomization. These analyses were implement¬
ed in SAS using PROC LOGISTIC (with option
Scale=Williams) and stratified by age at randomization
45-49, 50-54, 55-59, 60-64 years). When the later
cohorts are included, further stratification by cohort has
been added. Age-specific results have been derived from
fitting interaction terms for age with trial arm, but
including all women in the modelling process. Cumula¬
tive mortality curves are expressed as rates/104 women
entered, but are adjusted to take account of women-
years at risk.
In analyses with adjustment for SES in the logistic
regression model, terms for SES (one of SES-1, SES2,
Princ_Comp, Carstairs_Score) have been fitted to the
total trial population (i.e. all age groups) even when age-
specific results are reported. This means that the effect
of SES has been taken to be independent of age at entry
to the trial and this assumption has been verified by con¬
firming that the interaction of SES and age-at-entry is
not statistically significant.
Results
Table 1 shows, firstly, the number of women and
women-years at risk using the longer follow-up now
available, by 5 year age ranges at entry. The total num¬
bers of other-cause deaths in the trial population are
6675 (initial cohort) and 309 (later cohorts). Analyses of
other-cause mortality (Figure 1) show continued evi¬
dence of the difference between the two trial arms
which has previously been reported.
Derivation of Carstairs Score
Both Princ_Comp and GP-DEPCAT were normally dis¬
tributed over the trial population but Princ_Comp had a
larger range (-2.35-2.40) and variance (1.14) than GP-
DEPCAT (range: 1.46-5.42, variance: 0.76). In the
sequel, Princ_Comp is replaced by a linear function
with the same mean and range as GP-DEPCAT. Specifi¬
cally, Princ_Comp was replaced by (Princ_Comp+2.35)
x 0.80-1.96. The variance of Princ_Comp after transfor¬
mation was 0.79.
Table 1 Trial population and women-years of follow-up
Cohort and age at
entry (years) Intervention arm Control arm
Number of women Women-years of Number of women Women-years of
follow-up follow-up
Initial cohort
45-49 5777 78 761 5594 75 726
50-54 5878 78 838 5168 68 316
55-59 6109 79 500 5749 73 507
60-64 5162 64 055 4831 58 814
45-64 22 926 301 155 21 342 276 363
1982-3 cohort
45^19 2495 29 414 2381 28 029
1984—5 cohort
45-49 3207 31 693 2292 22 658
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Year
Group —•—• Intervention arm Control arm
Fig. 1 Cumulative other-cause mortality (initial cohort only).
Mean differences between Princ_Comp and GP-
DEPCAT for women in the two arms of the trial who
were still alive at the end of the follow-up period are
0.05 (intervention arm) and -0.06 (control arm). These
were taken to be the best available estimates of the bias
in GP-DEPCAT caused by the timing of recording of
addresses. Therefore, the new (bias corrected) measure




Table 2 Comparisons by trial arm of individual Carstairs
index (DEPCAT) with status of initial GP practice for women
who have died" during follow-up






"Of causes other than breast cancer
^Adjusted for age (four levels)
Both Pearson and Spearman rank correlation coeffi¬
cients of Carstairs_Score with Princ_Comp were high
when calculated for GP practices (0.94, 0.93) and indi¬
vidual women (0.92, 0.91).
In order to examine the evidence for a drift of SES
for women who had died, the differences between the
individual Carstairs index and Princ_Comp,
Carstairs_Score were computed for women who had
died (of causes other than breast cancer during the fol¬
low-up period). Use of either measure of practice SES
(Table 2) shows a statistically significant difference by
trial arm, with women in the intervention arm lower rel¬
ative to their (initial) GP practice than those in the con¬
trol arm.
Figure 2 displays histograms of Carstairs_Score
(using counts of all trial women) for intervention and
control arms.
Validation: adjusted analyses of other-cause mortali¬
ty (14 years follow-up)
Figure 1 displays cumulative other-cause mortality by
trial arm; Table 3 shows comparisons by trial arm
unadjusted for SES and with adjustment using each of
SES-1, 2 and Princ_Comp Carstairs_Score. The unad¬
justed analyses and those adjusting for the original mea¬
sures of practice SES reveal significantly lower
other-cause mortality in the intervention arm. However,








■ Intervention arm [H Control arm
Fig. 2 Distribution of Carstairs_Score.











Age at entry and cohort
Initial rnhort All cohorts"
45-64 45-49
0.84 (0.79-0.90) 0.82 (0.69-0.97)
0.89 (0.84-0.95) 0.88 (0.76-1.02)
0.93 (0.88-0.98) 0.95 (0.87-1.04)
0.94(0.88-1.00) 0.93 (0.80-1.08)
0.98(0.92-1.04) 0.98 (0.85-1.13)
"'Unadjusted analysis' here also includes terms for cohort
b'Unadjusted analysis' includes terms for age at entry
adjustment for the new measure as a continuous variate
effectively removes the difference by trial arm.
Adjusted analyses of breast cancer mortality (7,10
years follow-up)
Table 4 gives breast cancer mortality results at 7 and 10
years of follow-up, with adjustment for Carstairs_Score.
The estimated benefit in the intervention arm is larger
than in previously published results. Risk ratios for the
younger women have wide confidence intervals, but
show no indication that benefit for them is either small
or emerges later.
The Williams dispersion parameters were approxi¬
mately equal to 1 (to within 0.1%) in all analyses, indi¬
cating that there was no over-dispersion in the data.
Table 4 Adjusted analyses of breast cancer mortality" (risk
ratios5 for intervention arm compared with controls)
Follow-up Group analysed
Initial cohort (all ages) 45-49 years0
7 years 0.79(0.52-1.21) 0.75 (0.32-1.77)
10 years 0.76(0.55-1.06) 0.77(0.44-1.33)
"Breast cancer as underlying cause
bWith 95% confidence intervals
"Note that all women, including those entered 1982-1985, have the
full follow-up period included in this analysis
Discussion
Randomisation in clinical, prophylactic and other trials
is intended to ensure comparability of the groups com¬
pared for all relevant factors apart from the intervention
being evaluated. The ability of randomisation to achieve
equivalence of the groups is related to the number of
randomisation units, rather than the number of individu¬
als randomised. The ERT recruited and randomised a
large number of women (over 50 000), but the number
of randomisation units (clusters), was just 87. Optimal
cluster randomisation requiros the use of heterogeneous
clusters which are similar to one another. GP practices
are relatively homogeneous with respect to social and
economic factors and dissimilar to one another. With
hindsight, it is not too surprising that the randomisation
process left differences between the trial arms in the
ERT. Clearly, individual randomisation is preferable, but
it was unacceptable to Edinburgh GPs in 1978. Despite
strenuous efforts we have not, until now, succeeded in
quantifying socio-economic status for the clusters in a
way which can explain differences in all-cause (i.e.
'other'-cause) mortality.
Two alternative continuous variates have been con¬
sidered here as methods of quantifying GP practice
socio-economic status. Both are based on similar 1981
census data for the small areas into which individual
addresses fall. The first (Princ_Comp) has the strength
that it was derived before any data on breast cancer mor¬
tality were available; its weaknesses are, firstly, that it
uses residences of just 20% of subjects and, secondly,
that it has not proved able to explain differences of
other-cause mortality between the two arms of the trial.
The second variate (Carstairs_Score) uses all
addresses of living women and, in addition, uses the
Carstairs index, which has been extensively validated
and shown to be as powerful a predictor of mortality as
personal SES" and to correlate highly with alternative
UK indices5,6. Its weaknesses are, firstly, that it has been
derived after examination of breast cancer mortality and.
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secondly, that there is a potential bias due to updating of
addresses in the intervention arm. We have shown
(Table 2) that this bias is a real problem for women who
have died, since their SES has drifted downwards com¬
pared with their peers in the same GP practices at entry.
These data provide warning to others, using socio-eco¬
nomic indicators based on addresses, that times of
recording these should be carefully specified.
We have sought to minimise the problem of differen¬
tial dates of recording addresses by restricting attention
to living women and, in addition have made the best
available bias correction. The best demonstration that
this variate is optimal for classification of practice SES
is its ability to explain almost totally the difference in
other-cause mortality (Table 3). The categorical vari¬
ables are worse than the continuous ones from which
they derive. This is a natural consequence of the imbal¬
ance by arm at the extreme ends of the spectrum (Figure
2).
Use of new variate to adjust for SES in breast cancer
mortality analyses (Table 4) gives estimates of benefit in
the intervention arm which are larger than those report¬
ed previously and, at 10 years of follow-up, approach
statistical significance. Future analyses of ERT data
should use this method of adjustment confidently in the
knowledge that, after it is made, no bias between the
two trial arms remains in terms of non-breast cancer
mortality.
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Measurement of cyclic variation in ultrasonic
integrated backscatter in conscious, unsedated,
clinically normal dogs
Virginia Luis Fuentes, VetMB; Carmel M. Moran, BSc, PhD; Karsten Schober, DVM;
Joanna Dukes McEwan, BVMS, MVM; Helen Brown, BA, MSc; George R. Sutherland, MBChB, MRCP;
W. Norman McDicken, BSc, PhD
Objective—To assess the feasibility and repeatability
of measuring ultrasonic integrated backscatter in un¬
sedated conscious dogs, using a protocol previously
validated in pigs with open thorax.
Animals—11 clinically normal conscious unsedated
German Shorthair Pointers.
Procedure—A modified commercially available echo¬
cardiography system was used to record long-axis
views of the heart. The radiofrequency data from 15
consecutive frames were digitized and analyzed.
Regions of interest were chosen within the myocar¬
dium, and the ultrasonic integrated backscatter within
each region was calculated in the time domain for
each frame.
Results—Cyclic variation in integrated backscatter val¬
ues was observed, with maximal values at end-diastole
and minimal values at end-systole. Mean ± SD
amplitude of cyclic variation was 5.81 ± 3.86 dB over
all the regions chosen.
Conclusions—Results agreed with those obtained
by other investigators working with dogs with open
thorax and those with closed thorax while under gen¬
eral anesthesia. The analysis of the components of
variance indicates that this is a consistent, reliable
technique in conscious unsedated dogs.
Clinical Relevance—Integrated ultrasonic back-
scatter measurement provides a noninvasive means
of tissue characterization. Use of this protocol reliably
yields cyclic variation in integrated backscatter and
could be applied clinically to dogs with myocardial dis¬
ease. (Am J Vet Res 1997;58:1055-1059)
The interaction of ultrasound waves with biologicaltissue is strongly influenced by the physical char¬
acteristics of the tissue, and this interaction can be ex¬
ploited to provide a noninvasive method of ultrasonic
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tissue characterization. Ultrasonic tissue characteriza¬
tion techniques have been documented to be capable
of distinguishing normal from ischemic myocardium
in studies of dogs with open thorax and in human
patients,1-2 and normal myocardium from that of human
beings with dilated cardiomyopathy,3 hypertrophic
cardiomyopathy,4 and diabetic myocardial disease.5
A number of methods have been described for the
quantification of myocardial ultrasonic reflectivity by
measuring small amplitude radiofrequency (RF) sig¬
nals. However, techniques vary among laboratories, and
there is no standard in vivo technique against which
other techniques can be compared. Integrated back-
scatter (IB) is the most commonly measured in vivo
variable, although a number of calculations have been
used to derive IB, including frequency domain6 and time
domain techniques.7 A cyclic variation with the phase
of the cardiac cycle has been a consistent finding in
myocardial IB, with maximal reflectivity generally cor¬
responding to end-diastole. The magnitude of this cyclic
variation has been found to vary with the myocardial
site studied,8 the angle of insonification, and left ven¬
tricular function. Most experimental studies have used
dogs or pigs with open thorax. Of the few studies in
which IB in dogs with closed thorax has been measured,
anesthetized mixed breed dogs have generally been
used.911 To the authors' knowledge, reports of the mea¬
surement of IB in conscious, unsedated dogs do not
exist.
The objective of the study reported here was to
assess the feasibility of measuring ultrasonic IB from
transthoracic views in conscious, unsedated dogs, using
the protocol described by Moran et al12 in pigs with
open thorax. We also aimed to examine subject varia¬
tion when a single breed of dog was used, and to mea¬
sure intradog, interdog, and interobserver variability.
Materials and Methods
Dogs—Eleven German Shorthair Pointers (8 females, 3
males) were studied. Mean age was 6.0 (range, 1.5 to 12)
years, and mean (± SD) body weight was 25.6 (± 3.5) kg.
All dogs were considered to be healthy on the basis of histor¬
ical findings and physical examination. All dogs were sub¬
jected to a routine two-dimensional, M-mode and Doppler
echocardiographic examination to rule out any evidence of
cardiac disease. All animals were used in accordance with the
regulations and guidelines laid down in the UK Animals (Sci¬
entific Procedures) Act, 1986.
Imaging system and RF data acquisition—A modified
commercially available digital echocardiography system" with
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a 5 MHz phased array transducer (bandwidth, 2.5 to 7.5
MHz), and simultaneous ECG was used to acquire the two-
dimensional echocardiographic images (Fig 1). Dogs were po¬
sitioned in right lateral recumbency on a modified table, to
allow placement of the transducer on the thoracic wall from
below. Right parasternal long-axis views were used to obtain
images of the left ventricle. Transmit power and time gain
compensation controls were set at preadjusted levels for the
studies, and the gain was adjusted at the start of each study,
then was kept constant. The RF signals were digitized at 12
MHz to 16 bit. Fifteen consecutive frames of RF data were
collected, and manually controlled so that the first frame oc¬
curred shortly before end-diastole. Each echo line of RF data
consisted of a maximum of 4,096 samples, depending on the
image depth. A single image consisted of 128 lines with up to
4,096 samples/line at 2 bytes/sample, occupying 1 megabyte
(MB) of storage memory/frame. The RF acquisition system
was equipped with a 16-MB memory board, of which 1 MB
was reserved for control registers, so that a maximum of 15
complete frames of RF data could be acquired. The two-di¬
mensional images were also stored on video, and hard copies
were made of each frame.
Figure 1—Block diagram showing the system used for'the
acquisition of radiofrequency (RF) data. TGC = time gain
compensation.
The RF data were collected from each scan and down¬
loaded onto a workstationb for signal processing. The RF data
were rectified, low-pass filtered, logarithmically compressed,
and scan converted before the reconstruction of two-dimen¬
sional images similar to the images obtained by the original
echocardiography machine. Myocardial regions of interest in
the reconstructed images were chosen within the left ventric¬
ular free wall and interventricular septum, using a mouse-
driven cursor (Fig 2). Care was taken to avoid the specular
echoes of the endocardial and epicardial surfaces. Regions of
interest in the same myocardial area were tracked through
each frame. These data were then related to the original un¬
compressed RF data, and the IB value was calculated. A set of
calibration scans was also recorded, using a standard gray¬
scale test tissue phantom to compensate for the effects of
transducer characteristics, time gain compensation, depth, and
dynamic range settings of the ultrasound machine. The cali¬
bration scans were recorded for each depth and focus setting
used during the in vivo scans, and the RF data were down¬
loaded to the workstation in similar manner. The regions of
interest chosen for each canine scan were then superimposed
on the phantom scan RF data, and the IB was calculated ac¬




where V(t) is the amplitude of the uncompressed RF signal
from the myocardial region of interest, P(t) is the amplitude
of the uncompressed RF signal from the phantom, 8t is a small
increment of time over the timegate, and 2At is the timegate
over the region of interest.
Figure 2—Reconstructed image on the workstation, show¬
ing region of interest chosen in the left ventricular free wall
(arrow).
Protocol—All 11 dogs were scanned at least twice, and
for each scan, values for IB were obtained for 3 myocardial
regions over 15 frames (the basal left ventricular free wall, the
apical left ventricular free wall, and the interventricular sep¬
tum). In this manner, a set of IB values over 15 frames for
each cardiac cycle was acquired in 86 sites. Ten scans from 8
dogs were analyzed by 3 independent observers over 3 regions,
yielding 90 data sets comprising 15 frames for each data set.
Three dogs were scanned 4 times, and 1 dog was scanned 3
times.
Analysis of data—The logarithm of each recorded IB
value was multiplied by 10, and the mean value was sub¬
tracted to yield the variation about the mean, so that the mean
value was designated as 0 dB. Using the concurrently recorded
ECG, the 15 frames of RF data were synchronized for each
scan by defining the end-diastolic frame as the frame recorded
at the start of the R wave, and the end-systolic frame as the
frame with the smallest left ventricular volume. The amplitude
of cyclic variation was defined as the difference between the
maximal and minimal values.
Statistical analysis—A random effects model was used
to obtain variance component estimates for intradog, interdog,
and interobserver variation within scans and within dogs. It
was also used to obtain best least squares means and 95%
confidence intervals. All calculations were carried out, using
statistical analysis software.'
Results
Mean IB values for each frame from all the scans
in all the regions of interest were obtained (Fig 3 top
left), with the associated 95% confidence limits. Mean
backscatter values and 95% confidence intervals for the
individual regions (basal left ventricular free wall, apical
left ventricular free wall, and interventricular septum)
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Figure 3—Mean integrated backscatter (IB) over 11 frames (from end-diastolic frame to end-systolic frame) for all
scans and all observers. Mean IB levels for all 3 regions of interest and all 3 observers in all scans with 95%
confidence intervals (top left). The same variables for the basal portion of the left ventricular (LV) free wall only (top
right), apical portion of the LV free wall (bottom left), and the interventricular septum (bottom right).
Basal LV free wall
frame
All regions and observers
frame





Amplitude of cyclic variation + SD (dB)
III l»l
PW1 PW2 IVS All
regions/observers
Figure 4—Mean ± SD amplitude of cyclic variation in
basal region, of the left ventricular free wall (PW1), apical
region of left ventricular free wall (PW2), and interven¬
tricular septum (IVS).
also were determined (Fig 3 top right, bottom left, and
bottom right). Amplitude of cyclic variation in each of
the various regions was compared (Fig 4) and was
greatest in the basal portion of the left ventricular free
wall (PW1), with a mean ± SD value of 6.17 ± 3.19
dB. The apical portion of the left ventricular free wall
was similar (5.55 ± 3.5 dB), but the interventricular
septum had a lesser degree of cyclic variation (3.04 ±
3.4 dB). The variance components for interdog, intra-
dog, and interobserver variation for each frame were
compared (Table 1). The intradog variance ranged from
0.94 dB2 for end-diastole to 1.08 dB2 for end-systole,
decreasing to approximately zero at mid-systole. Inter¬
dog variance was lowest at end diastole (0.45 dB2) and
end-systole (0.78 dB2), and highest at mid-systole (1.75
dB2). Variance components attributable to different ob¬
servers (whether within each dog or within each scan)
were smaller, reaching a maximum of 0.54 dB2 for ob¬
server variance within each scan at end-systole. Other
values are expressed as mean ± SD unless otherwise
stated.
Discussion
Ultrasonic tissue characterization can provide
unique insight into structural and functional changes in
the myocardium, without recourse to invasive tech¬
niques, such as endomyocardial biopsy. Integrated
backscatter measurement has been found to differenti¬
ate viable "stunned" ischemic myocardium from non¬
viable ischemic myocardium within 15 minutes of
coronary occlusion in dogs before return to normal of
any conventional echocardiographic variables, such as
percentage of wall thickening.1 Integrated backscatter
has also been documented to differentiate hypertrophy
attributable to athleticism from hypertrophic cardio¬
myopathy,13 as well as hypertrophic cardiomyopathy
from hypertrophy secondary to systemic hypertension.14
A cyclic variation in IB, corresponding with the cardiac
cycle, has been one of the most consistent findings in
studies measuring IB in contracting myocardium.915'23
The precise mechanism of this cyclic variation is un¬
known. It has been proposed that the intracellular and
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Table 1—Variance components for integrated backscatter (IB) in all regions and all observers
Integrated Observer variation within Observer variation within
backscatter (dB) Intradog variation each dog each scan Interdog variation
Frame Mean SEM Variance (dB2) SD (dB) Variance (dB2) SD (dB) Variance (dB2) SD (dB) Variance (dB2) SD (dB)
End-diastolic 2.78 0.23 0.94 0.97 0.00 0.00 0.43 0.66 0.43 0.66
2 2.56 0.21 0.85 0.92 0.12 0.35 0.22 0.47 0.65 0.81
3 2.28 0.2 0.49 0.70 0.21 0.46 0.07 0.26 0.96 0.98
4 1.68 0.17 0.32 0.57 0.04 0.20 0.27 0.52 0.44 0.66
5 0.83 0.21 0.00 0.00 0.10 0.32 0.31 0.56 0.95 0.97
6 -0.32 0.26 0.00 0.00 0.14 0.37 0.39 0.62 1.34 1.16
7 -1.25 0.33 0.00 0.00 0.20 0.45 0.48 0.69 1.75 1.32
3 -2.30 0.25 0.53 0.73 0.14 0.37 0.12 0.35 1.29 1.14
9 -2.83 0.19 0.30 0.55 0.32 0.57 0.09 0.30 0.81 0.90
10 -2.96 0.26 0.65 0.81 0.03 0.17 0.28 0.53 0.55 0.74
End-systolic -2.99 0.31 1.08 1.04 0.13 0.36 0.54 0.73 0.78 0.88
extracellular elastic domains are cyclically altered in di¬
astole and systole, thereby leading to dynamic changes
in local acoustic impedance mismatch.22 However, other
research workers found that changes in IB occur in iso¬
tonic but not isometric contraction of canine papillary
muscle, suggesting that tissue elastic properties may be
unimportant.24 In a study of backscatter variables in the
frequency domain, using dogs with open thorax, ma¬
nipulation of heart rate, preload, and mean arterial pres¬
sure did not affect the backscattcr variables, and the
authors suggested that the cyclic variation was caused
by an effective change in shape, area, and orientation of
the scattcrcrs within the myocardium.6 Results of a re
cent study have suggested that cyclic variation in IB may
be directly related to sarcomere length.25
The IB values in this study varied in magnitude
corresponding with the cardiac cycle, in agreement with
the findings in most other studies. The maximal value
was found at or near the end-diastolic frame, and the
minimal value was seen at or near the end-systolic
frame. The amplitude of cyclic variation was also similar
to the findings of other groups, as well as to other stud¬
ies using this protocol.812 Other authors have also re¬
ported that the left ventricular free wall has greater
amplitude of cyclic variation than that of the interven¬
tricular septum.8
Calibration of backscatter measurements by use of
a tissue phantom has been described by Yao et al.26 Us¬
ing the ratio of the signal from the canine scans and the
phantom scans eliminates the effects of the transducer
characteristics. Attenuation of the RF signal by the tho¬
racic wall in dogs with closed thorax will inevitably vary
between systole and diastole, thus affecting the results.
However, the IB values reported in this study corre¬
spond with those previously reported in dogs with open
thorax, suggesting that these effects are probably mini¬
mal.911
A potential problem associated with the described
protocol is the use of a 5-MHz probe when digitization
of the RF signal is carried out at 12 MHz, thus intro¬
ducing the possibility of signal aliasing. However, a
fourth-order Butterworth filter was used within the
echocardiography machine to limit aliasing and reduce
noise. Calculations derived from this system suggest
that < 12% of the signal power is likely to be derived
from the aliased signal. Another limitation of this pro¬
tocol is the inability to acquire more than 15 frames/
scan. As with nearly any other cardiac variable, some
beat-to-beat variation is inevitable, and this study as¬
sessed as few as 2 cardiac cycles in some dogs. Despite
this, the SD value for intradog variation was approxi¬
mately 1 dB for end-diastole and end-systole, and was
negligible around early systole. The interdog variation
was even less for end-diastole and end-systole (0.66 and
0.88 dB, respectively). Another disadvantage of this sys¬
tem is lack of an integrated timing reference, so that the
simultaneous ECG was linked to the frames of the con¬
ventional scan, not to the specific RF data. The SD value
for the end-diastolic to end-systolic amplitude of vari¬
ation was large, although this may reflect the imprecise
nature of the timing of individual frames, and does not
take account of any phase delay of the cyclic variation.9
However, the cyclic nature of the IB values was readily
apparent (Fig 3), and this cyclic pattern would not be
fully appreciated if analysis was limited to examination
of end-diastolic and end-systolic frames only.
The advantage of the described protocol is the abil¬
ity to collect RF data from the entire two-dimensional
scan image. This provides freedom for the observer to
choose specific regions of interest during subsequent
off-line analysis, instead of limiting the data acquisition
to regions predetermined at the time of scanning. The
results suggest that the described protocol reliably in¬
dicates cyclic variation in integrated backscatter in nor¬
mal, conscious dogs. Ultrasonic IB measurement offers
the opportunity to measure myocardial tissue charac¬
teristics noninvasively, and has wide potential applica¬
tions in the study of myocardial disease in small
animals. Using the protocol described, this technique
could be applied to clinical cases.
" ATL Ultramark 9 (UM9), Advanced Technology Laboratories, Both-
ell, Wash.
b
Sparc System LX, Sun Microsystems Inc, Mountain View, Calif.
c PROC MIXED, SAS Institute Inc, Cary, NC.
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Case-control study of sudden infant death syndrome in
Scotland, 1992-5




























Objective: To investigate the relation between routine
infant care practices and the sudden infant death
syndrome in Scodand.
Methods: National study of 201 infants dying of the
sudden infant death syndrome (cases) and 276
controls by means of home interviews comparing
methods of infant care and socioeconomic factors.
Results: Sleeping prone (odds ratio 6.96 (95%
confidence interval 1.51 to 31.97)) and drug treatment
in the previous week (odds ratio 2.33 (1.10 to 4.94))
were more common in the cases than controls on
multivariate analysis. Smoking was confirmed as a
significant risk factor (odds ratio for mother and
father both smoking 5.19 (2.26 to 11.91)). The risk
increased with the number of parents smoking
(P < 0.0001), with the number of cigarettes smoked by
mother or father (P= 0.0001), and with bed sharing
(P < 0.005). A new finding was an increased risk of
dying of the syndrome for infants who slept at night
on a mattress previously used by another infant or
adult (odds ratio 2.51 (1.39 to 4.52)). However, this
increased risk was not established for mattresses
totally covered by polyvinyl chloride.
Conclusions: Sleeping prone and parental smoking
are confirmed as modifiable risk factors for the
sudden infant death syndrome. Sleeping on an old
mattress may be important but needs confirmation
before recommendations can be made.
Introduction
There has been considerable interest in recent years
about the role of infant care practices and environment
in the sudden infant death syndrome. Previous studies
showed the risk associated with sleeping prone,'2 and
modification of this practice has been associated with a
major reduction in the syndrome worldwide.3 This
improvement prompted our search for other modifi¬
able risk factors. We report a four year case-control
investigation of risk factors for the sudden infant death
syndrome in Scodand from 1992 to 1995, when the
rate of deaths from the syndrome fell from 1.1 to 0.7
per 1000 live births.
Methods
Population
The registrar general for Scodand reported to us all
infant deaths occurring after the seventh day of life to
the end of the first year. The computerised maternity
record for each infantwas provided by the information
and statistics division of the Common Services Agency.
In the case of deaths from the sudden infant death
syndrome our office was also notified directly by the
pathologist responsible for the necropsy. We defined
the sudden infant death syndrome according to
Beckwith as the sudden death of any infant or young
child which is unexpected from the history and in
which a thorough postmortem examination fails to
show an adequate cause for death.4
Consistency in classification was sought by the use
of a standard necropsy protocol with agreed diagnostic
criteria5 In addition, all death certificates of infants
aged 1 week to 1 year were scrutinised for possible
misclassification of explained deaths. Overall, 201 out
of 798 postperinatal infant deaths were diagnosed as
the sudden infant death syndrome. Six other sudden
deaths may have been misdiagnosed as broncho¬
pneumonia and were not included in the study.
We identified two controls for each case of the
syndrome—the births immediately before and after the
index case in the same maternity unit In this way con¬
trols were matched for age, season, and maternity unit
After permission had been obtained from the general
practitioner a fieldworker employed by the study
contacted the mother by letter, asking for her coopera¬
tion in completing a questionnaire during a home visit
All home visits were made within 21 days of the index
case's death to minimise differences in age related
circumstances between cases and controls. Question¬
naires were completed on 147 cases out of a total of
201 reported and on 276 controls. The failure to
acquire data on the remaining 54 cases was largely due
to delay in notification by the pathologist or parents
not being at home on at least two occasions, making a
visit within 21 days of the death impossible. For 108
cases there were two controls, for 27 cases there was
one control, and for 12 cases there were no controls.
For 29 controls there was no case interview. The
characteristics of the cases without an interview were
compared with the characteristics of those with an
interview and were similar in terms of maternal age,
social class, and deprivation category.8 There was a
small difference in age at death of cases (the mean age
of cases whose parent was interviewed was 15 weeks
and that of those who were not was 18 weeks; P= 0.04).
Data collection
The questionnaire provided core medical and social
data about the infant, as well as details of infant care
practices in the home. Data were collected on routine
childcare practices for cases and controls and on prac¬
tice on the night of death for cases only.
The questionnaire was divided into six main
categories: social and prenatal factors, feeding regi¬
men, sleeping habits, sleeping environment, exposure
to smoking, and illnesses.
Socioeconomic status was assessed by two methods.
The first was assessment of deprivation on the basis of
postal code in seven categories in ascending order of
deprivation.6 These categories take cognisance of over¬
crowding, male unemployment, low socioeconomic
status, and a lack of a car, The second was the registrar
general's social class from standard occupational
classification.
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The tog value (warmth rating) ofboth clothing and
bedding was calculated with the scoring system
supplied by the Shirley Institute, Manchester.7 We used
the average of day and night tog values in analyses.We
took special note of the extra thermal implications of
swaddling and how much of the bodywas swaddled.
Exposure to smoking was assessed in two ways. The
first used the following ordinal scale: neither parent
smoked, father only smoked, mother only smoked,
mother and father both smoked. The second
calculated a dose response by determining the total
number of cigarettes (0, 1-9, 10-19, S20) smoked daily
by mother, father, or other household member.
Exposure to old mattresses was assessed by asking
parents if their infant routinely slept at night on a new
mattress or on one previously used by another infant
or an adult
Data analysis
The primary analyses focused on routine childcare
practices (see table 1), but routine practice and practice
on the night of death were compared for cases (see
table 2). The baseline comparison group always had
the opposite definition—for example, maternal age
<27 was compared with maternal age 527—unless
otherwise stated in the footnotes to table 1,
Univariate analysis
Binary and categorical factors were analysed by
conditional logistic regression analyses, which were
fitted using the proc phreg program in SAS. This
method allows for the matched nature of the data
but is unable to use information on the unmatched
cases and controls. Quantitative factors were analysed
in random effects models fitted by the proc mixed
program in SAS. Matched set was fitted as a random
effect to allow for any correlations in the data due
to matching. This method has the advantage that
it uses information from unmatched cases and
controls.
Over 100 factors were analysed, and about half of
these were significant However, many of the significant
factors became non-significant when adjusted for
obvious confounding factors or for socioeconomic
factors. Results for the factors that remained significant
after these adjustments are presented in table 1.
Quantitative factors were categorised in this table so
that all factors could be directly compared by odds
ratios. Cut off points correspond to values expected to
be most relevant on the basis ofprevious knowledge or
as defined within other studies. All results in table 1 are
based on comparisons between routine sleeping prac¬
tices of cases and controls.
Table 1 Summary of risk factors for sudden infant death syndrome
Proportion (%) of:
Risk factor Cases Controls
Univariate analysis
odds ratio (95% CI) P value
Multivariate analysis
odds ratio (95% CI)* P value
Exposure to smoking:
Mother and father smoke 83/146 (57) 48/275 (17) 7.92 (4.32 to 14.55) 5.19 (2.26 to 11.91)
Mother only smokes 32/146 (22) 45/275 (16) 5.26 (2.31 to 11.98) 5.05 (1.85 to 13.77)
Father only smokes 11/146 (8) 45/275 (16) 1.72 (0.94 to 3.13) 2.12 (0.99 to 4.55)
Neither parent smokes 20/146 (14) 137/275 (50) 1.00 (reference) 0.00011 1.00 (reference) 0.0001}
Does not regularly change position during sleep 93/146 (64) 148/274 (54) 1.88 (1.01 to 2.50) 0.05 2.67 (1.42 to 4.99) 0.002
Old mattress used at night 91/145 (63) 108/274 (39) 2.50 (1.61 to 3.85) 0.0001 2.51 (1.39 to 4.52) 0.002
Maternal age <27 125/201 (62) 109/276 (39) 2.87 (1.85 to 4.45) 0.0001 2.37 (1.23 to 4.58) 0.01
Deprivation score of 7 46/.195 (24) 25/266 (9) 9.59 (3.32 to 27.68) 0.0001 2.56 (1.20 to 5.49) 0.02
Drug treatment in previous week 49/131 (37) 43/186 (23) 1.99 (1.22 to 3.26) 0.02 2.33 (1.10 to 4.94) 0.03
Routine position put down to sleep2:
Prone 13/146 (9) 5/275 (2) 5.37 (1.70 to 16.95) 6.96 (1.51 to 31.97)
Side 75/146 (51) 104/275 (38) 1.58 (1.01 to 2.46) 1.51 (0.76 to 2.98)
Variable 13/146 (9) 19/275 (7) 1.56 (0.71 to 3.42) 1.68 (0.52 to 5.42)
Supine 45/146 (31) 147/275 (53) 1.00 (reference) 0.0001f 1.00 (reference) 0.04}
Has moved under bedclothes 35/146 (24) 35/274 (13) 2.48 (1.42 to 4.34) 0.001 2.18 (1.03 to 4.64) 0.04
Unmarried mother} 130/200 (65) 87/276 (32) 4.22 (2.90 to 6.13) 0.0001 1.87 (1.00 to 3.48) 0.05
Social class IV or V§ 88/201 (44) 53/276 (19) 2.55 (1.66 to 3.93) 0.0001 1.84 (0.99 to 3.43) 0.05
Male sex 138/201 (69) 138/275 (50) 1.84 (1.22 to 2.77) 0.004 1.76 (0.97 to 3.20) 0.06
Cot bumper not used routinely 104/146 (71) 154/274 (56) 2.00 (1.23 to 3.22) 0.005 1.74 (0.94 to 3.21) 0.08
Routinely sleeps with parents 11/146(8) 6/275 (2) 3.92 (1.35 to 11.37) 0.01 2.90 (0.75 to 11.26) >0.1
Any symptoms in previous week 113/147- (77) 162/275 (59) 2.16 (1.32 to 3.52) 0.002 1.58 (0.83 to 3.01) >0.1
Gestation $36 weeks 44/196 (22) 17/276 (6) 4.49 (2.25 to 8.17) 0.0001 2.47 (0.67 to 9.12) >0.1
Was usually swaddled in previous week 55/146 (38) 71/275 (26) 1.71 (1.06 to 2.76) 0.03 1.60 (0.77 to 3.33) >0.1
Other infant death in family 21/146 (14) 14/276 (5) 2.76 (1.30 to 5.84) 0.008 2.45 (0.32 to 18.76) >0.1
Usually sweaty on waking 68/146 (47) 77/275 (28) 1.93 (1.26 to 2.96) 0.003 1.27 (0.68 to 2.34) >0.1
Tog value a 1011 45/147 (31) 50/275 (18) 1.98 (1.17 to 3.34) 0.01 1.10 (0.50 to 2.42) >0.1
Mother left school aged $16 124/144 (86) 168/276 (61) 4.28 (2.41 to 7.62) 0.0001 1.07 (0.48 to 2.38) >0.1
Not currently breast fed 137/147 (93) 209/275 (76) 4.35 (2.13 to 9.09) 0.0001 1.01 (0.39 to 2.71) >0.1
Two or more previous live births 78/197 (40) 64/276 (23) 2.28 (1.46 to 3.56) 0.0003 0.99 (0.50 to 1.96) >0.1
Birth weight <2.5 kg 42/197 (21) 19/276 (7) 3.79 (2.05 to 6.99) 0.0001 0.99 (0.29 to 3.38) >0.1
*0dds ratios are adjusted for all other factors listed in table.
tFor linear trend.
frlncludes mothers who were single, divorced, or cohabiting.
((Obtained from father's occupation or from mother's occupation if father's was unknown; includes 60 subjects for whom neither parent had an occupation to
prevent their deletion in the multivariate model.
IIAverage of day and night total tog values.
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Multivariate analysis
A multivariate analysis was carried out to determine
which factors were independently significant when
adjusted for all other factors found to be important in
the study. This was carried out using a conditional
logistic regression model that included all of the
factors listed in table 1.
Interactions
Interactions with factors of particular interest were
tested in conditional logistic regression models.
Results
Frequencies, odds ratios, and P values for factors that
remained significant after adjusting for obvious
confounding factors and for socioeconomic factors are
presented in table 1.
Nearly all of the people who smoked did so during
and after pregnancy. Overall, 79% of mothers of cases
(115/146) smoked compared with 34% of control
mothers (93/275; univariate odds ratio 5.91 (95%
confidence interval 3.61 to 9.68)). There was a dose
relation, with the risk of the sudden infant death
syndrome increasing with the number of cigarettes
smoked by the mother (P = 0.0001), father
(P = 0.0001), and other people in the household
(P = 0.001); each factor was analysed separately. The
risk also increased significandy with exposure (table 1).
The risk caused by maternal smoking increased when
the infant shared a bed (P < 0.005). Given that smoking
is causal, the population attributable risk of smoking
during and after pregnancy was 62%.
Sleeping prone remained a significant risk factor,
although few infants in the control population were
routinely placed prone (2%(5/275)); 9% of the index
mothers (13/14b) opted tor this position routinely,
resulting in an increased risk for their infants (table 1). At
Table 2 Sleep practices routinely at night and at death in 147
babies who died of sudden infant death syndrome. Values are
numbers of cases
Routinely At death
Placed prone 13 19
Found prone 16 50
Placed on side 75 78
Found on side 43 44
Placed variably 13 0
Found variably 21 0
Placed supine 45 47
Found supine 65 51
Total tog &10 45 40
Shared bed with parent 11 48
Duvet used 31 50
Pillow used 20 35
Swaddled 55 43
s 3 Old mattress, type of cover, and risk of sudden infant death syndrome
uding routine bed sharers)
Proportion (%) ot:







78/130 (60) 101/264 (38) 2.27 (1.46 to 3.52) 2.46 (1.34 to 4.52)
24/36 (67) 30/50 (60) 0.92 (0.22 to 3.77) 0.44 (0.09 to 2.05)
53/93 (57) 70/213 (33) 2,27 (1.29 to 4.00) 4.07 (1.90 to 8.68)
sted for all factors in table 1. Odds ratios remained virtually identical when infants bed sharing at
were excluded.
death 50 of the 147 infants were found prone (34%),
though only 19 (13%) had been placed prone (table 2).
Sleeping on the side was also a significant risk
factor on univariate analysis (odds ratio 1.58 (1.01 to
2.46)). 51% of the index mothers (75/146) placed their
babies on their sides, compared with 38% of controls
(104/275). Sleeping on the side was the most labile
sleeping position, but cases and controls routinely
tended to move from sleeping on their side to sleeping
supine if they moved at all rather than to sleeping
prone. We noted that routinely only 44% (33/75) of
index babies placed on their sides were found in a
different position on wakening, compared with 68%
(70/104) of controls (odds ratio 0.37 (0.20 to 0.68).
Indeed, regardless of the position in which they were
put down or found, controls were more likely than
cases to change position regularly during sleep (odds
ratio 0.53 (0.40 to 0.99)).
Mattresses used previously by at least one other
infant or an adult seemed to place an infant at increased
risk of the sudden infant death syndrome. The risk from
routinely being on an old mattress at night also
increased for infants who had undercovers with a lower
tog value (P= 0.05), who had colds (P= 0.02), and who
were off their feeds (P= 0.02). No significant interactions
occurred with smoking, sleeping place—for example, cot
or pram—sleeping position, and birth order, so we could
not draw any firm conclusions on the influence of these
factors. There was no detectable increase in risk with old
mattresses completely covered by polyvinyl chloride
(table 3). The increase in risk was associated with both
the so called combination mattresses, in which the
bottom two thirds of the mattress is covered by polyvinyl
chloride and the top third consists of ventilated foam
covered by netting, and with cloth covered mattresses.
We had insufficient data to investigate interaction of old
mattresses with routine bed sharing. However, 34% of
the index cases (48/142; table 2) were sleeping with par¬
ents at death—30% (42/142) in an adult bed and there¬
fore on mattresses used by others.
We asked parents whether they had ever found that
their baby had moved under the bedclothes. Over¬
all, 24% of parents of cases (35/146) said that they
had compared with 13% of controls (35/274), and this
difference was significant on multivariate analysis
(odds ratio 2.18 (1.03 to 4.64)) (table 1). On the day or
night of death 13% (19/146) of the index cases were
found under bedcovers.
Receiving any drug treatment in the week before
death emerged as a strong risk factor in the multi¬
variate analysis (table 1). After adjustment for
symptoms in the previous week, consultation with a
general practitioner, prematurity, and low birth weight,
no individual drug was significant. We noted that the
index cases were more likely to have had one or more
of a range of symptoms and to have been seen by their
general practitioner because of illness during the previ¬
ous week. The symptoms with the highest odds ratios
on univariate analysis were unusual sleepiness (odds
ratio 2.61 (1.26 to 5.51)), snuffles (1.61 (1.07 to 2.44)),
and sickness (1.69 (0.92 to 3.10)). The only symptom
more common in controls was increased irritability.
Poverty was confirmed as a significant risk factor for
the syndrome, the rate increasingwith deprivation score,
as shown in table 4. Low socioeconomic status (classes
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Table 4 Association between deprivation score and sudden
infant death syndrome
No (%) of:
Deprivation score Cases (n=195) Controls (n=266)
1 6(3) . 22 (8)
2 10(5) 26 (10)
3 27 (14) 70 (26)
4 48 (25) 56 (21)
5 39 (20) 35 (13)
6 19 (10) 32 (12)
7 46 (24) 25 (9)
P<0.0001 for trend.
IV and V) was also significant even when adjusted for
deprivation score in the multivariate model.
Factors significant on univariate • but not on
multivariate analysis were being male, sleeping on the
side, non-routine use of cot bumper, routine sleeping
with parent(s), any symptoms in previous week,
gestation 36 weeks, usually being swaddled in
previous week, previous infant death in family (sibling,
half sibling, or first cousin), usually being sweaty on
wakening, tog value of bedding and clothing SlO,
mother leaving school at 16, bottle feeding at time of
death, two or more previous live births, birth weight
<2500 g. However, their significance on univariate
analysis makes them noteworthy. In particular, the
finding of a high thermal score of bedding plus cloth¬
ing is consistent with other published data." A high
thermal score seemed to be more risky for boys than
for girls (P = 0.03).
Examples of factors that were not significant on
univariate analysis included the time between the last
two pregnancies, twin birth, non-European mother,
complementary feeding (combined breast and bottle
feeding), age at introduction of solids, sleeping room,
sleeping place (other than parents' bed), use of pillow,
use of duvet, type of mattress covering, use of
sheepskin, swaddling, heated sleeping room, and
admission to hospital in week before death. Signifi¬
cantly more babies died on a Saturday or Sunday than
would be expected by chance (42% (84/201), P < 0.01);
11% (17/158) of deaths occurred when the infants
were away from their usual place of residence.
The decrease in the rate of the sudden infant death
syndrome over the four years was 0.4 per 1000 live
births. We assessed whether attributable risks were
likely to have changed during the study by testing
whether factors had changed during the study in the
control group. The following factors changed signifi-
candy; the number of parents who smoked was
reduced (P = 0.02), more infants were placed supine
(P = 0.01), and mothers were older (P = 0.008). Thus,
assuming constant relative risks, population attribut¬
able risks had decreased for parents' smoking, use of
prone and side sleep positions, and younger mothers.
Discussion
Smoking
Parental smoking during and after pregnancy is a
major, potentially modifiable, risk factor found in many
other studies.®10 If only the father smoked the risk was
almost significant. The finding of a dose response witii
the number of people smoking in the household adds
weight to the possibility of smoking being causally
related to the sudden infant death syndrome, as does
the increased risk related to the number of cigarettes
smoked. If smoking is causal two thirds of the cases of
the syndrome might be avoided if mothers did not
smoke during and after pregnancy. Health promotion
initiatives to discourage young girls from starting to
smoke and to help smokers reduce their habit are
urgently required." 12
Sleeping position and place
Although sleeping prone remains a strong risk factor,
its low prevalence in the infant population in Scotland
indicates that only a small percentage of deaths from
the syndrome can now be attributed to this. Sleeping
on the side was more risky than sleeping supine and
since 38% of control infants were routinely placed this
way, a significant number of deaths may be attributed
to this sleep position. Sleeping on the back is the safest,
so parents should be advised to use this position
wherever possible.
The significance of failure to change position
during sleep (table 1) supports observations by
Schechtman et al that infants considered at increased
risk of the syndrome show fewer spontaneous arousals
from sleep and fewer movements during sleep than do
control infants."
The New Zealand cot death study found an
increased risk for infants sleeping with a parent only if
the mother smoked.14 A subsequent report from
California failed to confirm this risk," but our data are
consistent with the New Zealand findings. In addition,
the gready increased incidence of bed sharing in cases
at death concerns us. We accept that routine bed
sharing may be underreported, but it is difficult to
believe that it could account for an increase from 8%
routinely to 34% at death.
In Scotland most infants routinely share a room
with their parent(s) at night—78% of index cases and
75% of controls. As nearly all the mothers in the study
were European, the high prevalence of room sharing
was not associated with an ethnic minority group, as
noted in some studies.1"17 In our study it was not a sig¬
nificant factor (odds ratio 1.20 (0.69 to 2.09) on
univariate analysis. This differs from the data of Scragg
et al, who found it to be protective.1* We recognise that
our data, in contrast to those of the New Zealand
study," were collected when the incidence of the
syndrome and the rate ofprone sleeping (2%) were low
and the rate of room sharing was high (75%) in
controls, making comparison difficult. On the basis of
our results, however, we believe that advice on room
sharing is not at present indicated in Scotland.
Mattresses and other factors
The results from the mattress analysis were unexpected.
There is an increased risk of some kind, regardless of
parity and social deprivation, for infants sleeping on
mattresses previously used by others, although the risk
was not established for mattresses completely covered
by polyvinyl chloride. Our findings therefore lend no
support to the hypothesis that household fungi interact
with fire retardant chemicals in the plastic covering of
cot mattresses and release toxic gases, which in turn
cause sudden infant death.'® The failure to establish risk
with mattresses completely covered with polyvinyl chlo¬
ride may be because they can be kept clean, regardless
of age, while others cannot
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Factors affecting completeness of excision and outcome,
whether conservation or mastectomy, in 152 patients with
localized impalpable breast cancer undergoing therapeutic
needle-guided wide local excision were assessed by
univariate and multivariate analyses using multiple
logistic regression. Independent factors related to
completeness of excision at the first operation were
operator experience (P = 0-0001), and size of the lesion
(P~ 0-005). Factors related to outcome were operator
experience (P = 0-0003), more experienced operators
having a higher rate of breast conservation, and tumour
size (P = 0-0001), larger lesions being more likely to be
treated by mastectomy. Patients initially operated on by
the two most experienced surgeons were more than four
times less likely to undergo mastectomy than those whose
initial wide local excision was performed by a less
experienced surgeon.
Excision biopsy for impalpable breast cancer results in up
to 60 per cent of patients having an incomplete excision1-.
It is now possible, with the use of stereotactic and
ultrasonographically guided fine-needle aspiration
cytology, to identify the majority of patients with
impalpable malignant lesions before operation3 and
permit the first surgical procedure to be therapeutic. It is
the policy in the authors' unit to perform a therapeutic
needle-guided wide local excision for patients with
localized impalpable lesions (4 cm or less) from which
malignant cytology has been obtained4. If the initial
excision is incomplete then patients are selected for either
re-excision or mastectomy5. The aims of this study were to
determine which factors affect the completeness of
excision at initial operation and which influence whether
the patient is ultimately treated by breast-conserving
therapy or mastectomy.
Patients and methods
A total of 152 patients with localized (4 cm or less on
mammography) screen-detected impalpable breast tumours
diagnosed by stereotactic or ultrasonographically guided fine-
needle aspiration cytology underwent a therapeutic wide local
excision between 1 January 1991 and 30 June 1993. The notes of
these patients were reviewed and data extracted on the factors
listed in Table 1. These factors were then correlated with the
outcome of surgery.
Patients were defined as having had a complete excision if the
mammographic lesion had been completely excised and all
resection margins were 1 mm or more clear of invasive and in
situ disease on histological assessment.
Surgeons
Two surgeons performed almost 70 per cent of the operations
and these have been designated as experienced operators (Table
2). One was a consultant and the other a senior registrar with a
specific interest in breast disease who had been attached to the
unit three times for a total of 3-5 years. In contrast, six of the
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Table 1 Factors studied
Nature of mammographic lesion
Presence of microcalcification
Type of microcalcification (branched or non-branched)
Presence of mass lesion
Distortion of architecture
Combination of these features
Operator
Experience (log of number of operations performed during the
study)
Experience (more than 20 operations ) versus no experience




Size of lesion (cm)
Volume of excision
Invasive cancer or in situ disease
Type of invasive or in situ cancer
Presence of extensive in situ component within invasive cancer
Histological axillary node involvement
seven inexperienced surgeons were attached to the unit for short
periods of training. During their attachment to the breast unit,
senior registrars and registrars were trained to perform wire
localization biopsy in patients undergoing diagnostic excision.
Thereafter, they were supervised during the first three wire-
guided therapeutic wide local excisions for cancer and were then
allowed to perform these procedures with no consultant present
at the operating table, but available in the theatre suite.
Operative procedure
All patients underwent wire-guided local excision. This was
performed using stereotactic guidance in 121 patients and
ultrasonographic guidance in 31. After removal of the specimen
it was orientated with ligaclips and orientated specimen
radiography was performed in an attempt to achieve complete
excision at one operation as previously described4. The external
surfaces of the specimen were painted with ink and the specimen
placed on a trimming jig with the anterior surface uppermost.
Serial slices (4 mm thick) were taken in a plane parallel to the
chest wall and subjected to radiography. The appropriate areas
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Table 2 Operators*
Grade of surgeon
No. of Total no. of Percentage of Senior
surgeons operations all operations Consultant registrar Registrar
Experienced 2 106 71 1 1
Inexperienced 7 46 29 1 4 2
*Experienced surgeons performed more than 20 operations during the study period while inexperienced surgeons carried out less than
were blocked to include all six possible resection margins and all
areas of radiological abnormality.
Protocol
A standard policy for re-excision and mastectomy was employed
throughout the study period (Table 3).
Statistical analysis
Univariate analysis using logistic regression, x1 and Fisher's exact
tests and multivariate analysis using multiple logistic regression
were used to relate the factors in Table 1 with completeness of
excision at the first operation and outcome (breast conservation
or mastectomy). Analyses were performed for the whole group
(both invasive and in situ disease) and for the groups of patients
with invasive and in situ disease separately.
Table 3 Unit protocol for re-excision and mastectomy
Re-excision
One (focal) margin involvement and tumour either DCIS or
invasive cancer and ElC-negative
Mastectomy
Focal margin involvement and invasive cancer and EIC-
positive
More than one margin involved
Margin involvement but impossible to determine extent or
location of residual disease
Multifocal invasive cancer
DCIS more than 4 cm irrespective of margin involvement
DCIS, ductal carcinoma in situ; EIC, extensive in situ component
Results
Som& 100 patients had invasive cancer and 52 in situ
disease. The pathological size of the lesions ranged from
0-3 to 5 cm. Twelve patients had invasive tubular cancer
and 22 of 100 with invasive cancer had an extensive in situ
component. The volumes of excision ranged from 13 to
240 ml and seven of the 132 patients who had axillary
nodes excised had involved axillary nodes.
A total of 122 lesions (80 per cent) were completely
excised at the first operation, including five patients with
ductal carcinoma in situ (DCIS) extending over a distance
of more than 4 cm and two with multifocal disease.
According to the protocol in Table 3 these latter seven
patients underwent mastectomy. Some 126 patients (83
per cent) were treated ultimately by conservation therapy
and this included 115 who had an adequate excision at the
first operation and 11 who underwent successful re-
excision. Twenty-six patients (17 per cent) were treated by
mastectomy.
Univariate analysis: all cancers
Of factors influencing the likelihood of complete excisionand surgical outcome, operator experience and lesion size
were significant in univariate analysis (Tables 4 and 5).
The frequency of complete excision for each individual
surgeon related to the number of operations carried out
by that surgeon during the study is shown in Fig. 1. One of
the inexperienced surgeons was a consultant who
performed only a few procedures (Table 2). During their
first operations the six inexperienced surgeons who were
not consultants were supervised and 11 of these 18
excisions had clear histological margins compared with
nine of 28 in later operations which were unsupervised.
This difference was not statistically significant. A major






Experienced 106 102 (96) 4(4) 00001
Inexperienced 46 20 (43) 26 (57)
Microcalcification
Yes 80 59 (74) 21 (26) 0-037
No 72 63 (88) 9(12)
Mass
Yes 64 57 (89) 7(11) 0-024
No 88 65 (74) 23 (26)
ElCt
Yes 22 15 (68) 7(32) 0 022
No 78 69 (88) 9(12)
Mean(s.e.m.) — 1-40(0 09) 2-17(0-22) 0-0001
size (cm) ~\
Values in parentheses are percentages, t Invasive cancers only.
EIC, extensive in situ component




No. of One Re- Mast¬
operations excision excision ectomy P
Surgeon
9(8) 00002Experienced 106 96 (91) 1(1)
Inexperienced 46 19 (41) 10 (22) 17 (37)
Mass
Yes 88 59 (67) 9(10) 20 (23) 0-031
No 64 56 (88) 2(3) 6(9)
Invasive
Yes 100 81 (81) 6(6) 13 (13) 0-062
In situ
Yes 52 34 (65) 5(10) 13 (25)
Values in parentheses are percentages. *Size also significant see
Table 6
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No. of operations per surgeon
Fig. 1 Lesions completely excised compared with experience
(plotted as the number of operations performed during the study
- log scale)
problem during unsupervised operations was removal of
areas of microcalcification in more than one piece, which
made assessment of completeness of excision difficult.
The three possible outcomes, namely complete excision at
one operation, re-excision and mastectomy, according to
whether the initial operation was performed by an
'experienced' or 'inexperienced' surgeon are given in Fig.
2. Patients who had their initial operation performed by
an 'inexperienced' surgeon were greater than four times
more likely to require a mastectomy than those whose
initial operation was undertaken by a more experienced
surgeon. The size of the lesion related to outcome is
presented in Table 6: the mean size of the lesion increased
as the extent of local surgery increased. The 12 patients
with tubular cancer had a complete excision at the first
operation but this was not significantly different from the




Fig. 2 Outcome in patients for a all cancers and b in situ cancers
related to whether their initial operation was performed by an
experienced (□) or inexperienced (el) surgeon
Table 6 All cancers: size of lesion related to outcome
No. of Mean(s.e.m.)
Outcome patients size (cm)
Single excision 115 1-25(0-06)
Re-excision 11 1-86(0-33)
Mastectomy 26 2-74(0-29)
Multivariate analysis: all cancer
Margins. The two factors retaining independent
significance for completeness of excision were operator
experience (P = 0-0001), more experienced operators
achieving a higher rate of complete excision, and size of
lesion (P = 0-005), larger tumours being less likely to be
completely excised (Table 7).
Outcome. Factors related to outcome were operator
experience (P = 0-0003) and tumour size (P = 0-0001).
Patients were less likely to be treated by mastectomy if
their initial operation was performed by a more
experienced surgeon and larger tumours were more likely
to be treated by mastectomy (Table 7). There were no
significant relationships between other factors and
outcome.
Invasive cancer
In multivariate analysis only operator experience
(P = 0-005) was related to completeness of excision (Table
7). Both operator experience (P = 0-006) and tumour size
(P = 0-028) were identified as significant factors related to
whether patients had breast conservation or mastectomy.
In situ cancer
Lesion extent and operator experience were the only
independent significant factors predicting completeness of
excision and outcome (Table 7). Experienced surgeons
were more than twice as likely to excise an in situ tumour
completely at one operation than less experienced
surgeons (Fig. 2). The mean size of in situ lesions
requiring mastectomy was over 3-5 cm (Table 8).
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Values in parentheses are s.e.m.
Table 8 In situ cancer: size of lesion related to outcome
No. of Mean(s.e.m.)
Outcome patients size (cm)
Single excision 34 1-53(0-15)
Re-excision 5 2-30(0-66)
Mastectomy 13 3-56(0-33)
Table 9 Reasons for mastectomy
Residual disease
No. of in mastectomy
Reason patients specimen
Invasive cancer
Multifocal disease 3 Oof 3
Focal margin involvement and 3 1 of 3
ElC-positive
Widespread margin involvement 2 1 of 2
Uncertainty about completeness 5 3 of 5
of excision
In situ
Extensive margin involvement 4 2 of 4
More than 4 cm margins clear 5 3 of 5
Uncertainty about completeness 4 3 of 4
of excision
Total 26 13 of 26
EIC, extensive in situ component
Reasons for mastectomy
Seven patients underwent mastectomy after an apparently
complete initial wide local excision because of DCIS
extending over a distance of greater than 4 cm (five
patients) or because of multifocal invasive cancer (two).
The reasons for the remaining 19 patients having a
mastectomy are outlined in Table 9. Of the 26 patients
who underwent mastectomy, 13 were identified as having
residual disease in the excised breast after mastectomy.
Nine patients underwent mastectomy because of
uncertainty over completeness of excision; all had their
operations performed by unsupervised, 'inexperienced'
surgeons. The finding of residual disease in six of nine of
these patients justified mastectomy.
Discussion
The main role of screening is to reduce death from breast
disease, but a secondary aim is to reduce morbidity. One
way of achieving this is to treat more patients with breast
cancer by breast-preserving surgery. Morbidity can also be
reduced by identifying those patients with breast cancer
before operation to permit the surgeon to perform a
therapeutic excision as a first surgical procedure4. This
study investigated those factors in patients with apparently
localized impalpable breast cancer which affect whether
the surgeon achieves a complete excision at initial
operation and which influence whether patients are
ultimately treated by breast conservation or mastectomy.
The extent of the lesion was a major factor in determining
the surgeon's ability to excise the lesion completely at the
first operation. Disease extent also correlated with
surgical outcome, with larger lesions being much more
likely to require mastectomy.
The other major factor influencing completeness of
excision and surgical outcome was experience of the
surgeon who performed the initial wide local excision.
Experienced surgeons were more than twice as likely to
excise an impalpable tumour completely at one operation
and patients whose initial operation was performed by an
experienced surgeon were more than four times less likely
to be eventually treated by mastectomy. The majority of
inexperienced surgeons were those in training. They were
trained according to an agreed protocol and were allowed
to perform excision of impalpable tumours only when they
were deemed to be competent. An adequate complete
excision rate was achieved during the first few excisions
when the trainees were supervised. When they started to
perform operations alone, however, the rate of complete
excision declined because they frequently removed the
mammographic lesion in several pieces which made
assessment of completeness of excision and the site of any
residual disease difficult. In such cases, the authors'
protocol dictated that these patients should be treated
with mastectomy; a policy that seems justified by the high
rate of residual disease in the subsequent mastectomy
specimens.
It was also policy to perform a mastectomy for areas of
carcinoma in situ extending over 4 cm. As all
mammographic lesions measured less than 4 cm, a
pathological size of more than 4 cm indicated that the
histological extent of disease was greater than the
mammographic lesion and thus that in these patients was
not a reliable marker of the extent of disease. The policy
of advising mastectomy for these lesions is based on data
from analysis of whole breast specimens6. The fact that
residual disease was identified in three of five
mastectomies performed on patients with DCIS over 4 cm
which had apparently been completely excised justifies
this policy and suggests that it would not be prudent to
include DCIS lesions over 4 cm in size in the current UK
randomized study of treatment of DCIS.
The presence of multifocal disease is usually considered
an indication for mastectomy7. In the present series none
of the patients with multifocal disease had residual
disease in the removed breast. This suggests that breast
conservation therapy may be appropriate in patients with
localized multifocal disease8. The presence of an extensive
in situ component (EIC) within an invasive cancer is a risk
factor for residual disease in the breast after wide
excision9. In the present series patients with invasive
cancer which was EIC positive were significantly less likely
to have an initial complete excision than those with
tumours which were EIC negative (P = 0-022, Table 4).
However, only one of three patients who had focal margin
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disease in the breast at mastectomy but the numbers are
too small to draw any firm conclusions.
The findings of the present study have important
implications for the training of surgeons in the removal of
screen-detected impalpable tumours. The aim during the
study period was to train all senior registrars, and some
registrars, attached to the breast unit to remove
impalpable breast tumours safely. They started by
performing wire localization biopsy under supervision in
patients undergoing diagnostic excision. After performing
three or four biopsy procedures they proceeded to
supervise wire-guided therapeutic excision for breast
cancer. When considered to be competent, they were
permitted to perform these procedures without an
experienced surgeon supervising the operation. This study
demonstrates that there is a long learning curve to this
procedure and that it is not until a trainee has performed
10-15 of these operations that he/she becomes
competent.
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heart rates also declined in a similar manner to the first
study. The relationship between the reduction in exercise
heart rates and the increase in threshold for breathlessness
was statistically significant (P < 0-001).
Over the same time period, a further thirteen subjects
(age 31 ± 10 years, mean + g.d.) rebreathed C02 in oxygen
utilizing the Read rebreathing procedure. Neither the slope
nor the intercept of the VAS/VE rclationohip showed any
consistent effect of repetition. Heart rate data were
available on five subjects. There was no significant change
(Student's t test) either during the actual test or between
test days, whether one looked at the heart rates at a fixed
index (7% FeCOj), the slope of the fC/Fe002 relationship,
or at the beginning or end of the experiment.
The underlying mechanism for the observed changes in
the threshold response could include an alteration in the
criteria used by the subjects to estimate the magnitude of
the sensation, and physiological effects resulting from
repetitive exposure to the exercise i.e. a training response.
The data from these experiments suggest that at least some
of the change is associated with a cardiovascular training
effect; the rebreathing study does not support the concept
of a change in the assessment criteria as a result of
repetitive exposure.
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Maturational changes in the respiratory rhythm of
the mouse in vitro and in vivo
Julian F.R. Paton and Diethelm W. Richter
II Pkysiologisches Inslitul, University of Gottingen,
Humboldtallee 23, D-37073, Germany
The effects of raising body or hypothalamic
temperature on ventilation in the anaesthetized rat
M.J. Parkes*! and M.O. Harris!
^School of Sport & Exercise Sciences and t Department of
Physiology, University of Birmingham, Birmingham
B15 2TT
There is evidence for a relationship between raised body
temperature and apnoea in the neonatal period (Stanton,
1984). Since the adult rat makes certain respiratory
responses which resemble those of the human neonate
(Nevlon & Marshall, 1991), it may be useful to study this
relationship in the rat. Little, however, is known about the
effects of raising body temperature on ventilation in this
species (Gordon, 1990).
Adult rats therefore were anaesthetized with Hypnorm
(1 ml kg 1 r.p.) and diazepam (1 ml kg-' i.p.). The depth of
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anaesthesia was monitored carefully and a-chloralose(5 mg
doses l.v.) was given if pinching the tail produced a change
in blood pressure or heart rate. Oxygen-enriched air was
breathed spontaneously through a tracheal cannula. End-
tidal heart rate, blood pressure, rectal and
hypothalamic temperature were measured continuoucly.
In seven rats heat was applied over a 20-46 min period
via a heating blanket and an infrared lamp. Tho frcqucncy
of spontaneous breathing was 72 + 3 breaths min-1
(mean ± s.e.m.) at a hypothalamic temperature of 36-5 °C
and increased to 96 + 5 breaths min-1 at 39 °C (P < 0-001,
one-tail paired t test, n — 6). Heart rate increased from
447 + 31 beats min-1 at 36-5 °C to 490 ± 21 beats min-1 at
39 °C (P < 0-002, n = 5). Thorc was no significant change
in end-tidal or arterial Pmt (46 + 1 mmHg at 36-5 °C and
46 + 3 mmHg at 39 °C, P >0-05, n — 5). P^ fell,
however, by 1-5 mmHg in three rats, and rose by
4—9 mmHg in two rats. There was no obvious difference
between rats which could explain why ^co, rose in some
and fell in others.
In two rats localized heating in the pre-optic area (POA),
on the right side, was attempted by passing a 10 MHz
current for 60 s through a bipolar electrode. Tissue
temperature 1 mm lateral to the electrode was measured
and the position of the warming electrode confirmed
histologically at post-mortem. In one rat breathing
frequency was 61 breaths min-1 in the 85 s period
preceding the onset of heating and increased to
93 breathe min-' during the 85 s period following tho onset
of heating. In the other rat heating outside the POA
produced no increase in breathing frequency.
These results show that in the anaesthetized rat raising
body temperature or localized heating in the POA initially
increases the frequency of spontaneous breathing. Tho rat
therefore responds in a similar manner to other mammals and
is suitable for more detailed investigation of the relationship
between raised temperature and episodes ofapnoea.
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Stability of breathing patterns in men, rats and
rabbits
M. Dallak, Xiujie Luan*, H. Brown and L. Pirie
Department of Physiology, University of Edinburgh,
Edinburgh and *Bethune University of Medical Sciences,
Changchun, China
We intend to compare breathing pattern in conscious
emphysematous and normal rabbits. To estimate the
minimum number of emphysematous rabbits required to
give a statistically valid result we need to know the
variability of the pattern of breathing in normal rabbits.
Supplied by the British Library - "The world's knowledge" www.bl.uk
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We can find no record of such a measurement in the
literature, although rabbits are said to have a highly labile
pattern of breathing. The reproducibility of pulmonary
mechanics has been measured in cattle (Galivan &
McDonell, 1988) and breathing pattern of human beings
has been measured in single instances (Tobin et al. 1983)
and over time (Benchetrit et al. 1989).
We have adapted the whole body plethysmography
method of Bartlett & Tenney (1970) developed from the
method of Drorbaugh & Fcnn (1955) to measure the
breathing pattern of four rabbits and four rats on four
separate days. The plethysmograph consists of a chamber
through which a stream of air enters from a pump and
leaves via a narrow tube. This tube offers high impedance
to flow at the frequency of breathing of rats and rabbits.
The breathing of the occupant of the chamber is therefore
accurately reflected by small changes in pressure in the
chamber. To precisely measure tidal volume the inlet and
outlet of the chamber was closed for a few seconds. The
breathing pattern of four human subjects was measured on
four separate days, using an ultrasonic pneumotachograph
(FIP Instruments, Field Road, Huntingdon, Cambridge).
One hundred consecutive breaths were measured in terms
of their inspiratory duration (tj) expiratory duration (te)
and tidal volume (FT).
Variability of pattern was calculated as components of
variance using the commercial analysis program SAS (SAS
Institute Inc., SAS Circle, Box 8000 Cary, NC 27512-8000).
We calculate that to detect with 80% certainty a 10%
change in the mean values of inspiration, expiration and
tidal volume with the experimental protocol and species we
have used, would require twelve men, nineteen rabbits, or
eight rats respectively.
Sup{)orted by the Norman Salvesen Emphysema Research
Trust.
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Pulmonary receptors in the spontaneously
breathing anaesthetized rat
L. Pirie and A. Davies
Department of Physiology, University of Edinburgh,
Edinburgh EH8 9AG
It has been suggested that the rate of adaption of
pulmonary stretch receptors should be greater in species
with high respiratory rates to maintain effective reflex
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control of breathing (Bartlett & St John, 1979). Our
alternative suggestion is that a greater proportion of
rapidly adapting receptors exists in more rapidly breathing
species. This increases the overall rate of adaption. To test
this hypothesis the activity of seventy-three pulmonary
mechanoreceptors with afferent fibres in the left vagus
nerve was studied in sixteen spontaneously breathing
anaesthetized (6 ml kg-1 25% Urethane, i.p.) rats, during
eupnoea and sustained inflation of the lungs. Fifty-one
receptors discharged mainly in inspiration, and were
slowly adapting (PSRs). Twelve discharged exclusively
during early inspiration. Thirty discharged throughout
inspiration and in early expiration. Nine discharged
throughout inspiration and expiration.
Twontytwo rapidly adapting roooptom (RARo) were
spontaneously active during eupnoea (peak frequency
87-52 ± 6-10 Hz, mean frequencj' 28-77 + 1-25 Hz),
discharged almost exclusively during expiration
(2-59 + 0-23 impulses in inspiration, 13-34 ± 0-55 impulses
in expiration, 110 breaths) and, by definition, totally
adapted in 0-25 s.
The patterns and total numbers of discharges for RARs
were remarkably constant from breath to breath for
individual receptors (e.g. 12-4 ±0-4 impulses in five
consecutive expirations).
The discharge frequencies of these receptors were
comparable with thoso of other species (Widdicombe, 1954).
The abundance of RARs was greater than in larger species
(Roumy & Leitner, 1980).
The high proportion of RARs may represent an
evolutionary advantage in neural control of the high
frequency breathing of small mammals.
(Figures are means and standard errors of the mean).
Supported by the Norman Salveaen Emphysema Research
Trust.
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Low frequency heart rate components in sick and
healthy human neonates
G.C. Halley, J.H. Dripps, H. Janssens and N. Mcintosh
Department of Child Life and Health, University of
Edinburgh, 20 Sylvan Place, Edinburgh EH9 1UW
In the adult population it is well recognized that
oscillations in the heart rate at 0-05 and 0*1 Hz are present
and represent thermoregulatory and blood pressure control
mechanisms respectively. The objective of this observational
Btudy was to examine low frequency heart rate and
respiratory rate oscillations in healthy term infants and
compare these results with a group of sick infants at term.
Supplied by the British Library - "The world's knowledge" www.bl.uk
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The effects of gamolenic acid
on adult atopic eczema
and premenstrual exacerbation
of eczema
FRANCES HUMPHREYS, JULIAN A. SYMONS, HELEN K. BROWN,
GORDON W. DUFF, JOHN A.A. HUNTER
A double blind, parallel, placebo controlled study was performed to assess the effects of
four months treatment with gamolenic acid in evening primrose oil on adult atopic eczema.
Fifty-eight subjects entered the study and results were analysed for fifty-two of these. Sub-
jecfs were divided into three groups, women with, and women without, a reported pre¬
menstrual exacerbation of their eczema and men. Mean results for the three groups combi¬
ned showed a significant effect of evening primrose oil on erythema and surface damage
when compared with placebo. No significant effect on the mean clinical score for licheniri-
cation was found. When maximum severity was examined there was a significant effect of
evening primrose oil on erythema after four months treatment and on lichenification 2
months post-treatment but no effect on surface damage. Serum soluble interleukin 2 receptor
levels fell to a greater extent with evening primrose oil than with placebo but this was not
statistically significant. Women who reported a premenstrual flare of their eczema showed a
greater improvement with GLA compared with placebo than the other 2 groups. Adjunctive
treatment with gamolenic acid in evening primrose oil should be considered in patients with
chronic atopic eczema.
n the 1920's it was first noted that rats deprived of dietary
fatly acids failed to thrive and developed skin signs similar
to human atopic eczema [1]. It was found that oral admi-
stration of the unsaturated fatty acid, linoleic acid, the pre-
rsor of gamolenic acid, reversed these changes and the
m essential fatty acid (EFA) was coined [21. Furthermore, it
as discovered that topical administration of linoleic acid to
A-deficient rats restored the characteristically abnormal
irrier function of the epidermis to normal [3], Similar skin
anges were also noted in human infants whose diet lacked
sential fatty acids [4]. These changes were also reported in
itients suffering from fat malabsorption requiring parenteral
sding and the consequent skin signs and increased transe-
dermal water loss were reversed by the application of sun-
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flower oil, which is rich in linoleic acid [51. This led to the
supposition that dietary supplementation or some essential
fatty acids might have a therapeutic role in eczema. Further
work revealed that patients with atopic eczema have elevated
plasma levels of the essential fatty acid, linoleic acid, buthave reduced proportions of its metabolites suggesting a
block in the conversion pathway [61. However, interpretation
of these findings is hindered by the fact that these substances
can theoretically be precursors of anti-inflammatory as well as
pro-inflammatory molecules via the cyclo-oxygenase andlipoxygenase pathways.
Oil derived from the seed of the evening primrose plant is
rich in two essential fatty acids, gamolenic acid and linoleic
acid, and this oil has been used in the treatment (usually
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adjunctive) of atopic eczema in adults and in children. In the
published clinical trials to date, in which evening primrose oilhas been assessed in adult atopic eczema, conflicting results
have been obtained. Four studies have shown some beneficial
effects [7-10] and two larger studies have concluded that
there was no significant therapeutic benefit [11, 12]. In addi¬
tion a meta-analysis of some previously published and some
unpublished data was performed which showed a significant
therapeutic effect of ratty acid supplementation [13]. This
meta-analysis has been the subject of some criticism [14] and
it has been suggested that differences in baseline severity bet¬
ween the patient groups may have accounted for an apparent
effect of evening primrose oil, patients with more severe ecze¬
ma having more 'potential for improvement".
It has been previously noted that up to 30% of women with
chronic atopic eczema report a premenstrual worsening of
their symptoms [15]. In addition to its putative effects on ato-
Eic eczema evening primrose oil has been found to have aen ficial effect i pre-menstrual mastalaia [16] and the pre¬
menstrual syndrome [17]. Furthermore there are many docu¬
mented interactions between the hormonal system and arachi-
donic acid and its precursors.
For these reasons we designed a study to examine the effects
of evening primrose oil in adult atopic eczema with particular
emphasis on a group of patients who reported a premens¬
trual exacerbation of their symptoms.
In order to do this, severity of eczema was measured clinical¬
ly by an observer, subjective assessments of severity of ecze-
na were recorded by trie patients and serum soluble interleu-
kin 2 receptor (slL-2R) levels were measured. These have
oreviously been shown to be significantly raised in patientsrfvith atopic eczema compared with a control population and
0 correlate with disease activity [18].rhe primary aim of the study was to determine whether
4 months treatment with gamolenic acid in evening primrose
oil was of benefit in the treatment of adult atopic eczema. The
secondary aim was to detect if the effect (if any) of fatty acid
supplementation differed in patients reporting a pre-menstrual
1are of their eczema.
Materials and methods
:ifty-eight adults with moderately severe atopic eczema took
Dart in the study. All satisfied the diagnostic criteria of Hanifin
and Rajka [19]. The duration of the study was thirty weeks in
otal comprising a four weeks run-in period, sixteen weeks
reatment period and a further eight weeks evaluation after
stopping treatment. Female patients were assessed on six
Dccasions, a midcycle and a premenstrual visit being made
usually 14 days apart) before treatment, during the last
nonth of treatment and in the last month of the study. Male
Datients were assessed on five occasions, two visits a fortnight
apart being made prior to treatment, in the last month of
reatment and one visit being made two months after termina-
ion of treatment. At each visit a clinical scoring system was
jsed which scored severity of three parameters, erythema,
iurface damage and lichenification on a scale of 0-3. The
anterior and posterior surfaces of the body were each divided
nto ten regions and the percentage surface area affected by
jach of the three clinical signs or eczema was assessed. The
everity score for each parameter was then multiplied by the
aercentage area affected and the scores for each of the twen-
y areas added up to give a body total score for each para-
neter [20]. All containers of topical corticosteroid in use or
inished since the previous visit were weighed and new wei¬
ghed tubes were issued in order to estimate topical corticoste-
oid usage. In addition to this serum was collected at each
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visit and stored for subsequent measurement of slL-2R levels.
Serum slL-2R was measured by ELISA as previously described
[21] (T Cell Sciences Inc.; Laboratory Impex Ltd, U.K.). All
samples were coded and read blind in the assay.
All subjects kept diaries which were filled in daily by thefemale participants and weekly by the males. In the diaries
severity of itch, dryness, scaling, redness and overall assess¬
ment of eczema were recorded on 100 mm visual analogue
scales by all participants and female subjects also assessed
severity of six premenstrual symptoms (breast pain, bloated-
ness, depression, irritability, headache and clumsiness).
All patients continued during the study with their usual treat¬
ment in the form of topical corticosteroids, emollients and any
systemic treatment. Treatment with evening primrose oil and
placebo was randomly allocated (by computerised block allo¬
cation) on a double blind basis. The active treatment given
was gamolenic acid in evening primrose oil (GLA) 500 mg oil
plus 10 mg vitamin E in gelatin capsules (Epogam), twelve
capsules daily. The placebo used was liquid paraffin 500mg
with 10 mg vitamin E in identical capsules. Vitamin E is inclu¬
ded in these preparations as an anti-oxidant.
All patients were included in the main analysis. Clinical scores
were analysed before treatment (stage 1), in the last month of
treatment (stage 2) and two months after treatment (stage 3).
As patients visited twice during each stage, mean values of
the clinical scores were used and maximum severity over the
two visits was also examined. All results were analysed blind
using analysis of covariance. In this standard method of statis¬
tical analysis baseline measurements were fitted as the cova-
riate for each score. This reduces variations caused by ran¬
dom differences between groups at the start of the study, andalso corrects for any influence of baseline score on final score
[221. Using analysis of covariance results in the production of
"adjusted means" for comparison between the active treat¬
ment and the placebo groups.
In addition, tne women were studied to examine whether a
treatment by cycle interaction existed i.e. whether women
reporting a premenstrual exacerbation of their eczema
(Group A) reacted differently to treatment from women who
did not (Group B), at different stages of the menstrual cycle;and whether the women as a whole reacted differently at dif¬
ferent stages of the menstrual cycle.
SIL-2R levels and weight of topical corticosteroid used were
similarly examined by analysis of covariance.
The data from the patients' self-assessments were analysed
using Fortran programmes to calculate mean values for each
symptom at different stages of treatment. In addition, the
women's self-assessment aata were analysed to determine
any change in symptoms at different stages of the menstrual
cycle.The data were also examined to. determine whether there
were any interactions between treatment and group, age or
oral contraception.
This research was approved by the Lothian Research Ethics
Committee (Medicine/Clinical Oncology).
Results
Fifty-eight patients entered the study, twenty-six were women
who reported definite consistent premenstrual exacerbation of
their eczema (Group A), seventeen were women without exa¬
cerbation (Group B) and fifteen were men (Group C).
Three patients attended only for the initial explanatory visit
(all placebo). Three subjects defaulted within the first month of
treatment (two active, one placebo). These six subjects were
not included in the analysis because no post-treatment data
were available. All other subjects were included and if any
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defaulted later in the study the previous attendance was used
as the endpoint. Results from fifty-two patients were analysed,
twenty-six in Group A, twelve in Group B and fifteen in
Group C.
Demographic data are shown in Table I and show an even
distribution of subjects between the GLA and placebo groups
in terms of sex, age and duration of eczema.
The clinical scores for erythema, surface damage and licheni-
fication were found to follow a normal distribution when log-
?ed and therefore log scores were used in each analysis.able II s ows the mean scores for all patients for the three
clinical parameters measured before ana after 4 months treat¬
ment with GLA and placebo and 2 months post-treatment.
The GLA group has higher pretreatment clinical scores for
erythema and surface damage. These differences are not sta¬
tistically significant for erythema. A significant difference was,
however, round for surface damage (p = 0.04). The mean
scores for erythema and surface damage fell during active
Table I. Demographic data relating to subjects
n Age range Age at onset Duration
GLA 28 18-49 1 m-30 y 3-47 y
Placebo 24 16-64 3 m-21 y 2-47 y
Table II. Clinical scores for all patients
for erythema, surface damage
and lichenmcation before, after 4 months
treatment and 2 months post-treatment
(means i s.e.m.), GLA n = 27, placebo n = 25
Before 16 weeks Post-
Erythema GLA 397 ± 74 268 ± 63 339 ± 156
Placebo 246 ±45 240 ±46 318 ± 53
Surface damage GLA 411 ±70 277 ±71 313 ±145
Placebo 237 ±40 235 ±49 285 ± 47
Lichenification GLA 99 ± 23 136 ± 75 65 ±19
Placebo 122 ±29 97 ± 35 178 ± 67
Table III. Analysis of covariance. The adjusted
means after treatment with gamolenic acid
and placebo, 95% confidence intervals




GLA mean 111 102 24
95% CI (85-145) (79-138) (15-51)
Placebo mean 179 184 17
95% CI (135-240) (154-245) (9-35)
p-values 0.017 0.007 0.2
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treatment but not with placebo. Figure 1 shows the individual
changes in erythema with GLA and placebo. Twenty-three out
of 27 patients taking active treatment showed an improve¬
ment in their clinical score for eiythema by the end of the
treatment period compared with 11/23 in the placebo group.
The results for surface damage (Fig. 2) were very similar,
12/23 in the placebo group showing an improvement in cli¬
nical score, compared with 23/27 in the GLA group. Table III
shows the results of the analysis of covariance of the clinical
scores. The adjusted means after sixteen weeks GLA and pla¬
cebo and the p-values are shown. Highly significant diffe¬
rences in erythema and surface change were detected for
GLA compared with placebo after four months treatment and
also post-treatment. No significant difference was found for
lichenification.
When maximum severity was analysed using an ordered
logistic regression model a significant treatment effect was
found for erythema at sixteen weeks (p = 0.05) and for liche-
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nification two months post-treatment (p = 0.04) where GLA
patients had less severe scores.Investigation of treatment by cycle interactions in female
patients showed no conclusive evidence that the two groups
of women reacted differently to treatment at different stagesof their menstrual cycle. There was also no evidence that
women as a whole reacted differently to treatments at diffe¬
rent stages of the menstrual cycle.
To further examine the effect of active treatment and placebo
in the different patient groups, reduction in clinical score as a
percentage of original clinical score was calculated for eachindividual and the mean ± s.e. mean found. These results for
erythema (Fig. 3) and surface damage are illustrated (Fig. 4).
No statistically significant differences were found but patients
in Group A (women who reported a premenstrual flare) sho¬
wed the greatest difference in response between GLA and
placebo.
The slL-2R measurements were found to follow a normal dis¬
tribution when logged and log spores were also used in their
analysis. Table IV snows the mean slL-2R levels before treat¬
ment, after 16 weeks treatment ana 2 months later. The fall in
slL-2R levels was significant for bo|h GLA and placebo after
four months' treatment and for GLA 2 months post-treatment
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by the paired t-test. This fall was greater for the GLA group
but there was no statistically significant difference between
GLA and placebo when compared by analysis of covariance.
After treatment it can be seen that slL-2R levels remained
reduced in the GLA group but rose in the placebo group.
There was no significant change in the amount of topical cor¬
ticosteroid used in either the GLA or the placebo group. Prior
to the treatment period the active group were applying a
mean ± s.e. of 5.0 ±1.1 a potent topical steroid (betametha¬
sone valerate 0.025% or alternative topical steroid of equiva¬
lent potency) daily and the placebo group were using 3.5 ±
1.0 g compared with 5.1 ± 1.3 g and 3.1 ± 0.8 g respecti¬
vely at the end of the 4 month treatment period.
The pre-treatment data were analysed to determine whether
any factors were related to the three main clinical scores. No
factor was found to be statistically significantly related to any
score when all patients were looked at together. When
women only were examined it was found that scores for red¬
ness and surface damage were higher at the midcycle than
the premenstrual visit.
We also examined the hypothesis that patients with the worst
pre-treatment clinical scores would show the greatest improve¬
ment during the treatment period [14]. The relationship bet¬
ween pre- and post-treatment scores did not differ between
the active and the placebo group. There was a strong trend
for those with the least severe erythema scores to improve
most when active treatment was compared with placebo (p =
0.071.
Results from the patients' diaries are summarised in Table V.
This table shows the means and s.e. ms for all patients prior
to treatment, from 8 weeks to the end of treatment and in the
post-treatment period. There were no statistically significant
changes found between the GLA and placebo groups oy ana-
Table IV. Mean slL -2R levels (U/ml) before
and after 4 months' treatment, and two months
post treatment, the effect of gamolenic acid
and placebo (paired t-test),
GLA n = 27, placebo n = 25
Baseline 16 weeks 24 weeks















4 Figure 4. Mean
reduction in sur¬
face damage at
the end of treat¬







ned. (0 = gamole-
nic acid, ■ = place¬
bo).
Table V. Diary data all patients, (n = 52) mean ± s.e.m.
Pre-treatment End-treatment Post-treatment
GLA Placebo GLA Placebo GLA Placebo
Itch 42 ±3 39 ±3 36 ± 3 37 ±3 43 ± 4 43 ±4
Dryness 40 ± 3 35 ± 3 35 ± 3 35 ± 3 42 ± 4 39 ± 4
Scaling 33 ± 3 28 ± 4 29 ± 4 28 ± 3 35 ±4 31 ±5
Erythema 36 ± 4 34 ± 3 33 ± 4 37 ± 4 37 ± 5 38 ± 4
Overall 42 ± 3 37 ± 3 37 ± 3 37 ± 3 42 ± 4 40 ± 4
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lysis of covariance. A cyclical variation in diary symptoms,
apparently related to the menstrual cycle was noted in 9/23
women wno reported a premenstrual flare of eczema and in
5/16 who did not. However, no statistically significant varia¬
tion in diary symptoms was found at different times of the
menstrual cycle in the pre-treatment month in Group A or
Group B. Scores for redness were recorded both by the clini¬
cian and the patient, and a reasonable correlation between
these measurements was found (Spearman rank coefficients;
pre-treatment 0.631, end treatment 0.592).
Two patients in the GLA group developed diarrhoea during
the study, one of whom also developed colicky abdominal
pain. One patient in the placebo group reported similar
symptoms. These symptoms were lessened by increasing the
frequency and decreasing the dose of capsules taken at any
one time. One patient in the GLA group experienced worse¬
ning of her atopic eczema and an urticarial rash one week
after starting treatment. She had experienced a similar reac¬
tion on a previous occasion when taking evening primrose
oil. Treatment was stopped. Her results at the time of withdra¬
wal from the study were included in\the analysis.
Discussion
These data show a beneficial effect of 4 months' treatment
with GLA on erythema and surface damage in adult atopic
eczema. A significant effect on lichenification was found only
when maximum severity was examined and then only two
months post-treatment. The slL-2R levels fell during the treat¬
ment period in both the active and the placebo groups and no
statistically significant difference between the groups was found.
It is interesting that our study showed a positive result when
most previously reported studies have shown a small benefi¬cial effect of GLA, which was not necessarily statistically signi¬
ficant, or no significant benefit. The women in our study who
reported a premenstrual flare of their symptoms (Group A)showed a greater, though not statistically significantly diffe¬
rent, response to GLA when compared with placebo tnan the
other two groups (Fig. 31 and it is possible that our choice of
patients has resulted in these findings.
The patients in the GLA group had mean pre-treatment scores
greater than those of the placebo group. As it has been sug¬
gested that there may be a greater chance of detecting an
improvement when this is the case [14], we adopted analysis
of covariance in our treatment of the data, using the pretreat-
ment scores as the co-variate in order to minimise this effect.
Furthermore, our analysis of the data has shown that those
patients with the lower scores pre-treatment improve most,
and not the converse.
There are many putative mechanisms to explain a connectionbetween essential fatty acids and the pre-menstrual syndrome
in which low plasma levels of essential fatty acid metabolites
have been found [23]. Neither the clinical scoring system we
used nor the patients' self-assessment data confirmed a pre¬
menstrual exacerbation of eczema in Group A patients in our
study in the pre-treatment assessments, the mean clinical
scores were greatest at day ten and the best response to
treatment was seen at this time and not at day twenty-three of
the menstrual cycle. It is possible therefore that perception of
symptoms plays a role in reporting of premenstrual exacerba¬
tion of eczema. It is also possible that the one month pre-
treatment phase was not adequate to demonstrate any pre¬
menstrual exacerbation. The Group A patients showed a
greater difference in effect of GLA when compared with pla¬
cebo, and a smaller placebo response. Although this did not
reach statistical significance, we believe this should be exami¬
ned further.
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Although no statistically significant difference was demonstra¬
ted between the active ana the placebo groups, it was inter¬
esting to note a greater and more sustained fall in slL-2R
levels in the patients taking GLA. Such a fall could reflect
reduced inflammation consequent upon clinical improvement
in their eczema. However, there is evidence that essential fatty
acids have direct effects on production of interleukin 1,
tumour necrosis factor and interleukin 2 in vitro, and this is
an alternative explanation [24],
We did not find any fall in mean topical corticosteroid usage
in either group during the course of the study. However, we
noted that only the minority of patients were entirely reliable
in returning used containers.
Although we found a clear improvement in clinical scores sta¬
tistically, for most patients this meant a modest improvement
in the severity of their eczema clinically. However, the inci¬
dence of adverse events was very low. We feel, therefore,
that in the context of a chronic skin condition, treatment with
GLA should be considered and may be particularly effective
in women reporting a premenstrual flare of their symptoms. ■
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SUMMARY
Residual maximum likelihood (REML) is a technique for estimating variance components in multi-classified
data. In contrast to analysis of variance it can be routinely applied to unbalanced data and avoids some of
the problems of biased variance estimates found with standard maximum likelihood estimation. The full
REML method is of particular value for the analysis of unbalanced clinical trials as it allows recovery of all
the available information on treatment effects which can lead to significant improvements in their precision.
The use of REML has until recently been limited by heavy computational requirements and lack of readily
available software. This is no longer such a restriction, however, as REML procedures are now available in
several widely-used statistical packages, including BMDP, Genstat and SAS. This paper describes the
REML technique and discusses its application to three common types of clinical trial: crossover, repeated
measures and multicentre.
In a clinical trial, variation in response may arise from several sources associated with different
strata of the experiment. For example, in a crossover or repeated measures trial, there will be
a component of variance for responses on the same patient and a component for responses of
different patients. Similarly, in a multicentre trial, separate components of variance can be
identified among patients from the same centre and among the different centres. The stratum
variance components can be used to increase the precision of treatment estimates by allowing
information to be combined efficiently across strata using the method of generalized least squares.
Knowledge of the stratum variances may also help to improve treatment design in subsequent
experiments.
Fisher,1 in his book Statistical Methods for Research Workers, introduced the analysis of
variance (ANOVA) to a wide audience and outlined the basic method for estimating components
of variance by equating the mean squares from an ANOVA table to their expected values. Yates2
and Henderson3 showed how Fisher's technique could be extended to unbalanced (that is,
incomplete) data, but there is then no unique way of choosing the appropriate mean squares and
the ANOVA estimators are not fully efficient. Hartley and Rao4 proposed using maximum
likelihood (ML) to provide unique estimators of variance components. However, the ML
estimates are generally biased downwards as the method assumes that fixed effects are already
1. INTRODUCTION
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known, rather than also being estimated from the data. Indeed, in the balanced case, ML variance
estimators are generally smaller than the unbiased estimators from ANOVA.
Residual maximum likelihood (REML) overcomes the problem of bias by automatically
adjusting for the degrees of freedom corresponding to estimated treatment effects, as is done by
ANOVA for balanced data. Indeed, for balanced data, REML and ANOVA estimators are
identical. Also, when only one variance stratum is defined and all other effects are taken as fixed,
REML is equivalent to simple least squares analysis. The general technique for REML was
developed by Patterson and Thompson.5,6 The underlying mixed model and estimating equa¬
tions are given in the Appendix. Searle et al.1 provide a more detailed theoretical description of
REML and other variance estimation methods.
REML has been applied widely in agricultural research. It was introduced by Patterson and
Thompson5 in the context of incomplete block designs where the precision of treatment estimates
may be improved by including between-block information. The method has been used extensively
in animal breeding to estimate heritabilities and predict genetic gain from breeding pro¬
grammes.8,9 Talbot10 used REML to estimate variance components for variety trialling
systems carried out across several centres and years for different crops and was thus able to
compare their general precision and effectiveness. A wider review of applications is provided by_
Robinson.11
REML can also make an important contribution to the analysis of clinical trials. These are
frequently unbalanced either by design or due to events such as early study termination, missing
records, patient withdrawals, exclusions or incorrect randomizations. It is ethically important
that as few patients as possible are used in a trial and this requires that trials are efficiently
designed and analysed. However, in many analyses, information is lost by using least squares
estimation which ignores information from higher strata, or by deliberately discarding data to
ensure the trial data are balanced for treatments. Several authors12-14 have described methods
for using this information to improve the precision of special types of clinical trial. REML is
a general method that can be used for any multi-classified dataset and ensures an efficient analysis
regardless of the level of data imbalance.
REML techniques are computationally relatively costly and their restricted use could until
recently be explained by lack of readily available software. However, these drawbacks have been
largely overcome by the introduction of REML procedures in widely used general statistical
packages, including SAS,15 BMDP16 and Genstat.17 There is now a need to build up a body of
experience of applying the REML method so that it may be used confidently on a routine basis in
clinical trials.
As part of this process, our paper describes the application of REML in three different kinds of
clinical trial - crossover, repeated measures and multicentre - and outlines REML facilities
currently available in statistical computer packages.
2. CROSSOVER TRIALS
Crossover designs are used extensively in clinical trials to compare the efficiency of treatments
applied sequentially to patients. These designs have the advantage that treatment differences can
be compared against a background of within-patient variation, rather than the typically larger
between-patient variation.
When all patients receive all treatments equally, a conventional least squares analysis based on
within-patient comparisons is fully efficient for the simple additive treatment effects model.
However, crossover trials are often not fully balanced, either by design, for example when the
number of periods is less than the number of treatments, or, more commonly, due to missing data.
)
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1
Figure 1. Variance of difference in treatment effects with full recovery of between-patient information as a proportion of
the variance with no recovery for a two-period cross-over design with specified proportion of patients missing in the
second period, y is the ratio of between- to within-patient variance components
Additional information on treatment comparisons is then available between patients and may be
used to increase the precision of estimates.
The amount of extra information depends on the level of treatment imbalance and the relative
sizes of between- and within-patient variances. We illustrate this with a simple example. Consider
a two-period crossover trial for two treatments, A and B, with N patients in each treatment group,
and assume that, for a proportion p of patients in each group, only the response for the first period
is recorded. The variance in response within patients is a2, while the variance between patients is
(1 + y)(T2. Then the variance of the usual estimate for difference in treatment means for the
2N(l — p) within-patient comparisons is trj, = <j2/N(1 — p), while the corresponding variance
from between-patient comparisons for period 1 responses of the remaining 2Np patients is
al — 2<x2(l + y)/Np. The variance of the combined estimate of treatment difference from pooling
within- and between-patient information is then 2<r2(l + y)/N\_p + 2(1 + y)(l — p)]. So using the
between-patient information reduces the variance of treatment differences to a proportion
1 — P/LP + 2(1 + y)(l — p)] of the within-patient variance. This is plotted in Figure 1 for differ¬
ent values of p and y. These theoretical results are derived with the assumption that y is known. In
practice y is estimated and there may be a slight loss of information for the combined estimate in
small samples (see Section 7).
Yates2 described a method for recovering between-block information for balanced incomplete
block designs, but the benefits of incorporating this information in crossover studies is only now
becoming widely recognized.
Gough18 used REML with random patient effects to recover between-patient information in
a two-treatment, three-period crossover study,19 and showed that this led to a reduction of 20 per
cent in the variance of treatment estimates. Chi14 outlined an analysis of incomplete block trials
with recovery of information and applied it to three crossover trials:20 this led to reductions of
between 3 and 8 per cent in variances of treatment estimates. Both authors made allowance for
)
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Table I. Variances of estimates of differences of treatment and carryover effects for a
three-treatment, two-period design (in multiples of 2o2/r). y is the ratio of the







treatment effects being carried over to the next period in their analyses. Including carryover
effects in the response model will generally reduce the information on treatment effects from the
within-patient comparisons and consequently increase the importance of using the additional
between-patient information, particularly for two-period crossover trials.21
Here we consider a simple case of the three-treatment (A, B and C), two-period design with
r replicates of the six sequences AB, BA, AC, CA, BC and CB. The variances of treatment
differences for within- and between-patient comparisons and a combined analysis are expressed
as functions of y in Table I, for models both with and without carryover effects. In the absence of
carryover effects, the within-patient analysis will generally have high efficiency as the variance of
treatment estimates is never more than 4/3 of the variance for the full analysis. (This upper limit
occurs when y = 0 and corresponds to the reciprocal of the efficiency of the design.) The inclusion
of carryover effects, however, leads to a four-fold increase in treatment variance from with¬
in-patient analysis. There is however, substantial between-patient information on both treatment
and carryover effects and this information may be used in a combined overall analysis to provide
more precise treatment estimates. Then, for small y, the variance of treatment estimates is
increased by a factor of only (8 + 4y)/7 when carryover effects are included in the model.
To find out what values of y are likely to be met in practice we have analysed seven examples of
crossover trials given by Jones and Kenward.20 These cover a range of diseases and conditions
and five types of design (Table II). A standard model with period, treatment and carryover effects
as fixed and patient effects as random was fitted. REML estimates of y ranged from 0-5 to 27-2
with a median of 1-5. Table II also gives, for three of these trials, the y estimates derived by Chi14
using an ANOVA method. This method of estimation is generally inefficient and only equivalent
to REML for balanced complete or incomplete block designs.
Knowledge of the likely value of y can help with choice of design. Suppose, for example, we wish
to compare three treatments with a fixed number of patient sessions. Should we use a balanced
two-period crossover trial, as above, or a parallel group trial with one treatment per patient? For
the parallel group trial, there will be 4r patients receiving each treatment and the variance of
treatment differences will be <r2(l + y)/2r. If there are no carryover effects, the variance of
treatment differences from the crossover trial, including between-patient information (Table I),
will always be smaller than the parallel group trial. However, when carryover effects are present,
the crossover trial is expected to be less precise when y < 1; the potential increase in treatment
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Table II. REML estimates of ratio y of between-patient to within-patient components of variance for seven
crossover trials from Jones and Kenward.17 Figures in brackets are ANOVA estimates for three trials
derived by Chi14
Table* Measurement Number of Designt V
(study group) patients
2.1 FEV'(bronchial asthma) 17 2x2 6-8 (4 0)
2.13 Plaque score (unknown) 34 2x2 0-5
2.19 Log (EFT)5(women undergoing IVF) 23 2x2 3-7
4.3 Symptom score (Parkinson's disease) 17 2 x 21 27-2 (28-1)
4.9 Systolic BP (hypertension) 89 3x2 1-5 (1-5)
5.20 Systolic BP (hypertension) 23 3x3 1-4
5.23 LVET' (intermittent claudication) 14 4x4 0-8
* Table number in Jones and Kenward17
t periods x treatments
t Forced expired volume in one second
§ Visual/spatial test score
|| Left ventricular ejection time
1 four treatment sequences AA, BB, AB, BA
carryover effects. Note, however, that there are additional gains from using crossover trials if
costs depend on the number of patients in the trial, not simply on the number of sessions.
2.1. A crossover trial of analgesic drugs
Mead22 gives results of a two-period crossover trial to compare three analgesic drugs labelled A,
B and C. The trial involved 43 patients in total and the numbers receiving each treatment
combination were as follows: AB 7; BA 5; AC 7; CA 8; BC 8; CB 8. The effectiveness of each
treatment was assessed by the numbers of hours of pain relief provided. The design did not
include a washout period between treatments so there was a strong possibility of treatment
carryover effects. The fitted model was
Response = Overall mean + Patient effect + Period effect + Treatment effect
+ Carryover effect + Random error.
Period, treatment and carryover effects were taken as fixed. REML analyses were carried out with
patient effects specified first as fixed, then as random to allow recovery of between-patient
information. The estimated variance components and treatment effects are shown in Table III,
first omitting then including carryover effects. Comparison of the two analyses omitting carry¬
over effects shows that the average standard error for treatment differences from the combined
analysis with recovery of between-patient information is on average 12 per cent less than for the
within-patient analysis. The comparison A-B which has the largest standard error shows greatest
increase in precision, so that the combined analysis also leads to treatment estimates with
a smaller range of standard errors. For this trial the between-patient component of variance is
relatively small and recovery of between-patient information is clearly worthwhile.
Although the estimated carryover effects were not statistically significant, they are sufficiently
large to consider including in the model. This approach is advocated by Abeyasekera and
Curnow.23 When this is done the precision of estimates of treatment effects for the within-patient
analysis is dramatically reduced, with a doubling of their standard errors. By contrast, the
1
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Table III. REML estimates of variance components and treat¬
ment effects for a crossover trial comparing three analgesic






patients — 1-3 (1-89)
units within patients 10 8 (2-42) 10-7 (2-39)
Treatment effects
A-B 3-4 (105) 3-5 (0-91)
A-C 2 0 (0-99) 1-9 (0-88)
B-C - 1-4 (0-98) - 1-6 (0-87)
Including carryover
Variance components
patients — 1-3 (1-96)
units within patients 113 (2-60) 10-9 (2-44)
Treatment effects
A-B 3-7 (2-01) 3-8 (0-99)
A-C 2-6 (2-14) 1-9 (0-99)
B-C - 1-1 (208) - 1-9 (0-99)
Carryover effects
A-B 0-4 (3-43) 10 (1-45)
A-C 11 (3-66) 0-2 (1-41)
B-C 0-7 (3-72) - 0-8 (1-46)
Note that Mead's22 treatments estimate for the random patients model
without carryover are incorrect as his values for the standard errors of
treatment differences from between-patient comparisons are out by
a factor of
combined analysis with random patient effects shows only a small increase in standard errors
reflecting the improved estimation of carryover effects indicated in Table II.
For this trial the between-patients variance component is small compared to the within-
patients component (y = 012), suggesting that there is little advantage from using a crossover
trial for testing these analgesics, even if carryover effects can be avoided. Indeed, the predicted
average standard error for treatment comparisons for a parallel group trial with the same number
of patient sessions per treatment is 0-92, compared with 0-89 and 0-99 for the crossover analysis
ignoring and including carryover effects, respectively.
3. REPEATED MEASURES TRIALS
A sequence of observations are often made on each patient in clinical trials to observe the long
term effect of the treatments or their variability in reponse. For example, measurements of systolic
blood pressure or concentration of a test drug in the blood may be taken at intervals after
treatment. Responses for successive time periods in these repeated measures trials are frequently
correlated and it is important to allow for this in the statistical analysis.20 This may not be
straightforward using conventional least squares methods, particularly when the data are
APPLICATION OF REML IN CLINICAL TRIALS
Table IV. Possible covariance structures for four repeated measurements per patient
1607
(i) General model (ii) Autoregressive model
012 013 014 a2 0. 02 03
012 °2 023 024 0. a2 0. 02
V = V =
013 023 034 02 0. a2 0,
0.4 024 034 03 02 0, a2
(iii) Uniform covariance model (iv) Uncorrelated modei
<72 0 0 0 O2 0 0 0
e <T2 0 0 0 (J2 0 0
V = V =
e 0 a2 0 0 0 o2 0
0 0 0 o2 0 0 0 a2
of = variance of responses for time period i; 0y = covariance of response for periods i and j; when the
variances are all equal of = a2 for all i; in (ii) the covariances depend on the separation of the period,
with equal covariances 9tJ = 6 for all i and j
unbalanced. As a compromise, data are often analysed using univariate techniques applied
either to the mean responses over time or, if there is evidence of a treatment by time interaction,
to the individual responses at selected time periods. Neither approach is entirely satisfactory
since trials will often lack the power to detect such interactions and calculating a mean value
over time takes no account of missing values which are more likely to occur in later time
periods. Other summary statistics, such as the slope of the linear regression of response
against time, have also been used24 but do not have general applicability. A more direct solution
is to model the variance/covariance structure for responses at successive time periods
and estimate the corresponding parameters along with fixed effects. Maximum likelihood
provides a general method for this even when the data are unbalanced. Laird and Ware25 develop
the method of maximum likelihood for unbalanced longitudinal studies. Jennrich and Schluch-
ter26,27 demonstrate in more detail the application of ML techniques, including REML, in
repeated measures studies and discuss the structure of the covariance matrix. We suggest that
REML is used in preference to ordinary maximum likelihood to reduce the problem of biased
covariance estimates.
Table IV gives possible forms for covariance structure for repeated measures. In the most
general case (i), the variances of responses of differ for each time period i and the covariance
between periods i and j is For the general autoregressive model (ii), the variances are equal and
the covariance 9^ between periods depends on their separation \i — j|. This may be an appropri¬
ate model when time periods are evenly spaced. For the particular case of a first-order autoregres¬
sive model, the covariances decrease exponentially with time separation, 0;j- = 01'--". For the
uniform covariance model (iii), all covariances are equal. This is equivalent to the model with
random patients and uncorrelated errors used for crossover trials where 6 — o2y/( 1 + y). Finally,
for model (iv), responses are uncorrelated and there are no patient effects.
A drawback of fitting a general covariance structure is the large number of parameters to be
estimated. For example, with 10 time periods it would be necessary to estimate 10 variance
parameters and 45 covariance parameters, which is not feasible in a small trial with perhaps
!
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Table V. REML estimates of variances and correlations in response for different error models for eczema
trial
Error model Period Variances Correlations
General covariance structure 1 0-95
2 0-96 0-74
3 0-73 0-52 0-62
4 0-76 0-39 0-53 0-67
5 0-73 0-53 0-45 0-38 0-45
6 1-64 0-53 0-62 0-33 0-44 0-63
Uniform 1-6 0-94 0-48
Uncorrelated 1-6 0-87 0
Uniform with separate covariances 1-6 A 108 0-56
1-6 P 0-78 0-38
A = active treatment, P = placebo
several missing values. Simpler forms of covariance structure should therefore be considered and
tested for suitability.
Finally, the model can be extended to allow separate covariance structures for each treatment
group. This would be appropriate, for example, if active treatments are known to be more
variable in response than the placebo.
3.1. A parallel-group trial in eczema
Here we consider a parallel group trial to compare the efficacy of a treatment for eczema with
a placebo over a six-month period. The severity of eczema is measured by an overall redness score
for 20 parts of the body. Measurements were made on each patient before treatment, and then at
six time periods after treatment for female patients and at three time periods for male patients.
There were 36 women and 14 men in the trial and men missed the first two and the fifth
post-treatment assessments. There was a further imbalance because several patients did not
complete the study so their scores are only available for the earlier periods. Initially separate
analyses were carried out for women and men but no differences were observed so a combined
analysis is presented here.
The response model for redness score (RS) at different periods was defined by
log RS = Initial log RS + Patient effect + Treatment effect + Period effect
-I- Treatment x Period effect + Error,
where pre-treatment log redness score was included as a covariate to reduce patient to patient
variation. A logarithmic transformation was used for redness score to normalize its distribution.
Several different covariance structures for the error term were considered and their parameters
estimated using REML. With 50 patients in the trial, tests for comparing alternative covariance
structures should have reasonable power.
Initially an unstructured covariance matrix was used. This indicated no systematic pattern in
the size of the correlations with separation of time periods (Table V) so an autoregressive model
was not considered appropriate. There were, however, differences in variability of response for
individual periods; in particular the sixth period was more variable than the others. An alterna-
■)
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Table VI. Log-likelihood, degrees of freedom and estimated treatment differences for the
eczema trial






General 566 21 0-402 0-224
Uniform 592 2 0-416 0-218
Uncorrelated 646 1 0-534 0-125
Uniform with separate
treatment covariances 590 4 0-402 0-214
tive model assuming a uniform covariance structure was nevertheless found to give no worse a fit
than the general model (xig = 26, Table VI). The model with uncorrelated errors gave a signifi¬
cantly worse fit than the uniform covariance model (xi = 54). This was unsurprising as the
estimated correlation between repeated measures for the uniform model was 0-48, equivalent to
y = 0-92, which indicates a substantial component of variance due to patients. Finally a uniform
model was fitted with different covariances for each treatment. This gave no improvement over
the single covariance model (xi — 2) although there was some suggestion that the variance
component for the active treatment was higher than that for the placebo.
Table VI gives the estimated treatment difference and its standard error for each model.
The estimated standard error for the uncorrelated model is misleadingly small as it is erroneously
assumed that responses at different time periods provide independent estimates of treatment
effects. Differences among the treatment estimates and standard errors for the other three
models is small, suggesting that estimates are fairly robust to precise specification of
variance/covariance structure. No significant effect was observed for period or treatment by
period interaction.
4. MULTICENTRE TRIALS
So far we have considered the analysis of single centre trials. However, a clinical trial may be
carried out at several centres either because insufficient patients are available for the study at any
one centre, or with the deliberate intention of assessing the effectiveness of the treatments in
several settings. The extra variability in treatment response introduced with a multicentre trial
may be taken into account in the analysis by including an effect for centres and treatment by
centres interaction in the model. Deciding whether centre effects should be fixed or random in
such cases has been the subject of some debate.28-30 In practice, the choice will depend on the
purpose of the experiment and, particularly, whether treatment estimates are to relate only to the
set of centres used in the study or, more widely, to the circumstances and locations sampled by the
trial centres. In the former case, local treatment estimates for individual centres are provided by
taking centre and treatment by centre effects as fixed. To predict global treatment estimates,
centre and treatment by centre effects should be taken as random.
Taking centre effects as random also allows recovery of any between-centre treatment informa¬
tion which will be present when the relative sizes of the treatment groups differ between centres.
The amount ofextra information will depend on the degree of treatment imbalance across centres
(in extreme cases, some treatments may be completely omitted from some centres) and y, the ratio
of between-centres to treatments by centre variance components (see Figure 1).
/
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Including treatment by centre interaction as a random effect in the model will lead to an
increase in the standard errors of treatment differences when there is heterogeneity across centres.
Conventionally, the decision on whether to include a treatment by centre interaction in term in
the model is based on a significance test applied at an arbitrarily specified significance level. When
an interaction is present but shows as non-significant, this approach will lead to an underestimate
in standard error of treatment differences. We suggest a more appropriate strategy is to include
random treatment by centre effects whenever their variance component is positive, as advocated
by Patterson and Nabugoomu.31
The estimated variance components for the random effects may be of interest in themselves.
For example, knowledge of the relative sizes of centre, treatment by centre and patients variance
components may be used in trial design to calculate the increase in sample size required to allow
for the increased variability expected from sampling several centres. If the variance components
are to be interpreted and used with confidence it is important that estimates are based on
a reasonable number of observations.
Meta-analyses are increasingly used to combine results from several clinical trials assessing the
same treatments so as to provide a more precise overall estimate of the treatment effects.
However, the usual Peto estimates,32 which are based on the assumption of fixed trial effects, give
a false impression of accuracy if there is heterogeneity between the trials. This was recognized by
DerSimonian and Laird33 who described the use of a random effects model, including treatment
by trials interaction. This provides global treatment estimates and standard errors if the trials are
representative of the full range of possible circumstances.34 When the original data for each trial
are available, efficient estimates of the overall treatment effects and variance components for trials
and treatment by trials are obtained from a REML analysis in the same way as proposed for
multicentre trials. An alternative Bayesian approach which allows for heterogeneity between
trials or centres has also been considered.35-37
4.1. A multicentre trial in hypertension
Our example comes from a study of three treatments for the management of essential hyper¬
tension involving 29 centres. Each patient received one treatment at random and diastolic
blood pressure, the main response variable, was recorded before and after treatment. A total
of 285 patients completed the study and the distribution of treatment groups across centres
is shown in Table VII. At 21 of the centres, treatment groups were unequal, indicating that
additional information on treatment comparisons is available for recovery between
centres.
The full model for diastolic blood pressure (DBP), including treatment by centre interactions,
was taken to be
Final DBP = Initial DBP + Treatment effect + Centre effect
+ Treatment x Centre effect + Random error,
where initial diastolic blood pressure was included as a covariate to reduce between-patient
variation.
The model was fitted using REML, initially with treatment by centre interactions omitted.
Centre effects were taken first as fixed, then as random (Table VIII). Differences between centres
were small and, for the random model, the centres variance component was much smaller than
the patients variance component (y = 0 035). The extra treatment information recovered between
centres is reflected in the standard errors of treatment means for the random centres model which
)
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Table VII. Number of patients receiving each treatment at each centre
in a multicentre trial comparing three treatments for hypertension.






1* 13 14 12 39
2* 3 4 3 10
3* 3 3 2 8
4 4 4 4 12
5* 4 5 2 11
6* 2 1 2 5
7 6 6 6 18
8 2 2 2 6
9* 0 0 1 1
11 4 4 4 12
12* 4 3 4 11
13* 1 1 2 4
14 8 8 8 24
15* 4 4 3 11
18 2 2 2 6
23* 1 0 2 3
24* 0 0 1 1
25* 3 2 2 7
26* 3 4 3 10
27* 0 1 1 2
29* 1 0 2 3
30* 1 0 2 3
31 12 12 12 36
32* 2 1 1 4
35 2 1 1 4
36* 9 6 7 22
37* 3 1 2 6
40* 1 1 0 2
41* 2 1 1 4
Total 100 91 94 285
are on average 10 per cent less than for the fixed centres model and have a smaller range. Since
there are over twenty centres, their component of variance can be estimated with reasonable
precision and thus a random centres model, which combines between- and within-centres
treatment information, is preferred in this case.
We now consider the full model allowing for treatment by centre interaction. Taking these
effects as random, the REML estimate of the treatment by centre variance component is of similar
size to that for centre (Model 3, Table VIII). Including interaction effects in the model leads to an
increase in standard errors of treatment estimates. If a treatment by centre interaction is indeed
present in the study, omitting its effects in the model will lead to standard errors of treatment
estimates being underestimated.
Finally, if treatment by centre interactions are taken as fixed, we cannot logically estimate
overall treatment effects as all treatments do not appear at all centres. This problem is avoided by
assuming random treatment x centre effects.
!
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Table VIII. REML estimates for diastolic blood pressure (mmHg)
in multicentre hypertension trial













Variance component (standard errors)
Centre Treatment x Centre
2-65 (3-24) —









Treatment means (standard errors)
A B
961 (105) 94-4 (1 10)
95-8 (0-95) 94-4 (0-98)






REML is now available in SAS,15 BMDP16 and Genstat17 and other more specialized multilevel
modelling packages such as ML338 and FILM.39 Although the same estimation procedure is used
in all packages the presentation of the output and the terminology varies. More importantly,
there is no agreed procedure for significance testing, particularly in small samples. Some of the
features of the three packages are summarized in Table IX.
In SAS version 6.07 the mixed model may be fitted using the MIXED procedure which uses
REML as the default method. The procedure allows the user to specify the structure of an overall
covariance matrix, or separate covariance matrices for particular groups (for example, for
different treatments). Estimates of variance components and comparisons among fixed effects are
output with their standard errors. Test statistics and P-values are provided for the significance of
variance components (asymptotic z-tests) and for comparing fixed effects (f-tests). The overall
significance of fixed effects is tested by a Wald F-statistic.
In BMDP, REML is provided as an option in the linear model procedures 3V and 5V.
BMDP3V is used to fit the general mixed model while 5V is specifically for the analysis of
repeated measures data. BMDP5V allows several types of covariance structure to be specified as
in SAS. Estimates of variance components and their standard errors are output. Estimates of fixed
effects are output but standard errors of differences in effects have to be calculated from
a variance/covariance matrix. Wald F or y2 test statistics and F-values are given for overall tests
of fixed effects.
In Genstat, a REML analysis for the mixed model is provided by the VCOMPONENTS and
REML directives. Estimates of variance components and fixed effects are output with their
standard errors and separate standard errors may be obtained for all differences in fixed effects.
Fixed effects may be tested using the asymptotic Wald statistic or REML likelihood ratio test
which appears to be more conservative. Although Genstat allows the user to specify a general
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Table IX. Features currently available for REML analysis in BMDP, Genstat and SAS
BMDP Genstat SAS









Not directly Yes Yes
Significance tests:

























Not directly Yes Not directly
Significance tests provided by the packages should be interpreted cautiously, particularly
when the sample size is small. In particular, we have found that SAS and BMDP give different
P-values for testing the significance of fixed effects using the Wald F statistic. This is caused by
the different choice of degrees of freedom for the denominator.13 Genstat gives a likelihood
ratio test for fixed effects in REML but the basis for the test has not yet been published.
Uncertainty also exists over choice of degrees of freedom for t-tests of individual treatment
comparisons. Giesbrecht and Burns40 suggest how the degrees of freedom might be estimated,
but the approach is not used by any of the packages. For random effects only asymptotic tests
are provided. We recommend that random effects are tested by comparing deviances (that is,
— 2 log-likelihoods) of models with and without the effects, as was done in the repeated
measures example of Section 3. This is preferable to the z-test provided by SAS which com¬
pares each effect with its standard error.
Results should also be interpreted with caution when estimates of variance components
are given as negative or very close to zero. Negative estimates are allowed in Genstat and
as an option with SAS. A negative estimate can be caused by errors in the data or model
specification, but is most likely to indicate that the true variance component is zero. In this
case we recommend refitting the model with appropriate random effect term removed.
BMDP and SAS (by default) do this automatically when a variance estimate would be
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7. DISCUSSION
The main aim of this paper has been to demonstrate how the estimation of treatment effects in
clinical trials can be improved by taking full account of the variance/covariance structure of the
responses. With unbalanced, multi-classified data, a generalized (weighted) least squares analysis
provides efficient treatment estimates by combining information across all classification strata,
with weights derived from the stratum variance components. Until now, however, inefficient and
somewhat arbitrary methods have been used for estimating these variance components, for
example by equating sums of squares.14 REML is presented here as an efficient maximum
likelihood method which can be applied to any general data structure. By contrast to standard
maximum likelihood (ML) it gives identical treatment estimates to ANOVA for complete data
and for balanced incomplete designs.
Even using efficient REML estimates, variance components used for deriving weighted
estimates will still be poorly estimated in small samples. Then, as noted in Section 2, theoretical
efficiency gains from recovery of between-stratum information which are based on known
weights, may not be achievable. The loss of efficiency from estimating weights was investigated
by Yates2 and, more recently, by Nabugoomu and Allen.41 Cochran and Cox42 recommended
that interblock information should only be recovered when there is at least 10 degrees of
freedom for estimating the block mean square. This was the case for all the examples in this
paper and hence the estimated variances of treatment means can be used with some
confidence.
Comparison of REML estimates of variance components with ML estimates43 has shown that
REML estimates for block strata can be more variable than ML estimates. However, ML
estimates are generally biased downwards relative to the units variance and this bias can be
large.6,44 REML estimates of the standard errors of variance components are generally biased
upwards. A useful extension of REML allows different groups of patients (for example, grouped
by sex or treatment) to be described by different variance components. This was shown in the
repeated measures example where the response of patients in the active treatment group may be
more variable than the placebo group. Similarly, in a multicentre trial, the method can be used to
allow for treatment differences in the variability of response across centres.
The greatest obstacle at present to the routine use of REML in the analysis of clinical trials is
the lack of established procedures for significance testing. In least squares analysis, there is a well
developed Normal sample theory underlying the significance tests of fixed effects based on the
ratio of 'treatment' and 'error' sums of squares, both of which are x2 with known degrees of
freedom. The difficulty with inference in REML lies in identifying appropriate degrees of freedom
for the error as this is obtained by averaging across a number of strata. SAS and BMDP both
provide small sample Wald F-tests and t-tests but they disagree over the appropriate number of
error degrees of freedom. When errors are estimated with a large number of degrees of freedom,
then asymptotic Wald x2 test for overall significance of fixed effects, and z-tests for individual
contrasts, can be applied with greater confidence. However, tests based on large sample assum¬
ptions are unlikely to be acceptable to drug regulatory authorities unless a general rule can be
constructed to indicate when these assumptions are valid.
APPENDIX: MODEL SPECIFICATION AND PARAMETER ESTIMATION
The general mixed linear model can be specified for response variable y = (yi... y„) as
y = Xz + YJZJl}j + e (1)
1
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where a! = (a! ... a,) are t vectors of fixed effects with levels r,... r„ X is an n x g design matrix
with g = Y, r<> and e is a Normally distributed random error variable with mean 0, and variance
la2. The model includes c additional random variables pi ... pc where Pj (of length Sj) is Normally
distributed with mean 0, variance laj, and has n x sj design matrix Zr
The mean and variance/covariance matrix for y can be expressed as
E(y) = Xa,
and
var(y)=V=a2U + lZjZ'jyjl (2)
where y, = a]/a2. (For the repeated measures model, the errors e in (1) are not independent and
this leads to a different specification for the variance matrix V.)
We wish to estimate the fixed effects aj... a„ the unit variance a2 and variance ratios ^ ... yc for
random effects. If we know the variance matrix V we can use generalized least squares and
estimate the fixed effects as
a = (X' V~iX)~1 X' V_1y,
with
var (a) = (X'V~lX)~1. (3)
To estimate the variance components we could use maximum likelihood but this takes
no account of the information used in estimating fixed effects and so leads to biased treat¬
ment estimates. REML takes account of this loss of information by modifying the likeli¬
hood equation to exclude the contribution from fixed effects. The likelihood then
becomes
L= -\l2l\og\V\ + (y-XA)'V-l{y-XA) ~\og\X'V-lX\~l-\, (4)
where a are the estimated fixed effects from (3). Note that the REML equation differs from the
classical likelihood equation by a term log | X' V~1X \ ~1 associated with the variance of treatment
estimates. REML estimates of the variance parameters of Vmay then be obtained by maximizing
(4) using an iterative scheme.5
The full REML method thus consists of estimating fixed effects by generalized least squares
(3) and random effects by residual maximum likelihood (4). The difference between REML
and most other procedures lies in the method of estimating variance components. A good
review of alternative methods is given by Searle et al.1 The various ANOVA variance estimators
used by other authors2,3,14,21 are equivalent to REML estimators for complete data and
balanced incomplete block designs. Another family of variance estimators proposed by
Rao45,46 are the minimum norm quadratic unbiased estimators (MINQUE). Under normality
assumptions iterating the MINQUE equations once again gives the REML estimators.6,47
Finally, when there is only one variance component (the unit variance) REML reduces to simple
least squares analysis.
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Summary The Edinburgh Randomised Trial of Breast Cancer Screening recruited 44,288 women aged 45 - 64 '
years into the initial cohort of the trial during 1978-81, and 10 years of follow-up is now complete. A total of 1
22,944 women were randomised into the study group and were offered screening for 7 years; the remaining
women formed the control group. After 10 years, breast cancer mortality is 14-21% lower in the study group
than in the controls depending on the precise definition of the end point. These differences are not statistically Tf
significant; for breast cancer as the underlying cause of death the relative risk is 0.82 (95% confidence interval
0.61-1.11). Rates of locally advanced and metastatic cancer were substantially lower in the study group, but
screening has failed to achieve marked reductions in rates of small node-positive cancers. Those women who
accepted the final invitation to screening have been monitored over the 3 year period prior to their first screen
under the UK service screening programme. Interval cases, expressed as a proportion of the control incidence,
increased from 12% in the first year to 67% in the third year. The reduction in breast cancer mortality for
older women (aged at least 50 years) is the same as that for the total study group for this duration of
follow-up. For analyses of breast cancer mortality in younger women updates recruited to the trial from 1982
to 1985 (10,383 women with 6-8 years' follow-up) have been included. The reduction in breast cancer
mortality for women aged 45-49 years at entry was 22% (relative risk = 0.78, 95% confidence inter¬
val = 0.46-1.31).
The Edinburgh Randomised Trial of Breast Cancer Screening
(Roberts et ai, 1984) was started in 1978. A total of 44,288
women in Edinburgh were randomised into two groups of
approximately equal size. A total of 22,944 women entered
the study arm of the trial from 1978 to 1981; these women
were invited to participate in a screening programme that
included seven annual screens by clinical examination (for
seven consecutive years) and mammography (at the first
screen and at 2 yearly intervals). These same women formed
the Edinburgh component of the study population of the
Trial of Early Detection of Breast Cancer Screening or
TEDBC (UK Breast Cancer Detection Working Group,
1981). Mortality results for the TEDBC for 10 years of
follow-up have recently become available (UK Breast Cancer
Detection Working Group, 1993) and their data include com¬
parisons of the present study group with geographical con¬
trols. The control groups for the TEDBC and the Edinburgh
trial are entirely distinct.
The first report of the Edinburgh trial (Roberts et al.,
1990) included results for 7 years' follow-up for breast cancer
mortality and 5 years' follow-up for breast cancer incidence.
A reduction of 17% in breast cancer mortality in the study
group was observed at that time (relative risk = 0.83, 95%
confidence interval 0.58-1.18). The results of 10 years of
follow-up are now reported. In addition to the initial cohort
of the trial, younger women (aged 45-49 years) were entered
annually from 1982 to 1985; the results of shorter periods of
follow-up for these women have been included here.
Following the publication of the Forrest (1987) report,
mammographic screening for breast cancer was introduced
into National Health Service policy in 1988. Invitations to
service screening for women who had been screened during
the trial period were scheduled so that, so far as possible,
they were screened during their tenth year of follow-up and 3
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years after their last trial screen. In this way we are able to
provide the first estimates from a UK population of the
frequency of interval cases for women in regular screening
whose screens are scheduled to occur at 3 yearly inter¬
vals.
This report focuses on three topics: breast cancer mortality
after 10 years of follow-up, the effect of screening women




Detailed methods have been described previously (Roberts et
al., 1984). The geographical base for the trial comprised 87
general practices within the city of Edinburgh. These were
enrolled in turn between June 1979 and December 1981
(September 1978 for one practice). As each practice joined
the trial all women aged between 45 and 64 years and on the
practice list were admitted to form the initial cohort of the
trial. Women who attained the age of 45 after the practice
entry date and others (over 45 years of age) who moved into
the study area were entered from 1982 to 1985. In order to
maximise the numbers available for subgroup analyses of
younger women (aged 45-49 years at entry) these later en¬
trants have been included in these analyses and are referred
to as updates.
In 1985, women in the trial were flagged with the General
Registry Office in Edinburgh to obtain information on cancer
incidence and death. This ensures follow-up even for women
who have moved away from Edinburgh. The present report
is restricted to women who were successfully flagged (97% of
the total).
Women who had breast cancer diagnosed before entry to
the trial are ineligible, but this , was often established re¬
trospectively following receipt of a death nptification (see
below). »;
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Randomisation and screening
The 87 practices were randomised to study or control status,
which provided cluster randomisation for individual women
who derived their status within the trial from that of their
practice at entry. Women in the study group were offered
screening, and those who attended (61.3%) underwent two-
view mammography and clinical examination at their initial
visit (prevalence screen). Further screening (incidence screens)
used annual clinical examination for 6 years and included
single-oblique view mammography in alternate years. Atten¬
dance rates fell with time and were just over 50% during the
final (seventh) year of fieldwork (Roberts et al., 1990).
For the majority of women who continued in screening
each screen occurred within 1 year of the intended time - so
that, for example, the screen in 'year 3' occurred between 2
and 3 years from survey entry; these women are described as
having 'regular' screening. The NHS introduced service,
screening in Scotland in 1988 for women then aged 50-64
years. For practical and administrative reasons this had to be
introduced gradually and the Edinburgh programme was
coordinated with the present trial in such a way that all
women who were still in regular screening had their first
invitation to service screening at (approximately) 3 years
after their last (year 7) trial screen; this was during their
tenth year of follow-up.
Follow-up
Apart from the collection of medical information and screen¬
ing histories at the screening clinic, follow-up of women in
the two arms of the trial has been identical (Roberts et al.,
1984, 1990). For the field-work period of the trial (1978-88)
local follow-up for both breast cancer incidence and total
mortality were used as independent data sources alongside
flagging. Since then, flagging has provided the primary, and
for mortality data the only, source of follow-up. Scrutiny of
counts of death notifications from flagging suggests that
these data are virtually complete after a time lag of 6
months. Data for the present analysis were finalised in
January 1993 so that ascertainment of relevant deaths (occur¬
ring 1991 or earlier) could be ensured.
Whenever a death certificate mentioned breast cancer as a
cause of death for a woman who had not already been
identified as a breast cancer case the trial staff sought
confirmation of diagnosis. If this occurred before survey
entry date the woman was ineligible for the trial.
Flagging for cancer incidence may be less reliable than
flagging for mortality. Therefore the entire trial cohort was
matched against the Scottish Cancer Registration Scheme
database held centrally by the Information and Statistics
Division (ISD) of the Scottish Health Services Common
Services Agency. The cancer registration database is matched
annually with the Scottish hospitals inpatient database. Link¬
age with the trial database used probability matching and
included all notifications of cancer registered up to the end of
1991. These methods optimised ascertainment of breast
cancer incidence in the trial population for the full 10 years
of follow-up.
Analysis of breast cancer mortality
The primary end point for analysis is 'breast cancer mortal¬
ity' and, in the initial report (Roberts et al., 1990), this was
defined to be mention of breast cancer on either part 1 or
part 2 of the death certificate. We have continued to adopt
this definition here but have introduced two alternatives.
Coding of death certificates in Scotland permits one cause to
be underlined as the underlying cause of death, and this
procedure follows WHO rule 3 informally but does not use
the systematic approach adopted in England and Wales
(OPCS, 1985). Whenever breast cancer was underlined on the
death certificate the death has been classified as a breast
cancer death in the present analyses. We have checked all
remaining deaths of women with breast cancer diagnosed
during the trial period to derive two classifications of breast
cancer as underlying cause of death:
Definition 1: breast cancer was the underlined cause of
death on death certificate or formal application of WHO
rules (OPCS, 1985) attributed the death to breast cancer
when a non-specific cause was underlined.
Definition 2: breast cancer was the underlined cause of
death on death certificate or another cause was underlined
but case note review identified breast cancer as the under¬
lying cause.
For definition 2 doubtful cases were considered by a com¬
mittee of three doctors. This was more accurate but subject
to potential bias and definition 1 has been taken as the
principal definition of the end point.
As in the previous report, deaths occurring as results of
non-epithelial cancers in the breast (e.g. sarcoma, lymphoma)
are not included in the analysis.
Following the trial protocol (Roberts et al., 1984), the
main analysis has been of breast cancer mortality in the
whole of the initial cohort for 10 years from survey entry.
We also report the results of two subsidiary analyses focused
on possible differential effects of screening women over and
under 50 years of age. Firstly, breast cancer mortality over
the 10 year period for the initial cohort has been analysed
separately for the two age groups: 45-49 years and 50-64
years at survey entry. Secondly, we have included updates in
the analysis of younger women; women entered during
1982-83 are followed-up for 8 years and later updates for 6
years (since randomisation was in two groups by year at
entry). The analyses to be conducted were decided in advance
of data inspection.
For the statistical analysis mortality has been expressed as
rates of breast cancer deaths per 10,000 woman-years at
risk. Rates in study and control practices were compared and
their ratio calculated. As before (Roberts et al., 1990), a
modified logistic regression procedure incorporated adjust¬
ment for extrabinomial regression (Williams, 1982) so as to
respect the cluster randomisation. All analyses were imple¬
mented in 'GLIM' and stratified by age at survey entry
(45-49, 50-54, 55-59 and 60 - 64 years). Where updates are
included there has been further stratification by length of
follow-up. Cumulative breast cancer mortality curves are
expressed as rates per 10,000 women entering the study but
are adjusted to take account of women-years at risk. The
general practice 'clusters' have been classified into three
groups by levels of a socioeconomic score (SEG) as in the
previous report (Roberts et al., 1990).
Analysis of breast cancer incidence
Staging of disease follows standard UICC clinical staging
(UICC, 4th edn, 1987) and stage 0 corresponds to carcinoma
in situ; for cases which are stage I-II pathological inform¬
ation is also provided.
Cancers detected in women who had attended their last
trial screen (i.e. seventh screen, 6-7 years from entry) but
had not yet had a service screen are described as 'intervals';
cases arising in the period 36-42 months after the last trial
screen and before invitation to the service screening are
included as intervals. The proportional incidence of interval
cancers is the ratio of the incidence rate of these interval
cancers to that observed in the control group (adjusting for
the age distribution of the population at risk).
Cumulative incidence of cancers known to be advanced in
the total trial population have been plotted by year of
follow-up for two definitions of 'advanced': firstly, UICC
stages III and IV and, secondly, that used by Tabar et al.
(1985). These figures are adjusted for women-years at
risk.
Results
The trial population is shown in Table I with women-years
of follow-up. Of the study population 61.3% responded to
the initial invitation to screening, but only 44.1% attended
the seventh screen. The numbers of women known to be
ineligible on account of pretrial breast cancer are also shown;
prospective ascertainment is more complete for the study
group and, to avoid consequential bias, these women have
been retained in the calculations of women-years for the
denominators.
Breast cancer mortality
There have been 250 deaths in women with breast cancer
diagnosed during the trial period, including 196 (78.4%)
cases in which breast cancer was the underlined cause on the
death certificate and which were classified as breast cancer
deaths in all analyses. Case notes were reviewed for a ran¬
dom sample of 50 of these women, with the cause confirmed
in 47; three deaths were not attributable to breast cancer.
The three definitions of breast cancer death agreed,
positively (199) or negatively (23), for 222 (89%) of the 250
deaths, and the two definitions of underlying cause agreed
for 232 (94%). Patients in whom doubt about cause of death
was noted included just two of the younger women (aged
45-49 years).
Details of breast cancer mortality for the total initial
cohort are provided in Table II. The mortality rates are
lower for the study population for all definitions with reduc¬
tions of 14-21%. None of the results achieved statistical
significance, and the confidence intervals are wide. For the
principal end point (breast cancer as the underlying cause
using death certificate information) the reduction was 18%
(relative risk = 0.82, 95% confidence interval 0.61-1.11).
Cumulative breast cancer mortality by year of follow-up is
shown in Figure la.
Results for subgroup analyses using the principal end point
definition are reported in Table III. These provide no
evidence that a larger mortality reduction has been achieved
in older women (i.e. those aged 50 years or more at trial
entry). When the younger women were analysed separately
(Table III and Figure lb) the total numbers of breast cancer
Table I Trial population" and women-years of follow-up
Study population Control population
Age at Number of Women-years Number of Women-years
deaths were small and estimates of benefit consequently im¬
precise. The estimated mortality reductions are similar to
those for the entire study group. When the calculations
entry womenh of follow-up womenb of follow-up
45-49 5795 (59) 56750 5596 (32) 54588
50-54 5878 (65) 57021 5168 (40) 49603
55-59 6109 (112) 57993 5749 (56) 53872
60-64 5162 (102) 47451 4831 (49) 43758
Total 22944 (338) 219215 21344 (177) 201821
"These figures are for the initial cohort defined in the Methods
section and exclude women who were not successfully flagged;
corresponding figures for the updates aged 45-49 at entry are: study
population, 5,710 women (40,456 women-years); control population,
4,673 women (34,178 women - years). bFigures in brackets are
counted of women known to be ineligible because of prior breast
cancer diagnosis. Eligibility of screened women was established
prospectively, but ineligibility of control women and non-attenders is








Years from survey entry
Figure 1 Cumulative mortality from breast cancer in study (•)
and control ( + ) groups over 10 years of follow-up: (a) all ages;
(b) aged 45-49 years at survey entry and including updates.
Breast cancer death refers to the underlying cause from death
certificate information (definition 1: see Methods section).
Table II Breast cancer mortality in the initial cohort during 10 years of follow-up
Definition of breast Number of breast Mortality rate/10,000 Odds ratio (95%
cancer death Trial group cancer deaths women-years at risk confidence interval)
Death certificate" Study 105 4.79 0.79
Control 120 5.95 (0.60-1.05)
Underlying cause
Definition lb Study 96 4.38 0.82
Control 106 5.25 (0.61-1.11)
Definition 2C Study 101 4.61 0.86
Control 108 5.35 (0.66-1.13)
"Mentioned as a cause of death on the death certificate. bBreast cancer the underlying cause of death
from death certificate data (either the underlined cause or derived from formal application of WHO
rule 3). cBreast cancer underlined cause of death on the death certificate or confirmed as underlying
cause - case note review.
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reported in Table III were repeated for the other definitions
of breast cancer death, the results were qualitatively similar.
The mortality reduction for these women did not depend on
whether the age at diagnosis exceeded 50 years.
Breast cancer incidence
Altogether, 489 breast cancers were diagnosed in the 10 year
period in the study population (22.4/10,000 women-years)
and 400 in the controls (20.0/10,000 women-years).
The UICC stage distribution is more favourable for the
study population than for the controls (Table IV); percen¬
tages of invasive cancers classified as stages III or IV are
17% and 32% respectively. Cumulative rates (Figure 2a) in
the control group have always exceeded those in the study
group with a 2-fold excess after 10 years. Pathological
classifications of stage I and II cancers by size and node
status confirm the generally favourable characteristics of
cancers in the study group. The cancers are smaller in the
study group and, for each size, the proportions of node-
positive cancers are lower.
Tabar et al. (1985) have combined clinical and pathological
data to define a poor-prognosis tumour category (stage III or
IV, pathological size > 20 mm or node positive). The propor¬
tions of invasive cancers which are in this category are 53.5%
and 73.5% for study and control groups respectively; for the
never-screened women the percentage is 80%. However,
approximately half (152 or 47%) of all invasive cancers in
ever-screened women are poor prognosis according to this
definition, and of these 41 (27%) are small node-positive
cancers. Cumulative rates of poor-prognosis cancers (Figure
2b) show excesses in the study group for the first 7 years, but
thereafter a divergence in favour of the study group is emerg¬
ing.
The rates of interval cases in the 3 years after the trial
screening ended (Table V) are compared with rates in the
control population the proportional incidence of interval
cases increases markedly with time since the last screen from
12% in the first year to 67% in the third year.
Treatment
Altogether, 55% of women with operable invasive cancer
were treated with adjuvant systemic therapy. This percentage
increased with time from 36% in those diagnosed in study
years 1-5 to 79% for years 6-10. These percentages did not
differ between the two arms of the trial: 53% of the study
group and 57.5% of the control group received adjuvant
therapy. Corresponding figures for the updates were 63.5%
for the study group and 70.3% for the control group.
All-cause mortality and effect of socioeconomic status
All-cause mortality in the total trial population was 103.9/
10,000 women-years, which is similar to that expected in a
cohort of Scottish women of this age. The rates in the study
group were 15% lower than in the controls (relative risk =
0.85, 95% confidence interval 0.79-0.92). This difference
cannot be attributed to breast cancer, which represented only
4.7% of all deaths. When the trial population was split into
three groups by SEG of the general practice clusters, the
rates were 84.9, 104.1 and 126.1 with the lowest rates in the
highest SEG; the trend is statistically significant (P<
0.00001). More women in the study population were in the
Table III Breast cancer mortality": further analyses
Number of Mortality
Population Age at entry Follow-up breast cancer rate/10,000 Odds ratio
studies (years) First year Last year Trial group deaths women-years (95% CI)
Initial cohort 50-64 1 10 Study 79 4.86 0.85
Control 85 5.77 (0.62-1.15)
Initial cohort 45-49 1 10 Study 17 3.00 0.77
Control 21 3.85 (0.37-1.62)
Initial cohort Study 25 2.57 0.78
and updates 45-49 1 6,8,10b Control 31 3.49 (0.46-1.31)
"Underlying cause of death derived from death certificate data. bFollow-up period available depending on entry
year (see Methods section).
Table IV Classification of breast carcinoma in study and control populations
Study population Control
Pathological Ever Never population
UICC stage classification screenea" screened Total Total
0 TIS 39 3 42 11
I/II ^ 10 mm
N„ 57 3 60 27
N, 9 2 11 6
Total" 73 7 80 41
11 -20 mm
N„ 84 14 98 43
N, 32 7 39 28
Total" 126 24 150 85
21-50 mm
N0 54 11 65 45
N, 33 13 46 37
Total" 88 27 115 96
Size unknown 5 5 10 7
III 16 27 43 76
IV 7 24 31 49
Total' 364 125 489 400
"These women accepted at least one invitation to screening during the trial period.
bTotals include those for whom node status is unknown. Totals include those for
whom UICC stage is unknown.
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highest SEG group (percentages of women-years were 53%
and 26% in the study and control groups respectively) and
fewer were in the lowest SEG group (27% compared with























Years from survey entry
Figure 2 Cumulative incidence of breast cancer in the study (•)
and control ( + ) groups over 10 years of follow-up: (a) UICC
clinical staging III, IV; (b) advanced disease as defined by Tabar
et al., 1985.
Table V Cases arising during the 3 year interval" between trial and
service screens
Times from
negative screen Rate/10.000 Proportion of
(months) Number of cases women-years control incidence
0-11 2 2.0 0.12
12-23 7 7.1 0.42
24-35 11 11.3 0.67
36 or over 4 11.1 0.65
Total 24 7.3 0.43
year 7 of the trial.
explained at least in part by socioeconomic classifications. It
was not possible to calculate an overall RR for breast cancer
mortality with adjustment for practice SEG because of a
statistically significant interaction (P <0.005) between arm of
the trial and SEG. Since SEG is applied to GP practices
rather than individual women, the imbalance between the
two arms of the trial is independent of age.
Discussion
These results based on 10 years of follow-up confirm our
earlier findings (Roberts et al., 1990). There is a reduction in
breast cancer mortality of around 18% in the total study
population. This is not statistically significant and the
confidence intervals are wide so that, by themselves, the
results are inconclusive. They should be interpreted in con¬
text and are consistent with the consensus (Wald et al., 1991)
that mammographic screening reduces breast cancer mor¬
tality but by rather less than the 30% originally found in the
HIP study (Shapiro et al., 1982) and later by the Swedish
two-counties trial (Tabar et al., 1985). Other trials in Sweden
have achieved smaller reductions, and the recent Swedish
overview (Nystrom et al., 1993) which includes all the
Swedish trials estimates the reduction at 12 years of follow-
up to be 22%; this is based on 882 deaths and is highly
statistically significant. No other randomised trials of mam¬
mographic screening using an unscreened control group have
been conducted outside Sweden since the HIP study, which
was started in 1967. The Edinburgh trial, though numerically
small, provides useful indications that the benefits observed
in Sweden can be achieved elsewhere. This is important since
the breast cancer experience in Sweden is very different; for
example, cumulative mortality in the Edinburgh study group
after 10 years (4.38/10,000 women-years) exceeded that in the
Swedish two-counties control group after 12 years (4.15/
10,000 women-years, from Nystrom et al., 1993).
The TEDBC is larger than the Edinburgh trial but is a
geographical comparison. Our data are not independent since
the Edinburgh study group contributes to the TEDBC; the
controls are, however, entirely distinct. Estimated reductions
in breast cancer mortality for the TEDBC of 20% have
recently been reported (UK Breast Cancer Detection Work¬
ing Group, 1993); these are statistically significant but rely on
difficult adjustments using pretrial breast cancer standardised
mortality ratios (SMRs) for the geographical regions.
A number of design or execution problems for the study
have been discussed previously (Roberts et al., 1990) but
should be noted here; these include the attendance rate,
mammographic quality in the early years, loss of efficiency
from cluster rather than individual randomisation and statis¬
tical power. All of these will have a conservative effect. Other
potential sources of bias were, firstly, different use of
adjuvant systemic therapy (Early Breast Cancer Trialists Col¬
laborative Group, 1992) between the two groups and,
secondly, differential errors of ascertainment of breast cancer
deaths. We have demonstrated that the first doc3 not apply
and our methods of ascertainment avoid the latter.
Establishing whether death is attributable to breast cancer
is difficult in a small number of cases. The review of a
random sample of deaths with breast cancer underlined on
the death certificate has confirmed previous findings: over-
estimation of breast cancer as a cause of death of around 6%
(Brinkley et al., 1984; UK Breast Cancer Detection Working
Group, 1991). The review of case notes reveals that small
errors have occurred in the classification of the remaining
deaths of breast cancer patients, but these data are compati¬
ble with other recommendations (Brinkley et al., 1984) that
analyses should use death certificate classifications of the
underlying cause of death. Non-differential misclassification
in the data will be a further source of conservative bias.
An unexpected consequence of the use of cluster sampling
is the bias between the two arms of the trial, which is
evidenced in the differences in all-cause mortality. This is in
part explained by lower socioeconomic status in the control
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group (Alexander et al., 1989). There is a body of evidence
demonstrating that the direction of the association of
socioeconomic status with breast cancer is opposite to that
for all-cause mortality (Tomatis et al., 1990; Scottish Breast
Screening Programme, 1993). This suggests that the bias
should be conservative, but our data have not permitted
formal adjustment of the analyses for the effect of
socioeconomic status. Despite the possibility of confounding
in this study and inadequacy of SMR adjustment in the
TEDBC, the point estimates from the two studies are very
similar.
We conclude that our findings support the prevailing view
that mammographic screening does reduce mortality from
breast cancer - at least in women screened when 50 years and
over (Wald et al., 1991). Our data do not indicate that this
age range fared better than the younger women.
There is currently no consensus on the merits of screening
younger women (Beral, 1993; Elwood et al., 1993; Fletcher et
al., 1993). The principal difficulty is that no trial of tradi¬
tional design has been conducted with sufficient statistical
power to analyse this age group separately. In addition, most
authors fail to distinguish between the short and longer
follow-up periods. For short follow-up periods (i.e. 7 years or
less) all published trial results give point estimates of the
relative risk which are either close to unity or exceed it
(Shapiro et al., 1982; Miller et al., 1992; Nystrom et al.,
1993). This is supported by the Malmo trial (Andersson et
al., 1988) and the only relevant case-control study (Verbeek
et al., 1985). For longer follow-up periods the HIP trial
reported reductions in breast cancer mortality for younger
women (first screened when 40-49 years) which was even¬
tually of the same magnitude as that in older women
(Shapiro et al., 1988) and, in one analysis (Chu et al., 1988),
achieved statistical significance. This is the only trial with
follow-up exceeding 12 years but the Swedish trials have now
reported a reduction of 13% after 12 years. Similar results
have been reported by the Breast Cancer Demonstration
Project, although this latter is neither population based nor
randomised (Morrison et al., 1988).
The Edinburgh results are consistent with the emerging
consensus that modest reductions in breast cancer mortality
are achieved for women first screened when under 50 years,
but the benefits appear later than those for older women. At
7 years breast cancer mortality for women in the youngest
age group was almost identical for the two arms of the trial.
Now there is a reduction of 22% in the study group, but this
does not approach statistical significance. These results with
a randomised design and independent controls confirm the
findings of the TEDBC [relative risk = 0.74 (0.54-1.0)] (UK.
Breast Cancer Detection Working Group, 1993). The data
cannot be interpreted as evidence for population screening
for younger women; they do, however, indicate that the
optimal age to commence screening remains unknown; this is
an important public health question which requires resolu¬
tion by further randomised trials.
The classification of breast cancers by clinical stage and by
pathological size and node status reveals an encouraging
difference between study and control groups but is disappoin¬
ting in one critical respect. This is the failure of screening to
reduce the incidence of poor-prognosis disease as defined by
Tabar et al. (1985) and, in particular, to achieve major
reductions in the frequency of nodal metastases amongst the
smaller cancers (<20 mm). Half of all invasive cancers in
ever-screened women are poor prognosis compared with 33%
in the Swedish two-counties trial (Tabar et al., 1985). In both
trials the percentages in the never-screened women (80% and
73% respectively) exceeded those in the controls, but the
impact on the total study group is greater in Edinburgh on
account of the lower attendance rate. The cumulative
incidence of this poor-prognosis disease is not substantially
reduced in the Edinburgh study group - although the results
for the years 8-10 give preliminary indications that the
curves may be diverging strongly. In the two-counties trial
the changing incidence was reflected by the mortality curve
(Tabar et al., 1985), and subsequent analyses (Tabar ct al..
1992) have demonstrated that it is strongly predictive of
mortality. Much of the failure of our mortality reduction to
increase between 7 and 10 years of follow-up is likely to be
explained by delay in this aspect of performance. Although
we have detected large numbers of in situ cancer, this is
predicted to have less impact on mortality than reducing the
rate of small node-positive cancers (Tabar et al., 1992). One
of the strengths of the present trial database is that high
achievement in pathological classifications of nodal status
within one city has permitted an analysis which identifies the
problem more clearly than is possible using tumour size
alone (UK Breast Cancer Detection Working Group,
1993).
When service screening was introduced into Edinburgh we
took the opportunity of designing a protocol which would
enable us to report on the interval cancer rates over 3 years
in regularly screened women; these should be predictive of
eventual rates in the service programme with its 3 yearly
schedule. The optimum interval between examinations is
unknown; a randomised trial comparing 1 yearly intervals
with 3 yearly ones is currently in progress (N. Day, personal
communication) but will not report for several years. Mean¬
while, the best method of evaluating the inter-screening inter¬
val is to compare the proportional incidence of interval cases
across the period (Tabar et al., 1987). The proportions we
report are based on small numbers but exceed those for the
two-counties trial in both the second (42% compared with
29%) and third (67% compared with 45%) year (Tabar et
al., 1987). This indicates, firstly, that the interval could be
too long and should certainly not exceed 3 years - for the
population or for individual women. Secondly, it may be
further evidence that screening as practised during the trial
lacked sensitivity for detecting biologically important
cancers.
In conclusion, this trial has provided modest but important
contributions to the overall scientific evaluation of mammo
graphic screening. These include further evidence that screen¬
ing - at least for women over 50 years - can reduce mortality
from breast cancer by around 20%. With current standards
of mammography and higher attendance rates larger reduc¬
tions may be achievable. The extension of results from
scientific trials to routine health care can be problematic, but
current reports from UK service screening are encouraging
(Chamberlain et al., 1993; Scottish Breast Screening Pro¬
gramme, 1993). There is a need to determine the best age for
screening to commence. Since the benefits of screening take
at least 4 years to emerge, the present service screening
programme though targeted at women of 50 years and over
will have little impact on mortality from the disease in
women aged 50 54 years despite the fact that 20% of all
deaths of British women in this age group are due to breast
cancer (OPCS, 1989-93).
Finally, two warning messages emerge from this study:
firstly, follow-up and recall facilities must ensure that
minimal numbers of women wait for more than 3 years
between their invitations to screening. Secondly, screening
targets must focus on detection of cancers before nodal
metastases develop rather than relying on favourable size, it
follows that it is essential to the monitoring of the UK
service screening programme that histological evidence of
node status is available on all cases arising in the target
population.
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